WO2008030560A2 - Hsv-1 and hsv-2 vaccines and methods of use thereof - Google Patents

Hsv-1 and hsv-2 vaccines and methods of use thereof Download PDF

Info

Publication number
WO2008030560A2
WO2008030560A2 PCT/US2007/019537 US2007019537W WO2008030560A2 WO 2008030560 A2 WO2008030560 A2 WO 2008030560A2 US 2007019537 W US2007019537 W US 2007019537W WO 2008030560 A2 WO2008030560 A2 WO 2008030560A2
Authority
WO
WIPO (PCT)
Prior art keywords
hsv
another embodiment
strain
subject
mutant
Prior art date
Application number
PCT/US2007/019537
Other languages
French (fr)
Other versions
WO2008030560A3 (en
Inventor
Harvey Friedman
Elizabeth E. Brittle
Original Assignee
The Trustees Of The University Of Pennsyvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsyvania filed Critical The Trustees Of The University Of Pennsyvania
Priority to CA002663109A priority Critical patent/CA2663109A1/en
Priority to JP2009527427A priority patent/JP5639361B2/en
Priority to AU2007292905A priority patent/AU2007292905B2/en
Priority to CN200780038798.7A priority patent/CN101583381B/en
Priority to US12/440,223 priority patent/US8871223B2/en
Priority to EP07837889A priority patent/EP2059255A4/en
Publication of WO2008030560A2 publication Critical patent/WO2008030560A2/en
Publication of WO2008030560A3 publication Critical patent/WO2008030560A3/en
Priority to US12/415,152 priority patent/US8865185B2/en
Priority to US13/260,835 priority patent/US8911747B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation

Definitions

  • This invention provides methods of vaccinating a subject against Herpes Simplex Virus
  • HSV infection and disorders and symptoms associated with same and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other protein, optionally containing an inactivating mutation in a gene encoding a gD.
  • HSV herpes simplex virus
  • HSV-I usually causes oral ulcers and HSV-2 normally causes genital ulcers, but the reverse can also occur.
  • a person infected with HSV-I or HSV-2 will always be a carrier of the virus.
  • lesions heal and HSV exists in a dormant, latent state in sensory neurons.
  • HSV reactivates from latently infected neurons and causes new ulcers to form at the skin surface.
  • Newborn infants and immunosuppressed individuals are particularly vulnerable to HSV infection, often having a disseminated infection with fatal results.
  • Ocular HSV infection, a leading cause of blindness is another serious consequence of the virus.
  • genital HSV infection results in a two-fold increase in HIV transmission rate. Therefore, a vaccine to prevent transmission of HSV is urgently needed.
  • This invention provides methods of vaccinating a subject against a Herpes Simplex Virus
  • HSV infection and disorders and symptoms associated with same and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other protein.
  • the present invention provides method of treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection in a subject, comprising the step of contacting said subject with a composition comprising a mutant Herpes Simplex Virus vaccine strain, wherein said mutant HSV vaccine strain comprises an inactivating mutation in a Us8 gene.
  • the mutant HSV vaccine strain is an HSV-I strain, while in another embodiment, the mutant HSV vaccine strain is an HSV-2 strain.
  • the HSV infection is an HSV-I infection, while in another embodiment, the HSV infection is an HSV-2 infection.
  • the mutant strain is replication-competent in the skin tissue of said subject. In one embodiment, the neuronal viral spread of said mutant strain is impeded.
  • the mutant HSV vaccine strain further comprises an additional inactivating mutation in a Us7 gene, or, in another embodiment, in a Us9 gene, or, in another embodiment, in both Us7 and Us9 genes.
  • the mutant HSV vaccine strain further comprises an additional inactivating mutation in a gene encoding a membrane protein not required for virus entry, which in one embodiment, is Us5, in another embodiment, Us4, in another embodiment, UL53, in another embodiment, ULlO, or in another embodiment, any combination of Us5, Us4, UL53, and ULlO.
  • the mutant HSV vaccine strain further comprises an additional inactivating mutation in a gene encoding a membrane protein required for virus entry, which in one embodiment, is Us6.
  • the HSV infection is a genital HSV infection, while in another embodiment, the HSV infection is HSV encephalitis, while in another embodiment, the HSV infection is an ocular disease, while in another embodiment, the HSV infection is HSV labialis, while in another embodiment, the HSV infection is any combination of the above.
  • the subject is infected by HSV, while in another embodiment, the subject is at risk for infection by HSV, which in one embodiment, is a subject who is a neonate, in another embodiment, immunocompromised, in another embodiment, elderly, and in another embodiment, an immunocompromised neonate or an immunocompromised elderly subject.
  • the method induces an anti-HSV immune response in a subject, which in one embodiment, is an anti-HSV neutralizing antibody response.
  • the step of contacting comprises epidermal injection, in another embodiment, intramuscular injection, in another embodiment, subcutaneous injection, and in another embodiment, intra-respiratory mucosal injection.
  • the present invention provides an isolated mutant HSV-I strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation.
  • the gene encoding a gE protein is a Us8 gene.
  • the second inactivating mutation is in a Us7 gene.
  • the second inactivating mutation is in a Us9 gene.
  • the second inactivating mutation is in any other HSV-I gene known in the art.
  • the isolated mutant HSV-I strain contains inactivating mutations in genes encoding a gE protein, a gl protein, and a Us9 protein.
  • the present invention provides an isolated mutant HSV-2 strain comprising a first inactivating mutation in a gene encoding a gE protein and one or more additional inactivating mutations.
  • the gene encoding a gE protein is a Us8 gene.
  • the additional inactivating mutation is in a membrane protein not required for virus entry.
  • the additional inactivating mutation is in a Us7 gene.
  • the additional inactivating mutation is in a Us9 gene.
  • the additional inactivating mutation is in Us5, Us4, UL53, ULlO, or a combination thereof.
  • the additional inactivating mutation is in a membrane protein required for virus entry.
  • the additional inactivating mutation is in Us6. In another embodiment, the additional inactivating mutation is in any other HSV-2 gene known in the art. In another embodiment, the isolated mutant HSV-2 strain contains inactivating mutations in genes encoding a gE protein, a gl protein, and a Us9 protein.
  • Figure 1 HSV spread in neurons.
  • Figure 2 Typical HSV-I infection of a mouse flank.
  • Figure 3 Spectrum of skin disease in the mouse flank/vaccination model.
  • FIG. 7 Viral titers in skin after infection with vaccine or virulent HSV-I .
  • Figure 8 HSV detection in skin after infection with vaccine or wild-type HSV-I .
  • FIG. 9 Viral titers in dorsal root ganglia (DRG) after infection with vaccine or virulent
  • Figure 10 Survival of vaccinated or mock- vaccinated mice following challenge with 10 s pfu of WT HSV-I (NS).
  • FIG. 12 Viral titers in skin in vaccinated mice challenged with 10 5 pfu of WT HSV-I (NS).
  • Figure 13 HSV detection in skin of mock-vaccinated or vaccinated mice, challenged with 10 5 pfu ofWT HSV-I (NS).
  • FIG. 17 Cross protection of mice vaccinated with 5xlO 5 pfu HSV-l ⁇ gE against flank challenge with 10 5 pfu HSV-2(2.12).
  • "Mock Vac” denotes mock vaccination;
  • "DgE Vac” denotes vaccination with 5 x 10 5 pfu HSV-l ⁇ gE.
  • Error bars represent the Standard Error of the Mean ("SEM").
  • Figure 18 Protection of mice vaccinated with 5 x 10 5 pfu HSV-l ⁇ gE against latency following flank challenge with 5 x 10 5 pfu HSV-I(KOS). Error bars represent the SEM.
  • Ep. Scar epidermal scarification; “SubQ”: subcutaneously; IM: intramuscular) against flank challenge with 10 5 pfu HSV-I(NS).
  • DgE Vac denotes HSV-l ⁇ gE; Error bars represent the SEM.
  • Figure 21 Induction of neutralizing antibody response in mice vaccinated with 5 x 10 5 pfu
  • Figure 22 Protection of mice vaccinated with 5 x 10 5 pfu HSV-I ⁇ gE against flank challenge with 10 5 pfu HSV-I(NS, F or 17). Error bars represent the SEM.
  • FIG. 23 Protection of mice vaccinated with 5 x 10 5 pfu HSV-l ⁇ gE against flank challenge with 10 5"7 pfu HSV-I(NS). Error bars represent the SEM.
  • Figure 24 A. Alignment of HSV-I(NS) gE (SEQ ID NO: 2) with HSV-2(HG52) gE (SEQ ID NO: 2) with HSV-2(HG52) gE (SEQ ID NO: 2)
  • FIG. 25 Schematic diagram of the 4.5 kb region within the Us segment of the HSV-2 genome (155 kb total genome size) is depicted. The region equivalent to that deleted in the HSV-l ⁇ gE vaccine strain and area of proposed additional deletions are noted.
  • Figure 26 A. Western blot to detect gD (Us6) and gl (Us7) in infected cell extracts.
  • KOS-gDA3C virus Stability of the KOS-gDA3C virus in vitro.
  • a PCR-amplified gD fragment obtained from the DRG of KOS-gDA3C-infected mice were cut with Sspl or left uncut.
  • FIG. 27 Entry of KOS, rKOS-gDA3C and KOS-gDA3C virus into (A) Vera, (B) B78-H1 ,
  • Figure 28 Single-step (A, B) and multi-step (C, D) growth curves of KOS, rKOS-gDA3C and KOS-gDA3C performed in AlO (A, C) or ClO (B, D) cells. Results are the mean + SE of three separate infections.
  • FIG. 29 Disease in the murine flank model. Inoculation (A) and zosteriform (B) site disease scores in mice inoculated with 5x10 5 PFU of KOS, rKOS-gDA3C or KOS-gDA3C. Error bars represent SE. C. Photographs of mice flanks taken 10 days post-infection with KOS, rKOS-gDA3C, or KOS-gDA3C.
  • FIG. 30 Virus titers and genome copy numbers in DRG.
  • DRG were dissected from mice infected with KOS, rKOS-gDA3C or KOS-gDA3C and assayed for virus titers (A) or viral genome copy number (B). Results represent the mean + SE.
  • FIG. 31 Prior infection with KOS-gDA3C protects against WT HSV-I challenge.
  • Results represent mean disease scores + SE at the inoculation (A) and zosteriform (B) sites from days 3-7 postinfection.
  • DRG viral titers (C) and genome copy number (D) were measured 5 days post-challenge with NS. Results represent the mean + SE.
  • FIG. 32 Model for KOS-gDA3C infection in mice.
  • KOS infects epithelial cells (E) and P-9066-PC produces disease at the inoculation site.
  • the virus spreads to neurons (N) in the DRG, replicates and spreads to adjacent neurons and then travels back to epithelial cells in the skin to cause zosteriform disease.
  • KOS-gDA3C is impaired in entry and infects fewer epithelial cells, which results in fewer neurons becoming infected in the DRG.
  • the defect in entry also reduces infection of adjacent neurons in the DRG and results in reduced zosteriform disease.
  • This invention provides methods of vaccinating a subject against Herpes Simplex Virus
  • HSV infection and disorders and symptoms associated with same comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, other protein, or combinations thereof.
  • the mutant strain of the HSV comprises an inactivating mutation in a gene encoding gE, which in one embodiment, is a gE null mutation.
  • the present invention provides pharmaceutical compositions comprising a mutant strain of HSV which comprises an inactivating mutation in a gene encoding gE, which in one embodiment, is a gE null mutation. In another embodiment, this invention provides pharmaceutical compositions comprising a mutant strain of HSV which comprises an inactivating mutation in a gene encoding a gE, gl, Us9, other protein, or combinations thereof.
  • the present invention provides a method of vaccinating a subject against an HSV infection, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of impeding HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of impeding HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of impeding primary HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of impeding primary HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein
  • the present P-9066-PC invention provides a method of impeding primary HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein
  • the terms “impeding HSV infection” and “impeding primary HSV infection” refer, in one embodiment, to decreasing the titer of infectious virus by 90%.
  • the titer is decreased by 50%.
  • the titer is decreased by 55%.
  • the titer is decreased by 60%.
  • the titer is decreased by 65%.
  • the titer is decreased by 70%.
  • the titer is decreased by 75%.
  • the titer is decreased by 80%.
  • the titer is decreased by 85%.
  • the titer is decreased by 92%.
  • the titer is decreased by 95%.
  • the titer is decreased by 96%. In another embodiment, the titer is decreased by 97%. In another embodiment, the titer is decreased by 98%. In another embodiment, the titer is decreased by 99%. In another embodiment, the titer is decreased by over 99%.
  • the terms refer to decreasing the extent of viral replication by 90%.
  • replication is reduced by 50%. In another embodiment, replication is reduced by 55%. In another embodiment, replication is reduced by 60%. In another embodiment, replication is reduced by 65%. In another embodiment, replication is reduced by 70%. In another embodiment, replication is reduced by 75%. In another embodiment, replication is reduced by 80%. In another embodiment, replication is reduced by 85%. In another embodiment, replication is reduced by 92%. In another embodiment, replication is reduced by 95%. In another embodiment, replication is reduced by 96%. In another embodiment, replication is reduced by 97%. In another embodiment, replication is reduced by 98%. In another embodiment, replication is reduced by 99%. In another embodiment, replication is reduced by over 99%.
  • Methods for measuring HSV infection are well known in the art, and include, in one embodiment, determination of appearance and severity of skin lesions and viral-mediated illness (Examples 1 and 4). Other embodiments of methods for measuring viral infection are described, for example, in Burgos JS et al. (Herpes simplex virus type 1 infection via the bloodstream with apolipoprotein E dependence in the gonads is influenced by gender. J Virol. 2005 Feb;79(3): 1605-12) and Parr MB et al. (Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites. J Neurovirol. 2003 Dec;9(6):594-602).
  • vaccination with gE-null HSV strains of the present invention protects against subsequent infection with virulent HSV.
  • the vaccination protects against disease caused by virulent HSV.
  • the vaccine strain does not itself cause significant disease, which in one embodiment is herpes (Examples 1 and 4), or, in another embodiment, result in significant symptomology.
  • Inactivating mutation in gE refers, in one embodiment, to a mutation that abrogates HSV neuronal spread. In another embodiment, the terms refer to a mutation that abrogates cell-to-cell spread of HSV. In another embodiment, the terms refer to abrogation of spread along axons. In another embodiment, the spread is retrograde (defined herein below). In another embodiment, the spread is anterograde (defined herein below). In another embodiment, spread in both anterograde and retrograde directions is abrogated.
  • neuronal spread is decreased by 90%. In another embodiment, neuronal spread is decreased by 60%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
  • the term refers to abrogating ability of gE protein to sequester host anti-
  • HSV antibodies In another embodiment, sequestration of anti-HSV antibodies by gE is reduced by 90%. In another embodiment, sequestration is reduced by 50%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
  • the term refers to abrogating ability of gE protein to bind IgG monomers.
  • binding of IgG monomers by gE is reduced by 90%.
  • binding is reduced by 50%.
  • the reduction is 65%.
  • the reduction is 70%.
  • the reduction is 75%.
  • the reduction is 80%.
  • the reduction is 85%.
  • the reduction is 95%.
  • the reduction is 96%.
  • the reduction is 97%.
  • the reduction is 98%.
  • the reduction is 99%. In another embodiment, the reduction is over 99%.
  • the term refers to abrogating ability of gE protein to bind IgG complexes.
  • binding of IgG complexes by gE is reduced by 90%.
  • binding is reduced by 50%.
  • the reduction is 65%.
  • the reduction is 70%.
  • the reduction is 75%.
  • the reduction is 80%.
  • the reduction is 85%.
  • the reduction is 95%.
  • the reduction is 96%.
  • the reduction is 97%.
  • the reduction is 98%.
  • the reduction is 99%. In another embodiment, the reduction is over 99%.
  • an inactivating mutation in gE comprises a deletion of amino acids 124-
  • an inactivating mutation in gE comprises a deletion of amino acids 110-500. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-552. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-50. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-100. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-250. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 100-300. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-400. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 200-500.
  • an inactivating mutation in gE comprises a deletion of amino acids 24-71. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 30-508. In another embodiment, an inactivating mutation in gE comprises a deletion of approximately amino acids 40-70. In another embodiment, an inactivating mutation in gE comprises insertion of a non-native sequence into a portion of the gene encoding gE, wherein said gE is inactivated as a result.
  • an inactivating mutation in gE comprises substitution of amino acid residues, such as a substitution of polar for non-polar residues, non-polar for polar residues, charged for uncharged residues, positively charged for negatively charged residues, or vice versa, or a combination thereof, as is known to one of skill in the art.
  • an inactivating mutation in gE consists essentially of any of the mutations listed hereinabove.
  • an inactivating mutation in gE consists of any of the mutations listed hereinabove.
  • an inactivating mutation in gE or other protein as described in the instant invention for a first HSV strain may also be mutated in an equivalent location of the corresponding protein in a second HSV strain, wherein the equivalent location of the insertion, deletion or substitution may be inferred by sequence alignment, as is well known in the art, wherein the region that aligns with the sequence of the mutation in the first strain would be mutated in the second strain.
  • Inactivating mutation in gD refers, in one embodiment, to a mutation that inhibits protein/receptor interactions, which in one embodiment is an interaction with a HVEM cell receptor, a nectin-1 cell receptor, or both, and in another embodiment, to a mutation that inhibits viral entry into a cell, inhibits downstream activation of gB, gH, and gL, inhibits fusion of the viral envelope with cell membrane, or a combination thereof.
  • an inactivating mutation in gD is in the amino terminus of the gD peptide, which in one embodiment is residue 1-15, and in another embodiment, the mutation inhibits formation of a hairpin loop structure when gD is bound to HVEM.
  • the mutation is at amino acids 3, 38, or both, and in one embodiment, alanine and tyrosine residues at those locations are replaced with cysteine residues (A3C/Y38C) to create a 3-38 disulfide bond and/or a fixed hairpin loop at the amino terminus.
  • inactivating mutations of the present invention are accomplished using tools known in the art.
  • the nucleic acids used in this invention and those encoding proteins of and for use in the methods of the present invention can be produced by any synthetic or recombinant process such as is well known in the art.
  • Nucleic acids can further be modified to alter biophysical or biological properties by means of techniques known in the art.
  • the nucleic acid can be modified to increase its stability against nucleases (e.g., "end-capping"), or to modify its lipophilicity, solubility, or binding affinity to complementary sequences.
  • transposons may be used to create inactivating mutations of a gene, where in one embodiment, the transposon may be Tn551, Minos, Hermes or piggyback. In another embodiment, the transposon may be AT-2 (tyl based transposon, Perkin Elmer; Devine et al. (1997) Genome Res. 7:551-563), GPS-I (New England Biolabs), GPS-2 (New England Biolabs), EZ::tn (Tn5 based transposon, Epicenter Technologies), SIF (Tn7 based transposon, Biery et al. (2000) Nucl Acid Res 28:1067-1077), or Mu (Finnzymes, Haapa et al.
  • RNA from individual transposon mutants may be used to verify transposon insertion.
  • sequence analysis, PCR and/or hybridization may be utilized to determine transposon insertion. Mutations may also be elicited using ethylmethanesulfonate (EMS) or radiation.
  • EMS ethylmethanesulfonate
  • mutagenesis with chemical agents may be used. Such chemical mutagens may comprise, in other embodiments, chemicals that affect nonreplicating DNA such as HNO2 and NH2OH, as well as agents that affect replicating DNA such as acridine dyes, which have been shown to cause frameshift mutations.
  • DNA can be synthesized chemically from the four nucleotides in whole or in part by methods known in the art. Such methods include those described in Caruthers (1985; Science P-9066-PC
  • DNA can also be synthesized by preparing overlapping double-stranded oligonucleotides, filling in the gaps, and ligating the ends together (see, generally, Sambrook et al. (1989; Molecular Cloning - A Laboratory Manual, 2 nd Edition. Cold Spring Habour Laboratory Press, New York)).
  • inactivating mutations may be prepared from wild-type DNA by site-directed mutagenesis (see, for example, Zoller et al. (1982; DNA. 1984 Dec;3(6):479-88); Zoller (1983); and Zoller (1984; DNA. 1984 Dec;3(6):479-88); McPherson (1991; Directed Mutagenesis: A Practical Approach.
  • the DNA obtained can be amplified by methods known in the art.
  • One suitable method is the polymerase chain reaction (PCR) method described in Saiki et al. (1988; Science. 1988 Jan 29;239(4839):487-491), Mullis et al., U.S. Pat. No.4,683,195, and Sambrook et al. (1989).
  • the present invention provides a method of impeding the establishment of a latent HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the latent HSV infection that is prevented follows primary HSV infection.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in protecting a subject against latent HSV infection, following primary HSV infection.
  • the present invention provides a method of inhibiting an HSV flare in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the flare that is prevented follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in protecting a subject against a formation of a flare, following an exposure of the subject to HSV.
  • the present invention provides a method of protecting a subject against an HSV flare, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the flare that is prevented follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in protecting a subject against a formation of a flare, following exposure of the subject to HSV.
  • the present invention provides a method of reducing the incidence of an
  • HSV flare comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the flare that is prevented follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in reducing the incidence of a flare, following exposure of the subject to HSV.
  • the present invention provides a method of inhibiting HSV recurrence in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the recurrence that is prevented follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in protecting a subject against a recurrence, following an exposure of the subject to an HSV.
  • the present invention provides a method of reducing the incidence of
  • HSV recurrence comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the recurrence that is prevented follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in reducing the incidence of a recurrence, following exposure of the subject to HSV.
  • the present invention provides a method of suppressing HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the present invention provides a method of suppressing HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the subject is human.
  • the subject is murine, which in one embodiment is a mouse, and, in another embodiment is a rat.
  • the subject is canine, feline, bovine, or porcine.
  • the subject is mammalian.
  • the subject is any organism susceptible to infection by HSV.
  • the present invention provides a method of protecting a subject against formation of a zosteriform lesion or an analogous outbreak in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of impeding formation of an HSV zosteriform lesion or an analogous outbreak in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the zosteriform lesion or analogous outbreak that is impeded follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in impeding formation of a zosteriform lesion or analogous outbreak, following an exposure of the subject to an HSV.
  • the present invention provides a method of impeding HSV zosteriform spread or an analogous condition in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the zosteriform spread or analogous condition that is impeded follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in impeding formation of a zosteriform spread or analogous condition, following exposure of the subject to HSV.
  • Zosteriform refers, in one embodiment, to skin lesions characteristic of an HSV infection, particularly during reactivation infection, which, in one embodiment, begin as a rash and follow a distribution near dermatomes, commonly occurring in a strip or belt-like pattern. In one embodiment, the rash evolves into vesicles or small blisters filled with serous fluid. In one embodiment, zosteriform lesions form in mice as a result of contact with HSV. In another embodiment, zosteriform lesions form in humans as a result of contact with HSV. P-9066-PC
  • Zerosteriform spread refers, in one embodiment, to an HSV infection that spreads from the ganglia to secondary skin sites within the dermatome. In another embodiment, the term refers to spread within the same dermatome as the initial site of infection. In another embodiment, the term refers to any other definition of "zosteriform spread” known in the art.
  • Break in another embodiment, refers to a sudden increase in symptoms of a disease or in the spread or prevalence of a disease, and in one embodiment, refers to a sudden increase in zosteriform lesions, while in another embodiment, "outbreak” refers to a sudden eruption of zosteriform lesions.
  • the present invention provides a method of impeding the formation of a dermatome lesion or an analogous condition in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the dermatome lesion or analogous condition that is impeded follows exposure of the subject to HSV.
  • dermatome lesions form in humans as a result of contact with HSV.
  • dermatome lesions in humans most often develop when the virus reactivates from latency in the ganglia and in one embodiment, spreads down nerves, in one embodiment, causing a recurrent infection.
  • dermatome lesions form in mice as a result of contact with HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in impeding the formation of a dermatome lesion or analogous condition, following exposure of the subject to HSV.
  • vaccination with gE-null HSV strains of the present invention protects against latent HSV infection (Example 5) and formation of zosteriform and dermatome lesions (Example 4) after subsequent infection with virulent HSV.
  • the vaccination protects against disease caused by or associated with latent HSV infection.
  • the vaccination does not itself cause significant disease (Example 2).
  • Virulent HSV refers, in one embodiment, to a naturally occurring HSV strain. In another embodiment, the term refers to an HSV strain capable of causing infection. In another embodiment, the term refers to an HSV strain capable of establishing latent infection.
  • the present invention provides a method of impeding neuronal spread of an HSV in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the neuronal spread that is impeded follows exposure of the subject to HSV.
  • the subject has been infected with HSV before vaccination.
  • the subject is at risk for HSV infection.
  • vaccination by a method of the present invention is efficacious in impeding neuronal viral spread, following an exposure of the subject to HSV.
  • Methods of measuring neuronal HSV spread are well known in the art, and include, in one embodiment, determination of the presence and extent of secondary dermatome lesion (Example 2).
  • Other embodiments of methods for measuring viral spread are described, for example, in Labetoulle M et al. (Neuronal propagation of HSVl from the oral mucosa to the eye. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2600-6) and Thompson KA et al. (Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000 Feb;6(l):25-32).
  • the present invention provides a method of reducing the incidence of herpetic ocular disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by the HSV.
  • the present invention provides a method of reducing the severity of herpetic ocular disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • the vaccine strain is from a different species from the challenge strain.
  • the vaccine strain is of the same species as the challenge strain.
  • the present invention provides a method of reducing the incidence of an HSV-] corneal infection, herpes keratitis or any other herpetic ocular disease in a subject, the method comprising the step of administering to said subject a mutant strain of HSV of the present invention, thereby reducing an incidence of an HSV-I cornea] infection or herpes keratitis in a subject.
  • administering to said subject a mutant strain of HSV of the present invention elicits an immune response against the HSV-I .
  • the present invention provides a method of reducing the incidence of a genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV
  • the present invention provides a method of reducing the severity of genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • genital ulcer disease is characterized by ulcerative lesions on the genitals. Methods for determining the presence and extent of genital ulcer disease are well known in the art.
  • the present invention provides a method of reducing the incidence of
  • HSV-I -mediated encephalitis in a subject comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • HSV-I encephalitis refers, in one embodiment, to encephalitis caused by HSV-I . In another embodiment, the term refers to encephalitis associated with HSV-I. In another embodiment, the term refers to any other type of HSV-I -mediated encephalitis known in the art.
  • the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV.
  • the vaccine strain is from a different species from the challenge strain. In another embodiment, the vaccine strain is of the same species as the challenge strain.
  • HSV-I refers, in one embodiment, to a Herpes Simplex Virus 1.
  • the term refers to a KOS strain.
  • the term refers to an F strain.
  • the term refers to an NS strain.
  • the term refers to a CLlOl strain.
  • the term refers to a "17" strain.
  • the term refers to a "17+syn" strain.
  • the term refers to a MacIntyre strain.
  • the term refers to an MP strain.
  • the term refers to an HF strain.
  • the term refers to any other HSV-I strain known in the art.
  • HSV-2 refers, in one embodiment to a Herpes Simplex Virus 2. Tn another embodiment, the term refers to an HSV-2 333 strain. In another embodiment, the term refers to a 2.12 strain. In another embodiment, the term refers to an HG52 strain. In another embodiment, the term refers to an MS strain. In another embodiment, the term refers to an 186 strain. In another embodiment, the term refers to a G strain. In another embodiment, the term refers to any other HSV-2 strain known in the art. P-9066-PC
  • the present invention provides a method of reducing the incidence of
  • HSV-2-mediated encephalitis in a subject comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • HSV-2 encephalitis refers, in one embodiment, to encephalitis caused by HSV-2. In another embodiment, the term refers to encephalitis associated with HSV-2. In another embodiment, the term refers to any other type of HSV-2-mediated encephalitis known in the art.
  • the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV
  • the present invention provides a method of reducing the severity of herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk ofinfection by HSV.
  • the herpes-mediated encephalitis treated or prevented by a method of the present invention is a focal herpes encephalitis.
  • the herpes-mediated encephalitis is a neonatal herpes encephalitis.
  • the herpes-mediated encephalitis is any other type of herpes-mediated encephalitis known in the art.
  • the present invention provides a method of reducing the incidence of disseminated HSV infection in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by the HSV.
  • the present invention provides a method of reducing the severity of disseminated HSV infection in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • the present invention provides a method of reducing the incidence of a neonatal HSV-I infection in an offspring of a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the offspring is contacted the subject with the mutant HSV strain.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • the present invention provides a method of reducing the incidence of a neonatal HSV-2 infection in an offspring of a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • the present invention provides a method of reducing the transmission of an HSV-I infection from a subject to an offspring thereof, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of reducing the transmission of an HSV-2 infection from a subject to an offspring thereof, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of reducing HIV-] transmission to an offspring, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • HSV-2 infection increases HIV-I viral shedding in genital secretions (Nagot N et at. Reduction of HIV-I RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007 Feb 22;356(8):790-9).
  • methods of the present invention of inhibiting HSV-2 infection are also believed to be efficacious for reducing HIV-I transmission to an offspring.
  • the mutant HSV strain is an HSV-I strain.
  • the mutant HSV strain is an HSV-2 strain.
  • the present invention provides a method of reducing HIV-I transmission to a sexual partner, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • HSV-2 infection increases HIV-I viral shedding in genital secretions.
  • methods of the present invention of inhibiting HSV-2 infection are also believed to be efficacious for reducing HIV-I transmission to a sexual partner.
  • the mutant HSV strain is an HSV-I strain.
  • the mutant HSV strain is an HSV-2 strain.
  • the present invention provides a method of reducing susceptibility to
  • HIV-I the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • HSV-2 infection increases HIV-I replication (Ouedraogo A et al. Impact of suppressive herpes therapy on genital HlV-I RNA among women taking anti retroviral therapy: a randomized controlled trial.
  • mutant HSV strain is an HSV-I strain.
  • mutant HSV strain is an HSV-2 strain.
  • the present invention provides a method of reducing die severity of a neonatal HSV infection in an offspring of a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the subject is infected by HSV.
  • the subject is at risk of infection by HSV.
  • the present invention provides a method of reducing the incidence of a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of treating a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein, thereby treating a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject.
  • the disease, disorder, or symptom is fever. In another embodiment, the disease, disorder, or symptom is headache. In another embodiment, the disease, disorder, or symptom is stiff neck. In another embodiment, the disease, disorder, or symptom is seizures. In another embodiment, the disease, disorder, or symptom is partial paralysis. In another embodiment, the disease, disorder, or symptom is stupor. In another embodiment, the disease, disorder, or symptom is coma. In another embodiment, the disease, disorder, or symptom is any other disease, disorder, or symptom known in the art that is associated with or secondary to herpes-mediated encephalitis.
  • the present invention provides a method of treating a disease, disorder, or symptom associated with an HSV infection in a subject, comprising the step of contacting the subject P-9066-PC with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of reducing the incidence of a disease, disorder, or symptom associated with an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of treating a disease, disorder, or symptom secondary to an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the present invention provides a method of reducing the incidence of a disease, disorder, or symptom secondary to an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the disease, disorder, or symptom secondary to an HSV infection is oral lesions.
  • the disease, disorder, or symptom is genital lesions.
  • the disease, disorder, or symptom is oral ulcers.
  • the disease, disorder, or symptom is genital ulcers.
  • the disease, disorder, or symptom is fever.
  • the disease, disorder, or symptom is headache.
  • the disease, disorder, or symptom is muscle ache.
  • the disease, disorder, or symptom is swollen glands in the groin area.
  • the disease, disorder, or symptom is painful urination.
  • the disease, disorder, or symptom is vaginal discharge.
  • the disease, disorder, or symptom is blistering. In another embodiment, the disease, disorder, or symptom is flu-like malaise. In another embodiment, the disease, disorder, or symptom is keratitis. In another embodiment, the disease, disorder, or symptom is herpetic whitlow. In another embodiment, the disease, disorder, or symptom is Bell's palsy. In another embodiment, the disease, disorder, or symptom is herpetic erythema multiforme. In another embodiment, the disease, disorder, or symptom is a lower back symptom (e.g. numbness, tingling of the buttocks or the area around the anus, urinary retention, constipation, and impotence).
  • a lower back symptom e.g. numbness, tingling of the buttocks or the area around the anus, urinary retention, constipation, and impotence.
  • the disease, disorder, or symptom is a localized eczema herpeticum. In another embodiment, the disease, disorder, or symptom is a disseminated eczema herpeticum. In another embodiment, the disease, disorder, or symptom is a herpes gladiatorum. In another embodiment, the disease, disorder, or symptom is a herpetic sycosis. In another embodiment, the disease, disorder, or symptom is an esophageal symptom (e.g. difficulty swallowing or burning, squeezing throat pain while swallowing, weight loss, pain in or behind the upper chest while swallowing). In another P-9066-PC embodiment, the disease, disorder, or symptom is any other disease, disorder, or symptom is known in the art.
  • the HSV infection treated or ameliorated by methods and compositions of the present invention is, in one embodiment, a genital HSV infection.
  • the HSV infection is an oral HSV infection.
  • the HSV infection is an ocular HSV infection.
  • the HSV infection is a dermatologic HSV infection.
  • the HSV infection is an HSV-2 infection. In another embodiment, the HSV infection is an HSV-2 infection.
  • HSV is an HSV-I infection.
  • the HSV infection is any other type of HSV infection known in the art.
  • the present invention provides a method of inducing rapid clearance of an HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the present invention provides a method of inducing rapid clearance of an HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the present invention provides a method of inducing an anti-HSV immune response in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein, thereby inducing an anti-HSV immune response in a subject.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the present invention provides a method of inducing an anti-HSV neutralizing antibody response in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
  • the mutant HSV strain is a mutant HSV-I strain.
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the present invention provides a method of inhibiting HSV labialis in a subject, comprising the step of vaccinating the subject against an HSV by a method of the present invention.
  • the present invention provides a method of inhibiting HSV labialis in a subject, comprising the step of impeding an HSV infection in the subject by a method of the present invention.
  • the immune response induced by methods and compositions of the present invention is a cellular immune response.
  • the immune response comprises a CD8 + cytotoxic T lymphocyte (CTL) response.
  • the immune response comprises a CD4 + helper T cell response.
  • the immune response comprises a humoral immune response.
  • the route of administration of the mutant strains in the methods of the present invention is, in one embodiment, epidermal. In another embodiment, the mutant strain is administered by epidermal scarification or scratching. In another embodiment, the mutant strain is administered intramuscularly. In another embodiment, the mutant strain is administered subcutaneously. In another embodiment, the mutant strain is administered intranasally. In another embodiment, the mutant strain is administered transdermally. In another embodiment, the mutant strain is administered intravaginally. In another embodiment, the mutant strain is administered transmucosally, which in one embodiment, is intra- respiratory mucosally. In another embodiment, the mutant strain is administered intranasally. In another embodiment, the mutant strain is administered in an aerosol. In another embodiment, the mutant strain is administered via any other route known in the art.
  • the inactivating mutation in the gE-encoding gene of HSV strains as described in the methods and compositions of the present invention is a deletion mutation.
  • the inactivating mutation is an insertion mutation.
  • the inactivating mutation is a substitution mutation.
  • the inactivating mutation is a gE-null mutation.
  • the inactivating mutation is any other type of mutation known in the art.
  • the inactivating mutation in the glycoprotein-encoding gene of HSV strains as described in the methods and compositions of the present invention is a deletion mutation.
  • the inactivating mutation is an insertion mutation.
  • the inactivating mutation is a substitution mutation.
  • the inactivating mutation is a null mutation.
  • the inactivating mutation is any other type of mutation known in the art.
  • the insertion, deletion or substitution mutation comprises an insertion, deletion or substitution of a single amino acid, while in another embodiment, it comprises an insertion, deletion or substitution of 1-5 amino acids, 1-10 amino acids, 5-20 amino acids, 10-50 amino acids, 25-100 amino acids, 100-500 amino acids, 300-400 amino acids, 200-1000 amino acids, or 1000 or more amino acids.
  • the present invention provides an isolated mutant HSV-I strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation.
  • the gene encoding a gE protein is a Us8 gene.
  • the mutation is a gE-null mutation.
  • an isolated mutant HSV-I strain as described in the methods and compositions of the present invention further comprises one or more additional mutations, which in one embodiment are inactivating mutations.
  • the second or additional inactivating mutation is in a Us7 gene.
  • the second or additional inactivating mutation is in a Us9 gene.
  • the second inactivating mutation is in any gene which confers neurovirulence. In another embodiment, the second inactivating mutation is in any gene required for virus entry into a host cell. In another embodiment, the second inactivating mutation is in a host shut-off gene. In another embodiment, the second inactivating mutation is in the thymidine kinase gene. In another embodiment, the second inactivating mutation is in any other HSV-I gene known in the art.
  • the isolated mutant HSV-I strain contains inactivating mutations in a gene encoding a gE protein, a Us7 gene, and a Us9 gene. In another embodiment, an isolated mutant HSV-I strain as described in the methods and compositions of the present invention further comprises an additional mutation in a gene encoding a gD protein.
  • the present invention provides an isolated mutant HSV-2 strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation.
  • the gene encoding a gE protein is a Us8 gene.
  • the mutation is a gE-null mutation.
  • an isolated mutant HSV-2 strain as described in the methods and compositions of the present invention further comprises one or more additional mutations, which in one embodiment are inactivating mutations.
  • the second or additional inactivating mutation is in a Us7 gene.
  • the second or additional inactivating mutation is in a Us9 gene.
  • the second inactivating mutation is in any gene which confers neurovirulence. In another embodiment, the second inactivating mutation is in any gene required for virus entry into a host cell. In another embodiment, the second inactivating mutation is in a host shut-off gene. In another embodiment, the second inactivating mutation is in the thymidine kinase gene. In another embodiment, the second inactivating mutation is in any other HSV-2 gene known in the art. In another embodiment, the isolated mutant HSV-2 strain contains inactivating mutations in a gene encoding a gE protein, a Us7 gene, and a Us9 gene. In another embodiment, an isolated mutant HSV-2 strain as described in the methods and compositions of the present invention further comprises an additional mutation in a gene encoding a gD protein.
  • the Us7 gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the Us7 gene that is mutated is required for anterograde spread of the virus. In another embodiment, the Us7 gene that is mutated is required for retrograde spread of the virus. P-9066-PC
  • the Us9 gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the Us9 gene that is mutated is required for anterograde spread of the virus. In another embodiment, the Us9 gene that is mutated is required for retrograde spread of the virus.
  • the mutation in Us7 and/or Us9 is an inactivating mutation.
  • the mutation is a deletion mutation.
  • the mutation is an insertion mutation.
  • the mutation is a substitution mutation.
  • the mutation is any other type of mutation known in the art.
  • the additional gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the additional gene that is mutated is required for anterograde spread of the virus. In another embodiment, the additional gene that is mutated is required for retrograde spread of the virus.
  • the additional gene that is mutated is a virion membrane protein.
  • the additional gene is a virion membrane protein not required, or non-essential, for virus entry.
  • the membrane protein is a glycoprotein.
  • the additional gene is glycoprotein J.
  • the additional gene is glycoprotein G.
  • the additional gene is glycoprotein K.
  • the additional gene is glycoprotein M.
  • the additional gene is selected from glycoproteins J, G, K, and M.
  • “Anterograde” refers, in one embodiment, to spread from ganglia to skin. In another embodiment, the term refers to spread from the cell body towards the axon. In another embodiment, the term refers to any other definition accepted in the art.
  • “Retrograde” refers, in one embodiment, to spread from the site of infection to ganglia. In another embodiment, the term refers to spread from the axon towards the cell body. In another embodiment, the term refers to any other definition accepted in the art.
  • the additional mutation is introduced to enhance inhibition of anterograde spread of the mutant HSV-I strain.
  • the additional mutation is required, in combination with a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-I strain.
  • the gE mutation is insufficient to confer inhibition of anterograde spread of the mutant HSV-I strain.
  • the additional mutation is sufficient, in the absence of a gE mutation, to confer inhibition of anterograde spread of the mutant HSV- 1 strain.
  • the additional mutation is introduced to enhance inhibition of anterograde spread of the mutant HSV-2 strain.
  • the additional mutation is P-9066-PC required, in combination with a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-2 strain.
  • the gE mutation is insufficient to confer inhibition of anterograde spread of the mutant HSV-2 strain.
  • the additional mutation is sufficient, in the absence of a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-2 strain.
  • the additional mutation is introduced to enhance attenuation of virulence in the HSV-I or HSV-2 strain or both.
  • the additional mutation is required, in combination with a gE mutation, to attenuate virulence.
  • the additional gene that is mutated is a virion membrane protein.
  • the additional gene is a virion membrane protein required for virus entry.
  • the additional gene is glycoprotein B.
  • the additional gene is glycoprotein D.
  • the additional gene is glycoprotein H.
  • the additional gene is glycoprotein L.
  • the mutant HSV strain as described in the methods and compositions of the present invention is replication-competent in skin tissue of the subject.
  • the mutant strain is replication-competent in skin cell of the subject.
  • the mutant strain is replication-competent in skin tissue of the species to which the subject belongs.
  • the mutant strain is replication-competent in a cell line derived from skin tissue of the subject's species.
  • the mutant strain is replication-competent in a culture of skin cells of the subject's species.
  • the mutant strain is replication-competent in a cell line derived from a skin cell of the subject's species.
  • Replication competent refers, in one embodiment, to an ability to replicate. In another embodiment, the term includes strains that exhibit impaired but still detectable levels of replication. In another embodiment, the term refers to a strain that exhibits measurable replication.
  • the mutant HSV strain as described in the methods and compositions of the present invention is defective in its ability to spread from the site of inoculation to the dorsal root ganglia (DRG).
  • the dorsal root ganglia contain the neuron cell bodies of nerve fibres.
  • the mutant HSV strain is defective in retrograde spread.
  • the mutant HSV strain is impaired in retrograde spread.
  • the mutant HSV strain is significantly impaired in retrograde spread.
  • the mutant HSV strain is impaired in retrograde spread but is replication-competent in skin.
  • the mutant HSV strain as described in the methods and compositions of the present invention is defective in spread from DRG to the skin.
  • the mutant HSV strain is defective in anterograde spread.
  • the mutant HSV strain is impaired P-9066-PC in anterograde spread.
  • the mutant HSV strain is significantly impaired in anterograde spread.
  • the mutant HSV strain is impaired in anterograde spread but is replication-competent in skin.
  • DRG refers, in one embodiment, to a neuronal cell body. In another embodiment, the term refers to any other definition of "DRG" used in the art.
  • Flare or “recurrence” refers, in one embodiment, to reinfection of skin tissue following latent neuronal HSV infection. In another embodiment, the terms refer to reactivation of HSV after a latency period. In another embodiment, the terms refer to symptomatic HSV lesions following a non- symptomatic latency period.
  • a mutant HSV strain of the present invention is replication-defective, either in a particular tissue or in general (e.g. in neural tissue).
  • Methods for measuring viral replication include, in one embodiment, titering assays of tissue samples near a site of inoculation (Examples herein). In another embodiment, recovery of infectious virus from tissues near a site of inoculation is utilized (Examples herein).
  • Other embodiments as described in the methods for measuring viral replication are described, for example, in Thi TN et al. (Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR. Antiviral Res.
  • a mutant strain as described in the methods and compositions of the present invention is impaired in its spread in neural tissue of the subject.
  • the mutant strain is impaired in its spread in a culture of neural cells of the subject.
  • the mutant strain is impaired in its spread in neural tissue of the species to which the subject belongs.
  • the mutant strain is impaired in its spread in a cell line derived from neural tissue of the subject's species.
  • the mutant strain is impaired in its spread in a culture of neural cells of the subject's species.
  • the mutant strain is impaired in its spread in a cell line derived from a neural cell of the subject's species.
  • a mutant strain as described in the methods and compositions of the present invention is impaired in its ability to enter neural tissue of the subject.
  • the mutant strain is impaired in its ability to enter a culture of neural cells of the subject.
  • the mutant strain is impaired in its ability to enter neural tissue of the species to which the subject belongs.
  • the mutant strain is impaired in its ability to enter a cell line P-9066-PC derived from neural tissue of the subject's species.
  • the mutant strain is impaired in its ability to enter a culture of neural cells of the subject's species.
  • the mutant strain is impaired in its ability to enter a cell line derived from a neural cell of the subject's species.
  • the mutant HSV strain as described in the methods and compositions of the present invention induces an anti-HSV immune response.
  • the immune response impedes replication of the HSV in the subject.
  • the immune response impedes neuronal spread of the HSV in the subject.
  • the immune response results in killing of HSV-infected cells in the subject.
  • the mutant HSV strain as described in the methods and compositions of the present invention is a mutant HSV-I strain.
  • the mutant HSV-I strain confers protection against an HSV-I infection, spread, or a consequence thereof (e.g. zosteriform lesions or herpetic ocular disease).
  • the mutant HSV strain is a mutant HSV-2 strain.
  • the mutant HSV-2 strain confers protection against an HSV-2 infection, spread, or a consequence thereof (e.g. zosteriform lesions or herpetic ocular disease).
  • the mutant HSV strain is any other mutant HSV strain known in the art.
  • a mutant HSV-I strain of the present invention protects a subject against infection and disorders and symptoms associated with infection with wild-type HSV-I.
  • the disorders and symptoms include herpes labialis (cold sores or fever blisters).
  • the disorders and symptoms include HSV-mediated cornea disease.
  • the disorders and symptoms include herpes-mediated retinitis.
  • the disorders and symptoms include herpes-mediated encephalitis.
  • the disorders and symptoms include HSV-1-mediated genital ulcer disease.
  • a mutant HSV-I strain of the present invention provides substantial protection against HSV-I infection and partial protection against one or more symptoms associated with HSV-2 infection. In another embodiment, these HSV-2 symptoms include the symptoms described hereinabove.
  • the disorders and symptoms include HSV infections in an immunocompromised subject, including subjects with HIV.
  • a mutant HSV-I strain of the present invention prevents or inhibits transmission of genital HSV-I from a vaccinated mother to her newborn infant.
  • a mutant HSV strain of the present invention treats, suppresses, prevents or inhibits HSV in elderly subjects.
  • a mutant HSV-2 strain of the present invention protects a subject against infection and disorders and symptoms associated with infection with wild-type HSV-2.
  • the mutant HSV-2 strain prevents or inhibits transmission of genital HSV-2 from the vaccinated mother to her newborn infant.
  • the mutant HSV-2 strain prevents or P-9066-PC inhibits genital ulcer disease.
  • the mutant HSV-2 strain provides substantial protection against both HSV-2 and HSV-I infection.
  • the infection is an
  • the infection is an HSV-2 infection.
  • the vaccine strain is from a different species from the strain against which protection is conferred ("challenge strain"). In another embodiment, the vaccine strain is of the same species as the challenge strain.
  • a vaccine as described in the methods and compositions of the present invention protects a subject against a challenge with heterologous HSV.
  • the heterologous challenge is a different strain of the same species.
  • the vaccine confers protection against a heterologous HSV-I strain.
  • the vaccine confers protection against a heterologous HSV-2 strain.
  • the heterologous strain has an antigenic protein that is significantly heterologous relative to the vaccine strain.
  • the antigenic protein is gD.
  • the antigenic protein is gB.
  • the antigenic protein is any other antigenic protein known in the art.
  • the heterologous strain has a gD protein that is significantly heterologous relative to the vaccine strain.
  • the gD protein of the heterologous strain shares 50% homology with the vaccine strain.
  • the homology shared between the gD protein of the heterologous strain and the vaccine strain is 55%.
  • the homology shared is 60%.
  • the homology shared is 65%.
  • the homology shared is 70%.
  • the homology shared is 75%.
  • the homology shared is 80%.
  • the homology shared is 85%.
  • the homology shared is 90%.
  • the homology shared is 95%.
  • the homology shared is 98%.
  • the homology shared is greater than 98%.
  • the heterologous strain has a gB protein that is significantly heterologous relative to the vaccine strain.
  • the gB protein of the heterologous strain shares 50% homology with the vaccine strain.
  • the homology shared between the gB protein of the heterologous strain and the vaccine strain is 55%.
  • the homology shared is 60%.
  • the homology shared is 65%.
  • the homology shared is 70%.
  • the homology shared is 75%.
  • the homology shared is 80%.
  • the homology shared is 85%.
  • the homology shared is 90%.
  • the homology shared is P-9066-PC
  • the homology shared is 98%. In another embodiment, the homology shared is greater than 98%.
  • the heterologous challenge strain is HSV-I NS. In another embodiment, the heterologous challenge strain is HSV-I(F). In another embodiment, the heterologous challenge strain is HSV-I (17). In another embodiment, the heterologous challenge strain is any other HSV-I strain known in the art.
  • the heterologous challenge strain is HSV-2(2.12). In another embodiment, the heterologous challenge strain is any other HSV-2 strain known in the art.
  • the heterologous challenge strain is a different HSV species.
  • the vaccine confers protection against HSV-2 challenge.
  • the vaccine confers protection against HSV-I challenge.
  • a vaccine as described in the methods and compositions of the present invention protects a subject against a challenge with a large inoculum of HSV.
  • the large inoculum is 10 6 plaque-forming units (pfu).
  • the inoculum is 1.5 x 10 6 pfu.
  • the inoculum is 2 x 10 6 pfu.
  • the inoculum is 3 x 10 6 pfu.
  • the inoculum is 4 x 10 6 pfu.
  • the inoculum is 5 x 10 6 pfu.
  • the inoculum is 7 x 10 6 pfu.
  • the inoculum is 1 x 10 7 pfu. In another embodiment, the inoculum is 1.5 x 10 7 pfu. In another embodiment, the inoculum is 2 x IO 7 pfu. In another embodiment, the inoculum is 3 x 10 7 pfu. In another embodiment, the inoculum is 4 x 10 pfu. In another embodiment, the inoculum is 5 x 10 7 pfu. In another embodiment, the inoculum is 7 x 10 7 pfu. In another embodiment, the inoculum is 10 s pfu. In another embodiment, the inoculum is 10 3 - 10 6 pfu.
  • the inoculum is 10 3 -10 5 pfu. In another embodiment, the inoculum is 10 4 -10 6 pfu. In another embodiment, the inoculum is 3 x 10 4 - 3 x 10 6 pfu. In another embodiment, the inoculum is I ⁇ 4 -10 7 pfu. In another embodiment, the inoculum is 3 x 10 4 - 3 x 10 7 pfu. In another embodiment, the inoculum is 10 5 -10 8 pfu. In another embodiment, the inoculum is 3 x 10 5 -3 x 10 8 pfu. In another embodiment, the inoculum is more than 10 8 pfu.
  • a vaccine as described in the methods and compositions of the present invention exhibits enhanced safety relative to gE-containing HSV vaccine strains, due to its inability to infect the ganglia.
  • a method of the present invention exhibits enhanced safety relative to gE-containing HSV vaccine strains, due to its inability to spread in neurons.
  • the dosage is 10 3 pfu. In another P-9066-PC embodiment, the dosage is 2 x 10 3 pfu. In another embodiment, the dosage is 3 x 10 3 pfu. In another embodiment, the dosage is 5 x 10 3 pfu. In another embodiment, the dosage is 1O 4 pfu. In another embodiment, the dosage is 1.5 x 10 4 pfu. In another embodiment, the dosage is 10 4 pfu. In another embodiment, the dosage is 2 x 10 4 pfu. In another embodiment, the dosage is 3 x 10 4 pfu.
  • the dosage is 5 x 10 4 pfu. In another embodiment, the dosage is 7 x 10 4 pfu. In another embodiment, the dosage is 10 s pfu. In another embodiment, the dosage is 2 x 10 s pfu. In another embodiment, the dosage is 3 x 10 5 pfu. In another embodiment, the dosage is 5 x 10 5 pfu. In another embodiment, the dosage is 7 x 10 5 pfu. In another embodiment, the dosage is 1O 6 pfu. In another embodiment, the dosage is 2 x 10 5 pfu. In another embodiment, the dosage is 3 x 10 6 pfu. In another embodiment, the dosage is 5 x 10 5 pfu.
  • the dosage is 7 x 10 6 pfu. In another embodiment, the dosage is 10 7 pfu. In another embodiment, the dosage is 2 x 10 7 pfu. In another embodiment, the dosage is 3 x 10 7 pfu. In another embodiment, the dosage is 5 x 10 7 pfu. In another embodiment, the dosage is 7 x 10 7 pfu. In another embodiment, the dosage is 10 8 pfu. In another embodiment, the dosage is 2 x 10 s pfu. In another embodiment, the dosage is 3 x 10 s pfu. In another embodiment, the dosage is 5 x 10 8 pfu. In another embodiment, the dosage is 7 x 10 8 pfu.
  • the dosage is 10 3 pfu/dose. In another embodiment, the dosage is 2 x
  • the dosage is 10 3 pfu dose. In another embodiment, the dosage is 3 x 10 3 pfu/dose. In another embodiment, the dosage is 5 x 10 3 pfu/dose. In another embodiment, the dosage is 10 4 pfu/dose. In another embodiment, the dosage is 1.5 x 10 4 pfu/dose. In another embodi ment, the dosage is 10 4 pfu/dose. In another embodiment, the dosage is 2 x 10 4 pfu/dose. In another embodiment, the dosage is 3 x 10 4 pfu/dose. In another embodiment, the dosage is 5 x 10 4 pfu/dose. In another embodiment, the dosage is 7 x I O 4 pfu/dose.
  • the dosage is 10 5 pfu/dose. In another embodiment, the dosage is 2 x 10 5 pfu/dose. In another embodiment, the dosage is 3 x 10 s pfu/dose. In another embodiment, the dosage is 5 x 10 3 pfu/dose. In another embodiment, the dosage is 7 x 10 s pfu/dose. In another embodiment, the dosage is 10 6 pfu/dose. In another embodiment, the dosage is 2 x 10 6 pfu/dose. In another embodiment, the dosage is 3 x 10 6 pfu/dose. In another embodiment, the dosage is 5 x 10 6 pfu/dose. In another embodiment, the dosage is 7 x 10 6 pfu/dose.
  • the dosage is 10 7 pfu/dose. In another embodiment, the dosage is 2 x 10 7 pfu/dose. In another embodiment, the dosage is 3 x 10 7 pfu/dose. In another embodiment, the dosage is 5 x
  • the dosage is 7 x 10 7 pfu/dose. In another embodiment, the dosage is
  • the dosage is 2 x 10 8 pfu/dose. In another embodiment, the dosage is 3 x 10 s pfu/dose. In another embodiment, the dosage is 5 x 10 s pfu/dose. In another embodiment, the dosage is 7 x 10 s pfu/dose. In another embodiment, the dose is more than 10 8 pfu. In another embodiment, the dose is 10 3 -10 6 pfu. In another embodiment, the dose is 10 3 - 10 5 pfu. In another embodiment, the dose is 10 -10 pfu. In another embodiment, the dose is 3 x 10 4 - 3 x 10 6 pfu.
  • the dose is 10 4 - 10 7 pfu. In another embodiment, the dose is 3 x 10 4 - 3 x 10 7 pfu. In another embodiment, the dose is 10 5 -10 8 pfu. In another embodiment, the dose is 3 x 10 5 -3 x 10 8 pfu. P-9066-PC
  • treating refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove.
  • treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing, the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof.
  • "treating” refers inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof.
  • preventing refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof.
  • “suppressing” or “inhibiting” refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
  • symptoms are primary, while in another embodiment, symptoms are secondary.
  • primary refers to a symptom that is a direct result of the subject viral infection
  • secondary refers to a symptom that is derived from or consequent to a primary cause.
  • compositions and strains for use in the present invention treat primary or secondary symptoms or secondary complications related to HSV infection.
  • symptoms may be any manifestation of a HSV infection, comprising blisters, ulcerations, or lesions on the urethra, cervix, upper thigh, and/or anus in women and on the penis, urethra, scrotum, upper thigh, and anus in men, inflammation, swelling, fever, flu-like symptoms, sore mouth, sore throat, pharyngitis, pain, blisters on tongue, mouth or lips, ulcers, cold sores, neck pain, enlarged lymph nodes, reddening, bleeding, itching, dysuria, headache, muscle pain, etc., or a combination thereof.
  • the gE protein as described in the methods and compositions of the present invention has, in one embodiment, the sequence:
  • the gE protein is a homologue of SEQ BD No: 2.
  • the gE protein is a variant of SEQ ID No: 2.
  • the gE protein is an isomer of SEQ BD No: 2.
  • the gE protein is a fragment of SEQ ID No: 2.
  • the gE protein comprises SEQ ID No: 2.
  • the gE protein is encoded by a nucleotide sequence having the sequence: atggatcgcggggcggtggtggtggttttctcggtgtttgtgttgtatcgtgcttggcgggaacgcccaaaacgtcctggagacgggtgagtgtcg gcgaggacgtttcgttccagctccggggcctacggggcgcggccgacccagaaactactatgggccgtggaacccctggatgggtgcgg cccgacccagaaactactatgggccgtggaacccctggatgggtgcgg cccttacacccgtcgtgggtctcgctgatgccccccaagcaggtgcccgagacggtcgtggatgcggcgtgcatg
  • the gE protein is encoded by a nucleotide molecule that a homologue of SEQ ED No: 3.
  • the nucleotide molecule is a variant of SEQ ID No: 3.
  • the nucleotide molecule is an isomer of SEQ ID No: .3.
  • the nucleotide molecule is a fragment of SEQ ID No: 3.
  • the nucleotide molecule comprises SEQ ID No: 3.
  • the gE protein as described in the methods and compositions of the present invention has the sequence:
  • the gE protein is a homologue of SEQ ID No: 4. In another embodiment, the gE protein is a variant of SEQ ID No: 4. In another embodiment, the gE protein is an isomer of SEQ ID No: 4. In another embodiment, the gE protein is a fragment of SEQ ID No: 4. In another embodiment, the gE protein comprises SEQ ID No: 4.
  • the gE protein is encoded by a nucleotide sequence having the sequence:
  • the gE protein is encoded by a nucleotide molecule that a homologue of SEQ ED No: 5.
  • the nucleotide molecule is a variant of SEQ ID No: 5.
  • the nucleotide molecule is an isomer of SEQ ID No: 5.
  • the nucleotide molecule is a fragment of SEQ ID No: 5.
  • the nucleotide molecule comprises SEQ ID No: 5.
  • the gE protein as described in the methods and compositions of the present invention has the sequence:
  • the gE protein is a homologue of SEQ BD No: 6. In another embodiment, the gE protein is a variant of SEQ ID No: 6. In another embodiment, the gE protein is an isomer of SEQ ID No: 6. In another embodiment, the gE protein is a fragment of SEQ ID No: 6. In another embodiment, the gE protein comprises SEQ ID No: 6.
  • the gE protein is encoded by a nucleotide sequence having the sequence:
  • the gE protein is encoded by a nucleotide P-9066-PC molecule that a homologue of SEQ ID No: 7.
  • the nucleotide molecule is a variant of SEQ ID No: 7.
  • the nucleotide molecule is an isomer of SEQ ID No: 7.
  • the nucleotide molecule is a fragment of SEQ ID No: 7.
  • the nucleotide molecule comprises SEQ ID No: 7.
  • the gE protein is encoded by one of the following GenBank Accession
  • the gE protein is homologous to a sequence disclosed in one of the above GenBank Accession Numbers.
  • the gE protein is a variant of a sequence disclosed in one of the above GenBank Accession Numbers.
  • the gE protein is a fragment of a sequence disclosed in one of the above GenBank Accession Numbers.
  • a gE protein HSV-I glycoprotein E is a virion surface protein which is necessary for spread in neurons, and in one embodiment, is necessary for spread along axons in either direction, both to ("retrograde"), and from ("anterograde”), the neuronal cell body.
  • gE also facilitates evasion of the host immune system by sequestering host antibodies against HSV-I, rendering them inactive.
  • a gE-deleted HSV-I replicates in the skin, but cannot spread along neurons to establish latency or escape the host's antibody response.
  • infection with the live attenuated gE-deleted HSV-I or HSV-2 will elicit a robust immune response in the skin and protect the host from future encounters with the wild-type virus.
  • the gE protein is a HSV-I gE protein. In another embodiment, the gE protein is a HSV-I (NS) gE protein. In another embodiment, the gE protein is a HSV-1(17) gE protein. In another embodiment, the gE protein is a HSV-I (F) gE protein. In another embodiment, the gE protein is a HSV-I(KOS) gE protein. In another embodiment, the gE protein is a HSV-I(CLlOl) gE protein. In another embodiment, the gE protein is a HS V- 1 (Maclntyre) gE protein.
  • the gE protein is a HSV-I(MP) gE protein. In another embodiment, the gE protein is a HSV-l(17+syn) gE protein. In another embodiment, the gE protein is a HSV-I(HF) gE protein. In another embodiment, the gE protein is any other HSV-I gE protein known in the art.
  • the gE protein is a HSV-2 gE protein. In another embodiment, the gE protein is a HSV-2(HG52) gE protein. In another embodiment, the gE protein is a HSV-2(2.12) gE protein. In another embodiment, the gE protein is a HSV-2(MS) gE protein. In another embodiment, the gE protein is a HSV-2(186) gE protein. In another embodiment, the gE protein is a HSV-2(G) gE protein. In another embodiment, the gE protein is any other HSV-2 gE protein known in the art.
  • the gE protein is any other HSV-I or HSV-2 gE protein which in one embodiment has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology P-9066-PC to one of the gE proteins or nucleic acid sequences listed hereinabove.
  • the gE protein has 98.6 % homology to HSV(NS) or HSV(17), or both.
  • the gE protein is any other gE protein known in the art.
  • the gE protein is encoded by any Us8 nucleotide known in the art.
  • the Us8 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703448 or GenelD: 1487360, or encodes a protein sequence of glycoprotein E, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044670.1 or NP_044538.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us6 gene.
  • the Us6 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703444, GenelD: 1487358, NC_001806, NC_001798, EU029158, EF177451, EF177450, EF157322, EF157321, EF157320, EF157319, Z86099, AJ004801, X14112, AF147806, AY779754, AY779753, AY779752, AY779751, AY779750, AY517492, AY155225, AB016432, AF021342, U12183, U12182, U12181, U12180, or InterPro:IPR002896, or encodes a protein sequence of glycoprotein D, which in one embodiment
  • the gD protein is any other HSV-I or HSV-2 gD protein which in one embodiment has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology to one of the gD proteins or nucleic acid sequences listed hereinabove.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us9 gene.
  • the Us9 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneBD:2703452 or GenelD: 1487362, or encodes a protein sequence of Us9 membrane protein, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044672.1 or NP_044540.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us5 gene.
  • the Us5 gene has a nucleic acid sequence that corresponds to that set forth in P-9066-PC
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us4 gene.
  • the Us4 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneDZ>:2703404 or GenelD: 1487356, or encodes a protein sequence of glycoprotein G, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: • NP_044666.1 or NP_044534.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in. one embodiment, is an inactivation of the UL53 gene.
  • the UL53 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703425 or GenelD: 1487342, or encodes a protein sequence of glycoprotein K, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044656.1 or NP_044524.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the ULlO gene.
  • the ULl 0 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703379 or GenelD: 1487293, or encodes a protein sequence of glycoprotein M, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044611.1 or NP_044479.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the ULl gene.
  • the ULl gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703393 or GenelD: 1487292, or encodes a protein sequence of glycoprotein L, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044602.1 or NP_044470.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL22 gene.
  • the UL22 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703373 or GenelD: 1487306, or encodes a protein sequence of glycoprotein H, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044623.1 or NP_044491.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL27 gene.
  • the UL27 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703455 or GenelD: 1487312, or encodes a protein sequence of glycoprotein B, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044629.1 or NP_044497.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL44 gene.
  • the UL44 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703410 or GenelD: 1487331, or encodes a protein sequence of glycoprotein C, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044646.1 or NP_044514.1.
  • the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL49a ' gene.
  • the UL49a gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703419 or GenelD: 1487337, or encodes a protein sequence of glycoprotein N, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044652.1 or NP_044520.1.
  • the additional mutation is in an HSV-I or HSV-2 glycoprotein that, in one embodiment, has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology to one or more of the glycoproteins listed hereinabove.
  • HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gD, which in one embodiment is Us6.
  • HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gE, which in one embodiment is Us8.
  • HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gE and in a gene encoding gD.
  • the Us6 mutation is introduced to attenuate an HSV strain comprising a Us8 mutation that is highly virulent.
  • the Us6 mutation reduces virus entry.
  • HSV-I gD and HSV-2 gD have a large degree of homology.
  • the amino acid sequences of HSV-I gD and HSV-2 gD have 81% homology, or in another embodiment, greater than 80% homology, or in another embodiment, greater than 85% homology, or in another embodiment, greater than 90% homology, or in another embodiment, greater than 95% homology.
  • the P-9066-PC nucleic acid sequences of HSV-I gD and HSV-2 gD have 85% homology, or in another embodiment, greater than 80% homology, or in another embodiment, greater than 85% homology, or in another embodiment, greater than 90% homology, or in another embodiment, greater than 95% homology.
  • the gD protein derived of the methods and compositions of the present invention has the sequence:
  • the gD protein is a homologue of SEQ ID No: 14.
  • the gD protein is a variant of SEQ ID No: 14.
  • the gD protein is an isomer of SEQ ED No: 14.
  • the gD protein is a fragment of SEQ ID No: 14.
  • the gD protein comprises SEQ ID No: 14.
  • the gD amino acid sequence is an HSV-I amino acid sequence.
  • the gD protein is encoded by a nucleotide sequence having the sequence:
  • the gD protein is encoded by a nucleotide molecule that a homologue of SEQ ID No: 15.
  • the nucleotide molecule is a variant of SEQ ID No: 15.
  • the nucleotide molecule is an isomer of SEQ ID No: 15.
  • the nucleotide molecule is a fragment of SEQ ID No: 15.
  • the nucleotide molecule comprises SEQ ID No: 15.
  • the gD nucleotide sequence is an HSV-I nucleotide sequence.
  • the gD protein as described in the methods and compositions of the present invention has the sequence:
  • the gD protein is a homologue of SEQ ID No: 16. In another embodiment, the gD protein is a variant of SEQ ID No: 16. In another embodiment, the gD protein is an isomer of SEQ DD No: 16. In another embodiment, the gD protein is a fragment of SEQ ED No: 16. In another embodiment, the gD protein comprises SEQ DD No: 16. In one embodiment, the gD amino acid sequence is an HSV-2 amino acid sequence.
  • the gD protein is encoded by a nucleotide sequence having the sequence:
  • the gD protein is encoded by a nucleotide molecule that a homologue of SEQ ID No: 17.
  • the nucleotide molecule is a variant of SEQ ID No: 17.
  • the nucleotide molecule is an isomer of SEQ ID No: 17.
  • the nucleotide molecule is a fragment of SEQ ID No: 17.
  • the nucleotide molecule comprises SEQ ED No: 17.
  • the gD nucleic acid sequence is an HSV-2 nucleic acid sequence.
  • an inactivating mutation in a gene encoding gD comprises a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C).
  • an inactivating mutation in a gene encoding gD comprises a mutation in which an alanine at residue 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C), a tyrosine at residue 2 to alanine (Y2A), a leucine at residue 4 to alanine (WA), or a combination thereof.
  • an inactivating mutation in a gene encoding gD comprises a deletion of the alanine at residue 3 of HSV-I gD or HSV-2 gD, a deletion of the tyrosine at residue 2, a deletion of leucine at residue 4, or a combination thereof.
  • an inactivating mutation in a gene encoding gD comprises a mutation at amino acid positions 38, 222, 223, 215, or a combination thereof.
  • an inactivating mutation in a gene encoding gD comprises a Y38C mutation, while in another embodiment, it comprises a R222N, F223I, D215G mutation, or combination thereof.
  • an inactivating mutation in a gene encoding gD comprises mutations in amino acids 2 and 3, 3 and 4, 2-4, 1-5, 1-7, or 1-10.
  • an inactivating mutation in a gene encoding gD consists essentially of a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C).
  • an inactivating mutation in a gene encoding gD consists of a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C).
  • the numbering used to describe the location of the mutation refers to amino acid numbering of the mature peptide after cleaving of the signal sequence, which in one embodiment, is the first 25 amino acids for HSV-I or HSV-2 gD, as is known in the art.
  • a mutant HSV strain of the present invention comprising a mutation in gD has reduced virulence (Example 21) and ability to reach DRG (Example 22).
  • vaccination with a mutant HSV strain comprising a mutation in gD of the present invention protects against latent HSV infection (Example 23) after subsequent infection with virulent HSV.
  • the vaccination protects against disease caused by or associated with latent HSV infection.
  • the vaccination does not itself cause significant disease.
  • any of the mutant HSV strains of and for use in the methods of this invention will comprise an inactivating mutation of the present invention, in any form or embodiment as described herein.
  • any of the mutant HSV strains of this invention will consist of an P-9066-PC inactivating mutation of the present invention, in any form or embodiment as described herein.
  • the mutant HSV strains of this invention will consist essentially of an inactivating mutation of the present invention, in any form or embodiment as described herein.
  • the term "comprise” refers to the inclusion of the inactivating mutation, such as a mutation in gE or in gD, as well as inclusion of other mutations that may be known in the art.
  • the term “consisting essentially of” refers to a strain, whose only functional mutation is the indicated functional mutation, however, other mutations may be included that are not involved directly in the utility of the strain. In some embodiments, the term “consisting” refers to a strain, which contains mutation of a particular gene or a particular mutation.
  • plasmid complementation may be used to complement the inactivating mutation, which in one embodiment, allows at least one round of infection with a mutant HSV of the invention.
  • the present invention provides a composition for impeding formation of zosteriform lesions in a subject, the composition comprising a mutant HSV strain of the present invention.
  • the present invention provides a composition for impeding herpetic ocular disease in a subject, the composition comprising a mutant HSV strain of the present invention.
  • the present invention provides a composition for vaccinating a subject against an HSV infection, the composition comprising a mutant HSV strain of the present invention.
  • the present invention provides a composition for impeding HSV infection in a subject, the composition comprising a mutant HSV strain of the present invention.
  • the present invention provides a composition for impeding herpes- mediated encephalitis in a subject, the composition comprising a mutant HSV strain of the present invention.
  • a gE protein of the present invention is homologous to a peptide disclosed or enumerated herein.
  • Homology is, in one embodiment, determined by computer algorithm for sequence alignment, by methods well described in the art.
  • computer algorithm analysis of nucleic acid P-9066-PC sequence homology can include the utilization of any number of software packages available, such as, for example, the BLAST, DOMAIN, BEAUTY (BLAST Enhanced Alignment Utility), GENPEPT and TREMBL packages.
  • “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 70%. In another embodiment, “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 72%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 75%. In another embodiment, “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 78%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 80%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 82%.
  • “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 83%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 85%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 87%. In another embodiment, “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 88%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 90%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 92%.
  • “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 93%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 95%. In another embodiment, “homology” refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 96%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 97%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 98%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of greater than 99%. In another embodiment, “homology” refers to identity to one of SEQ ID No: 2-7 of 100%.
  • homology is determined via determination of candidate sequence hybridization, methods of which are well described in the art (See, for example, “Nucleic Acid Hybridization” Hames BD and Higgins SJ, Eds. (1985); Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N. Y).
  • methods of hybridization are carried out under moderate to stringent conditions, to the complement of a DNA encoding a native caspase peptide.
  • Hybridization conditions being, for example, overnight incubation at 42°C in a solution comprising: 10-20 % formamide, 5 X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7. 6), 5 X Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA.
  • Protein and/or peptide homology for any AA sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer P-9066-PC algorithm analysis of AA sequences, utilizing any of a number of software packages available, via established methods. Some of these packages include the FASTA, BLAST, MPsrch or Scanps packages, and, in another embodiment, employ the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example.
  • variant refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants.
  • an isomer refers to one of any of two or more substances that are composed of the same elements in the same proportions but differ in chemical and/or bological properties because of differences in the arrangement of atoms, which in one embodiment are stereoisomers, in another embodiment, constitutional isomers or tautomers.
  • an isomer is an optical isomer or entantiomer, a geometric isomer, a D- and L- isomer, positional isomer, or a cis-trans isomer.
  • nucleic acids or “nucleotide” refers to a string of at least two base-sugar-phosphate combinations.
  • the term includes, in one embodiment, DNA and RNA.
  • Nucleotides refers, in one embodiment, to the monomelic units of nucleic acid polymers.
  • RNA is, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, small inhibitory RNA (siRNA), micro RNA (miRNA) and ribozymes.
  • DNA can be, in other embodiments, in form of plasmid DNA, viral DNA, linear DNA, or chromosomal DNA or derivatives of these groups.
  • these forms of DNA and RNA can be single-, double-, triple-, or quadruple-stranded.
  • the term also includes, in another embodiment, artificial nucleic acids that contain other types of backbones but the same bases.
  • the artificial nucleic acid is a PNA (peptide nucleic acid).
  • PNA contain peptide backbones and nucleotide bases and are able to bind, in one embodiment, to both DNA and RNA molecules.
  • the nucleotide is oxetane-modified.
  • the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond.
  • the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art. The use of phosphothiorate nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al.
  • the present invention provides a kit comprising a compound or P-9066-PC composition utilized in performing a method of the present invention.
  • the present invention provides a kit comprising a composition, tool, or instrument of the present invention.
  • Contacting in one embodiment, refers to directly contacting the target cell with a mutant
  • methods of the present invention include methods in which the subject is contacted with a mutant HSV strain which is brought in contact with the target cell by diffusion or any other active transport or passive transport process known in the art by which compounds circulate within the body.
  • the mutant HSV strain is carried in the subjects' bloodstream to the target cell. In another embodiment, the mutant HSV strain is carried by diffusion to the target cell. In another embodiment, the mutant HSV strain is carried by active transport to the target cell. In another embodiment, the mutant HSV strain is administered to the subject in such a way that it directly contacts the target cell.
  • the methods of the present invention comprise administering a pharmaceutical composition comprising the mutant HSV strain and a pharmaceutically acceptable carrier.
  • “Pharmaceutical composition” refers, in one embodiment, to a therapeutically effective amount of the active ingredient, i.e. the mutant HSV strain, together with a pharmaceutically acceptable carrier or diluent.
  • a “therapeutically effective amount” refers, in one embodiment, to that amount which provides a therapeutic effect for a given condition and administration regimen.
  • compositions containing the mutant HSV strain can be, in one embodiment, administered to a subject by any method known to a person skilled in the art, such as parenterally, transmucosally, transdermally, intramuscularly, intravenously, intra-dermally, subcutaneously, intra- peritonealy, intra-ventricularly, intra-cranially, intra-vaginally or intra-tumorally.
  • the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation.
  • Suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like.
  • Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
  • the active ingredient is fo ⁇ nulated in a capsule.
  • the compositions of the present invention comprise, in addition to the active compound and the inert carrier or diluent, a hard gelating capsule.
  • the pharmaceutical compositions are administered by intravenous, intraarterial, or intra-muscular injection of a liquid preparation.
  • suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
  • the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration.
  • the pharmaceutical compositions are administered intra-arterially and are thus formulated in a form suitable for intra-arteiial administration.
  • the pharmaceutical compositions are administered intra-muscularly and are thus formulated in a form suitable for intra-muscular administration.
  • the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration.
  • suitable topical formulations include gels, ointments, creams, lotions, drops and the like.
  • the mutant HSV strain is prepared and applied as a solution, suspension, or emulsion in a physiologically acceptable diluent with or without a pharmaceutical carrier.
  • the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the mutant HSV strain is released over a period of time after administration.
  • Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils).
  • the composition is an immediate-release composition, i.e. a composition in which all the mutant HSV strain is released immediately after administration.
  • Wild-type HSV-I strain NS a low-passage-number clinical isolate, was used for generation of mutant viruses.
  • HSV-l(gEnuii) the entire gE coding sequence was excised from ⁇ CMV3gE-l with Xbal and cloned into pSPT18.
  • pSPT18 has the sequence:
  • a 1.1-kb Hpal-BglH fragment from amino acids (AA) 124-508 was excised, and the Hpal site was changed to a BgIII site.
  • a 4.3-kb fragment derived from pD6P containing the Escherichia coli ⁇ - galactosidase gene ( ⁇ -gal) under the control of the HSV ICP6 promoter was cloned into the BgIII site.
  • the resultant vector contains 374 bp of NS DNA sequences 5" and 225 bp 3' of the ICP6::lacZ cassette and was used to construct the gE null virus.
  • the Xbal fragment containing the flanking sequence vector was isolated, and 750 ng was cotransfected into Vero cells with 1.0 ⁇ g of NS DNA by calcium phosphate transfection.
  • the DNA-calcium phosphate mixture was removed, and cells were shocked with 15% glycerol. Cells were harvested when cytopathic effects were noted in 30-40% of cells and were sonicated to prepare a virus pool.
  • Recombinant gE null virus expressing ⁇ -gal was selected by infecting Vero cells and overlaying with 0.5% agarose, 5.0% fetal bovine serum (FBS), and 300 ⁇ g of 5-bromo-D- P-9066-PC galactopyranoside (X-GaI). Blue plaques were picked and purified twice in X-GaI agarose overlay and once by limiting dilution. Virus was purified from supernatant fluids of infected Vero cells on a 5-70% sucrose gradient.
  • HSV-l(Rescue sE miii) was prepared by co-transfection of Vero cells with 1.0 ⁇ g of NS-gEnull DNA and 1.5 ⁇ g of wild-type gE fragment purified from ⁇ CMV3gE-l , which was obtained by digesting HSV-I (NS) DNA with Nrul. Progeny viruses were examined by immunoperoxidase staining using anti-gE MAb IBAlO to confirm expression of gE on the surface of infected cells. Plaques were purified by limiting dilution, and virus pools were prepared.
  • Virus stocks were grown on confluent Vero cells (an African green monkey kidney epithelial cell line) at an MOI of 2.0. 24 hours post-infection, cells were scraped in the media and centrifuged at 3,000 x g. All but 1 mL of supernatant was removed, and cells were resuspended, sonicated for 3 seconds and distributed into 50 mcL (microliter) aliquots. For mock infections, similar aliquots were made using uninfected cells.
  • mice were anesthetized via intraperitoneal injection of 75 mcL of 14.3 mg/ml ketamine and 1.8 mg/ml xylazine in PBS, then infected by making 60 superficial scratches in a 1 cm 2 area of the flank, 1 cm dorsal to the spine, with a 26 3/8-gauge needle through a 10 mcL droplet containing 5 x 10 3 — 5 x 10 5 pfu HSV ( Figure 1).
  • HSV flank-infected mice secondary spread back to the skin from the neurons of one or more spinal ganglia results in a belt-like lesion ( Figure 2).
  • Mice were sacrificed by asphyxiation with CO 2 , followed by cervical dislocation. Mice were observed at 24-hour intervals starting at day 3 post-inoculation to record the appearance and severity of skin lesions and illness.
  • a standardized scoring system to describe lesion severity was used to provide consistency in observations (Figure 3).
  • mice were infected by making scratches through the inoculum, containing either HSV- l(gE null) or virus-free cell lysate (described above), on the right flank. Mice were challenged 28 days later on the opposite (left) flank by scratching through a droplet containing 1 x 10 5 pfu HSV- 1 (NS).
  • DRG Dorsal root ganglia
  • a 1-cm 2 area of skin at the site of inoculation was removed.
  • Half of the sample was placed in a tube containing 110 mcL DMEM (2.5% FBS) and frozen at -80 0 C until analysis.
  • the other half was placed on an index card with like-samples and immersed in 4% paraformaldehyde in IX PBS for 24 hours at 4°C, then the solution was replaced with IX PBS. Samples remained at 4°C until processing for histological analysis.
  • mice Groups of five mice were flank-infected by scarification of 10 3 " 5 , 10 4 S , or 10 5 ' 5 plaque-forming units (pfu) of the vaccine strain, HSV-I ( gE n uii)-
  • HSV-I gE n uii
  • another group of five mice was flank-infected with 10 5 ' 5 pfu of HSV-I (Rescu ⁇ gE nu n), the vaccine strain backbone with the gene encoding gE restored.
  • HSV-l(R esc ue gE nuii) infection resulted in illness and 60% mortality ( Figure 4). However, no clinical signs of disease, illness or death occurred following HSV-I (SE nu ⁇ i) vaccination.
  • HSV-l RescuC gE nu n
  • HSV-I gE null
  • HSV-I R e s cue g E n uii
  • HSV-l R e s cue g E n uii
  • Figure 6 no secondary lesions were seen following HSV-l( g E null) infection. Since secondary lesion formation along the dermatome depends on the ability of the virus to spread along neurons from the skin to the ganglia, and then back again, these results show that the vaccine is not able to spread within sensory neurons. Therefore, HSV( gEn uii) is unable to cause recurrent infection.
  • HSV infection in the absence of gE is limited to the skin of the host, and the immune system is able to detect and clear the virus rapidly.
  • HSV-I HSV-I (g E nu ii) vaccinated mice were challenged with a lethal dose of 10 s pfu WT HSV-I (NS strain) 28 days after vaccination. Whereas 100% of mock- vaccinated mice died following challenge, 100% of HSV-l( gE n ui ⁇ r vacc i nate d mice survived the lethal challenge ( Figure 10). All tested doses of HSV-l (gE nuii) (10 35 , 10 4 ' 5 , and 10 5 ' 5 pfu) were protective against challenge.
  • mice had undetectable levels of challenge virus in skin, at least 5 orders of magnitude less than mock- vaccinated mice ( Figure 12).
  • DRG and skin samples were removed from mice immediately after sacrifice (at 1, 3, 6, 8 or 13 dpi). Three mice were infected for each data point, but like tissues from these mice were analyzed individually. Tissues were placed in 110 mcL DMEM containing 2.5% FBS and stored at -80 0 C until analysis. To determine viral titer, tissue was thawed and pulverized with a disposable pestle. Infectious virus in 50 mcL of the supernatant, serially diluted (1: 10, 1:100 and 1:1000), was quantified by plaque assay on confluent Vero cells in 12-well dishes.
  • DRG were removed from the same (right) side of infection with HSV-l( gE m iii). All DRG from an individual mouse were placed in one well of a 12- well dish of confluent Vero cells bathed in DMEM (2.5% FBS). Medium was changed every 2 days and cells were monitored for signs of CPE, an indication that DRG contained infectious virus.
  • DRG were removed from vaccinated mice, 28 days post-challenge, and explanted in order to reactivate latent challenge virus. Reactivation from associated neurons of only 1/15 of the vaccinated mice occurred upon removal ( Figure 16).
  • mice Female Balb/C mice, 6-8 weeks old, were acclimated to the animal facility for 10 days. Mice were anesthetized and shaved and hair was removed by Nair treatment of the right flank. The following day, anesthetized mice were mock-vaccinated or vaccinated with 5 x 10 5 pfu HSV-l ⁇ gE (which is referred to, in one embodiment, as gE null) by scratching 60 times through a 10 mcl (microliter) droplet of inoculum with a 26 (5/8)-gauge needle. The opposite flank (left side) of each mouse was shaved and denuded as before, twenty-seven days later.
  • 5 mcl microliter
  • HSV-l ⁇ gE-vaccinated mice were epidermally challenged with wild-type HSV-2. None of the HSV-l ⁇ gE vaccinated mice died, while 80% of mock vaccinated mice died ( Figure 17, top panel). Vaccinated mice exhibited inoculation site disease that healed rapidly compared to the unvaccinated mice ( Figure 17, middle panel). Additionally, vaccinated mice were completely protected from the zosteriform disease and death observed in the mock-vaccinated mice ( Figure 17, bottom panel).
  • ⁇ gE HSV vaccination is capable of protecting subjects against heterologous HSV disease, even of a different species of herpes simplex.
  • EXAMPLE 7 VACCINATION WITH HSV-l ⁇ gE PROTECTS AGAINST HSV-I(KOS) AND INHIBITS ESTABLISHMENT OF HSV-I LATENCY
  • Vaccination and assessment of disease were performed as described for the previous Example, except that 5 x 10 5 pfu HSV-I, strain KOS, was used for the challenge.
  • mice were sacrificed 41 d post-challenge, and DRG from both right and left sides were removed, placed in DMEM/10% FBS, minced with scissors, and explanted onto sub-confluent Vero cell monolayers. Cultures were monitored daily for 20 d for plaque formation, indicative of reactivation from latency.
  • HSV-l ⁇ gE vaccination tested the ability of HSV-l ⁇ gE vaccination to protect mice from the disease associated with a heterologous HSV-I wild-type strain.
  • HSV-l ⁇ gE vaccination protected HSV-I KOS- challenged mice completely against zosteriform disease ( Figure 18, middle panel). Since HSV-I KOS infection of mice is not lethal, this strain was utilized to compare viral reactivation from latency in mock- versus HSV-l ⁇ gE-vaccinated mice at 4 weeks post-challenge.
  • EXAMPLE 8 VACCINATION WITH HSV lAgE PROTECTS AGAINST HSV-I VAGINAL
  • Vaccination was performed as described for Example 6.
  • Medroxyprogesterone acetate (2 mg) (Sicor Pharmaceuticals, Inc., Irvine CA), diluted to 100 mcl total volume in a 0.9% NaCl/10 mM HEPES buffer, was injected subcutaneously 33 days later into the neck area of each ' mouse.
  • mice Five days later (day 38), mice were anesthetized, intra-vaginally swabbed with a calcium alginate swab dipped in PBS, and challenged by intra-vaginal instillation of 5 x 10 5 pfu HSV-I (strain NS). Mice were allowed to recover in their cages, resting in a prone position. Challenged mice were observed daily for vaginal disease and survival. Daily intra-vaginal swabs were taken for analysis by viral titering on Vera cells.
  • EXAMPLE 9 VACCINATION WITH HSV-l ⁇ gE BY EPIDERMAL, SUBCUTANEOUS, AND INTRAMUSCULAR ROUTES PROTECTS AGAINST HSV-I CHALLENGE
  • Vaccination was performed with 5 x 10 5 pfu HSV-l ⁇ gE by scratching 60 times through a 10 mcl droplet of inoculum with a 26 (5/8)-gauge needle, injection of 100 mcl inoculum into the scruff of the neck subcutaneously, or by intramuscular injection of 100 mcl inoculum into the right rear thigh muscle.
  • mice were sacrificed 32 days post-challenge, and DRG from both right and left sides were removed, placed in DMEM/10% FBS, minced with scissors and explanted P-9066-PC onto sub-confluent Vero cell monolayers. Cultures were monitored daily (for 15 days) for plaque formation, indicating reactivation from latency.
  • mice vaccinated by the subcutaneous route had several discrete zosteriform lesions, which were not severe and resolved quickly (Figure 20, bottom right panel).
  • the ability of the vaccine to prevent latent infection was measured.
  • HSV- l ⁇ gE vaccination by all routes protected against the establishment of latency (Table 1).
  • Mock-vaccinated mice showed 100% reactivation (Table 1 ; also see Figure 18).
  • HSV-l ⁇ gE administered by epidermal, intramuscular or subcutaneous routes each protects against acute disease, flares and latent disease by wild-type HSV challenge.
  • EXAMPLE IQ VACCINATION WITH HSV-l ⁇ gE BY EPIDERMAL SCARIFICATION. SUBCUTANEOUS INJECTION AND INTRAMUSCULAR INJECTION INDUCES
  • mice were vaccinated as described in the previous Example. On day 21, mice were bled through jugular veins. On day 28, the opposite flank (left side) of each mouse was shaved and denuded as before. Neutralization assays on serum samples were done by incubating 50 me] serum dilution (1 :10 to 1 :320) with 10 2 pfu HSV-I (NS) in 5 mcl for 1 hour at 37°C, and then inoculating Vero cell monolayers.
  • HSV-l ⁇ gE vaccination by the epidermal scarification, intramuscular, and P-9066-PC subcutaneous routes of administration for induction of neutralizing antibodies were measured.
  • EXAMPLE 11 VACCINATION WITHHSV-IAeE PROTECTS AGAINST FLANK CHALLENGE WITH VARIOUS HETEROLOGOUS HSV-I STRAINS
  • HSV-l ⁇ gE vaccination ability of HSV-l ⁇ gE vaccination to protect against heterologous, higher virulence wild-type HSV-I strains (F and 17) was measured; with vaccination and challenged performed as described for Example 7, except that challenge utilized various strains.
  • HSV-l ⁇ gE vaccination protected mice completely from death upon epidermal challenge with HSV-I(NS), HSV-I(F) and HSV-1(17) ( Figure 22, top panel). Vaccination also reduced inoculation site disease, although challenge with HSV-I(F) caused slightly more disease at the inoculation site than HSV-I(NS) or HSV- 1(17) ( Figure 22, middle panel).
  • HSV-l ⁇ gE vaccination completely protected all mice challenged with HSV-I(NS) and HSV- 1(17) from zosteriform disease and 2/3 mice challenged with HSV-I(F); the other mouse challenged with HSV-I(F) had two small zosteriform lesions ( Figure 22, bottom panel).
  • HSV-l ⁇ gE vaccination protects mice against various heterologous strains of HSV-I .
  • EXAMPLE 12 VACCINATION WITH HSV-l ⁇ gE PROTECTS AGAINST FLANK CHALLENGE WITH DOSES UP TO 1 X IQ 7 PFU OF HSV-IfNS)
  • HSV-l ⁇ gE vaccination The ability of HSV-l ⁇ gE vaccination to protect against higher doses of wild-type HSV-I was measured; with vaccination and challenged performed as described for Example 7, except that challenge utilized higher doses of 10 5 , 10 6 or 10 7 pfu of HSV-I(NS).
  • Vaccinated mice were all completely protected from death and zosteriform disease ( Figure 23, top and bottom panels).
  • Vaccinated mice challenged with 10 s pfu HSV-I(NS) exhibited inoculation site disease that was slightly more severe than mock-challenged mice, indicating that most of the disease was caused by the scarification (needle scratch).
  • Vera cells are cultured in Dulbecco's modified Eagle's medium containing heat- inactivated 10% newborn calf serum (Life Technologies, Gaithersburg, Md.) plus 50 micrograms (meg) of penicillin/ml, 50 mcg/ml of streptomycin/ml, and 0.15 mcg/ml of Fungizone® (Life Technologies) at P-9066-PC
  • Clarified stocks of HSV-2 strains are prepared from infected Vero monolayers and stored at -8O 0 C until used. Titers of virus are determined by standard plaque assays.
  • MCS pBluescript SK+ multiple cloning site
  • HSV-2 virus (10 4 pfu) is instilled in the vaginal cavity following wet and then dry vaginal swabbing with a calcium alginate swab (Fisher Scientific, Pittsburgh, Pa.). Animals are assessed daily for symptomatic disease (as indicated by hair loss and erythema near the vagina) through 14 days post-inoculation (p.i.). Survival is followed through 21 days p.i. As an additional indicator of infection, vaginal swabs are collected and tested for viral content on Vero cells.
  • gE null HSV-2 virus is constructed from strain HG52, using a similar strategy as that used for HSV-I (Example 1).
  • the HSV-I (NS) gE (Examples 1-5) and HSV-2 (HG52) gE sequences are 72% identical and 79% similar (positive) ( Figure 24A).
  • an HSV-2( Res ⁇ ,e g E null) strain is constructed.
  • mice receiving the wt and HSV-2(R escue SE nu ⁇ i) virus are expected to die, those receiving the HSV -2( gE n u ll ) strain are expected to survive, and are not expected to exhibit significant signs of disease.
  • mice are vaccinated with HSV-2( gE nu ii) or mock- vaccinated as described in the previous Example, P-9066-PC and are challenged 28 days later with a lethal dose of WT HSV-2.
  • HSV-2( gE nu ⁇ i)-vaccinated mice are expected to be protected from the lethal challenge, whereas mock-vaccinated mice are expected to succumb to the infection.
  • HS V-2( 8E nuin vaccination is expected to substantially decrease or eliminate primary (inoculation site) disease after challenge with wt HSV-2.
  • no zosteriform disease is expected to be observed in vaccinated mice.
  • immunohistochemistry of equivalent skin samples is expected to demonstrate substantially reduced antigen levels in vaccinated mice several days post-challenge. Histological analyses are expected to reveal that vaccinated mice exhibit significant infiltration of immune cells.
  • HSV-2 (g E n uii) vaccine is tested in the mouse flank model (Examples 4-5), and is expected to be protective against HSV-2 infection.
  • EXAMPLE 15 EFFICACY OF HSV-2/, ⁇ w ⁇ i».i VACCINATION AGAINST EXISTING HSV-2 GENITAL INFECTION IN A GUINEA PIG MODEL
  • vaginal closure membranes are ruptured with a pre-moistened calcium alginate swab.
  • Vaginal vault is swabbed with a dry calcium alginate swab, and 10 5 ' 7 pfu of HSV-2 is instilled into the vaginal vault with a syringe and a 20-gauge plastic catheter. This dose is sublethal, while providing infection of nearly every inoculated animal.
  • animals are evaluated daily through day 14 p.i. for genital skin disease and urinary retention.
  • Disease is quantified by a skin lesion scoring system ranging from 0 (no disease) to 4 (severe disease characterized by large ulcers with maceration). Following acute disease, animals are distributed to produce statistically similar groups based upon disease severity. Daily scoring of each animal proceeds from day 21-56 p.i. to establish frequency of external recurrent herpetic lesions.
  • Guinea pigs spontaneously shed HSV-2 from the vaginal cavity even in the absence of signs of disease. Viral DNA can be detected in 10 to 20% of the vaginal swabs from latently infected guinea pigs, allowing for the study of viral shedding frequencies and comparisons of the magnitudes. Vaginal cavities are swabbed daily with a calcium alginate-tipped swab from days 22-43 p.i.
  • DNA is extracted from each swab sample using the QIAmp® DNA extraction system (Qiagen, Inc, Chats worth, CA), including mock swab blanks as monitors for sample contamination, and subjected to quantitative PCR for HSV-2 DNA, using primers targeting the DNA polymerase gene.
  • a separate reaction is performed for each of the specimens to address template quality and quantity, using a second set of primers to amplify the single- copy guinea pig albumin gene.
  • the resulting 498-bp amplimer is utilized for normalization of DNA P-9066-PC concentration and a more quantitative estimate of the HSV-2 burden in each specimen.
  • Positive specimens are compared to amplification of a series of 10-fold serial dilutions of established genomic equivalents using MS HSV-2 stocks. Reactions are run in a GeneAmp® PCR System 9600 (Perkin-Elmer Corp, Norwalk, Conn.) beginning with a "hot start” at 95°C for 2 min; then 35 cycles of denaturation at 95°C for 1 min, annealing for 1 min at 65°C, and 72°C extension for 1 min 30 s; and a final 7-min extension at 72°C. Amplification products of each sample, positive and negative controls, and the series of known standards are detected by Southern blotting. HSV-2 burdens are extrapolated from the linear relationship established from band density of a dilution series of known genomic equivalents amplified in parallel to the samples.
  • Sacral dorsal root ganglia (6-8 per animal) are dissected and weighed, viral DNA is extracted by using a QIAamp® DNA minikit (QIAGEN), and real-time PCR is performed. A standard curve is constructed for each experiment, using purified plasmid containing HSV-2 gD gene sequences. Data are normalized to probes specific for guinea pig lactalbumin DNA.
  • the guinea pig model is utilized to evaluate the efficacy of ISS against recurrent herpetic disease. This model provides a naturally occurring recurrent disease similar to that seen in human HSV-2 infections, and latently infected guinea pigs shed virus vaginally at a frequency similar to that observed in humans.
  • Guinea pigs are vaccinated with HSV-2( gE n uii) or mock-vaccinated and are challenged 28 days later with 10 5 ' 7 pfu of HSV-2.
  • HSV-2( g g n u ll ) vaccination is expected to significantly reduce the frequency of genital lesion development compared to mock- vaccinated animals and reduce the number of animals that experience any recurrences.
  • HSV-2( g e null ) vaccination is expected to significantly reduce the magnitude of viral shedding.
  • HSV-2 (gE n uii) vaccination on the establishment of latent HSV-2 infection
  • HSV-2 ⁇ SE n uii) vaccination is expected to significantly reduce the number of viral genomes in the DRG.
  • EXAMPLE 16 INTRODUCTION OF ADDITIONAL DELETIONS TO THE Us REGION IN ORDER TO FURTHER IMPAIR THE ANTEROGRADE SPREAD OF THE AeE-2 VACCINE
  • EXAMPLE 17 IDENTIFICATION OF ADDITIONAL MUTATIONS THAT IMPAIR ANTEROGRADE SPREAD OF THE ⁇ gE-2 VACCINE STRAIN
  • RNAi gene silencing methodology is utilized to identify genes other than gE, Us7 and Us9 that are involved in virus spread.
  • RNAi technology uses approximately 20-22 base-pair double-stranded RNA fragments with sequences identical to the viral gene targeted for silencing.
  • small RNA double-stranded fragments identical in sequence to the viral RNA are synthesized using standard techniques known in the art, and are introduced by transfection technology into cells that are then infected with HSV-I or HSV-2 wild-type or mutant virus.
  • Spread of defective virus is detected by screening for small plaques in human epidermal keratinocytes (HaCaT) cells (Collins WJ et al.
  • the genes targeted by the RNAi fragments that induce small plaques are used in gene deletion studies. Inactivating mutations are then introduced into the gene or genes identified by the above RNAi screening method to create mutant viruses.
  • Spread properties of mutant viruses are evaluated in vitro using rat superior cervical ganglion cell neuron cultures (Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, and Friedman HM. J.
  • Virol 79:13362-72, 2005 and the mouse retina eye infection model (Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, Friedman HM. J. Virol 79:13362-72, 2005).
  • the viral mutant strains identified that modify spread in vitro or in vivo are introduced into strains containing deletions of gE, Us7 or Us9 to develop strains containing deletions in multiple genes to identify the optimum combination of mutations that causes little or no disease when inoculated into laboratory animals, that results in low levels or no viral DNA in DRG, and that provides maximum protection against disease and establishment of viral latency when challenged by infection with wild type HSV-I or HSV-2.
  • virion membrane proteins e.g. glycoproteins J, G, K, and M.
  • Membrane glycoproteins required for virus entry e.g. glycoproteins B, D, H and L, are excluded. These virion membrane proteins are analyzed as described in the previous paragraph.
  • EXAMPLE 18 CHARACTERIZATION AND STABILITY OF HSV gD MUTANT
  • Wild-type HSV-I strain KOS was used to prepare gD mutants.
  • HSV-l( g D ⁇ uii) To construct HSV-l( g D ⁇ uii).
  • plasmid pSC594 was constructed by inserting A3C (alanine to cysteine) and Y38C (tyrosine to cysteine) mutations into plasmid pRM416 which contains the KOS gD open reading frame flanked by 474 base pairs 5' and 985 base pairs 3' of the open reading frame.
  • HSV-I gD-mull DNA and pSC594 DNA were co-transfected into VD60 cells. Recombinant virus was screened by replication in Vera cells and then plaque-purified.
  • rKOS-gDA3C Rescued KOS-gDA3C virus, referred to as rKOS-gDA3C, was generated by co-transfection of Vero cells with KOS-gDA3C and pRM416 DNA.
  • Virus stocks were grown in Dulbecco's minimum essential medium (DMEM), supplemented with 10% fetal calf serum (FCS).
  • DMEM Dulbecco's minimum essential medium
  • B78-H1 cells mouse melanoma cells that are non-permissive for HSV-I entry, were grown in DMEM with 5% FCS.
  • B78-H1-A10 cells (AlO) and B78-H1-C10 cells (ClO) stably express HVEM and nectin-1, respectively, and were grown in DMEM containing 5% FCS and 500 ⁇ g/ml of G418.
  • the gD-null virus was propagated in Vero cells stably transfected with gD DNA (VD60 cells).
  • HSV-I strain NS a low-passage clinical isolate, was used for challenge studies in mice. Viruses were grown in Vero cells, unless otherwise noted, purified on sucrose gradients and stored at -80
  • mice were allowed to acclimate to the biosafety level 2 animal facility with constant temperature and photoperiod (12 hours of light, 12 hours of darkness) for 1 week. Mice were shaved and depilated with depilatory cream (NairTM) along the right flank (for vaccination) or the left flank (for challenge), then washed with warm water.
  • NeairTM depilatory cream
  • mice were anesthetized via intraperitoneal injection of 75 mcL of 14.3 mg/ml ketamine and 1.8 mg/ml xylazine in PBS, then infected by making 60 superficial scratches in a 1 cm 2 area of the flank, 1 cm dorsal to the spine, with a 30-gauge needle through a 10 mcL droplet containing 5 x 10 s pfu HSV.
  • Mice were observed at 24-hour intervals starting at day 3 post-inoculation to record the appearance and severity of skin lesions and illness. Scores at the inoculation site ranged from 0 to 5 and at the zosteriform site P-9066-PC from 0 to 10. One point was assigned per vesicle or if lesions were confluent multiple points were assigned based on the size of the confluent lesions.
  • KOS-gDA3C, rKOS-gDA3C or KOS 400 pfu was incubated for one hour at 4°C with B78-H1, AlO, ClO or Vero cells. Cells were warmed to 37°C for 0, 10, 30, 60 or 120 minutes followed by washing to remove unbound virus and exposed to a citrate buffer pH 3.0 wash for 1 minute to inactivate vims that had bound but had not entered cells. After an additional wash, cells were overlaid with 0.6% low-melt agar in DMEM, and plaques were visualized and counted after 68 hours.
  • Single-step growth curves were performed on B78-H1 , AlO and ClO cells inoculated with KOS, KOS-gDA3C or rKOS-gDA3C virus at an MOI of 3. After one hour .at 37 ° C, cells were treated with citrate buffer pH 3.0 for one minute, and cells and supernatant fluids were collected immediately (time 0) or at 2, 4, 8, 10, 12, 20 and 24 hours. Samples were freeze-thawed once, sonicated three times each for 10 seconds and titered on Vero cells. Multi-step growth curves were performed in a similar fashion, except infection was performed at an MOI of 0.01 and titers measured at 24, 48 and 72 hours.
  • DRG nearest the site of inoculation were harvested and DNA was isolated using the Qia Amp- mini DNA kit (Qiagen).
  • the Us9 gene was amplified to quantify viral genome copy number in DRG.
  • the PCR reaction was performed in a 50 mcl volume with a minimum of 200 ng of DNA from DRG.
  • Mouse adipsin a cellular housekeeping gene was also amplified from DRG DNA under identical conditions.
  • the primers used for amplification were forward 5'gatgcagtcgaaggtgtggtta (SEQ ID NO: 1 1) and reverse 5' cggtaggatgacactcgggtat (SEQ ID NO: 12), while Taqman probe 5'tctcgcgtctgtggcaatggc (SEQ ID NO: 13) was used for detection.
  • the viral DNA copies were then normalized based on the murine adipsin copy number.
  • the molecular mass of gD and gl was evaluated by western blots of cells infected with WT, rKOS-gDA3C, or KOS-gDA3C virus.
  • the size of the proteins was similar for the three viruses (Fig. 26A), while DNA sequencing confirmed the integrity of the gJ gene in KOS-gDA3C (result not shown).
  • the stability of the gDA3C mutation was confirmed by restriction digestion using Sspl of PCR-amplified DNA fragments to confirm the presence of the cysteine P-9066-PC residue at position 3.
  • the Sspl site was maintained through 30 passages, suggesting that the change of alanine to cysteine at residue 3 was stable (Fig. 26B). This was confirmed by DNA sequence analysis after every five passages.
  • mice were scratch-inoculated on the flank with KOS-gDA3C, and DRG harvested five days postinfection to confirm the stability of the gDA3C mutation in vivo.
  • Virus was isolated from three individual plaques. All three isolates retained the Sspl site ⁇ Fig. 26C), suggesting that the cysteine residue at amino acid 3 was maintained, which was confirmed by DNA sequencing.
  • EXAMPLE 20 GROWTH CURVES OF HSV gD MUTANT VIRUS
  • Virus replication was examined by performing single-step growth curves at an MOI of 3.
  • KOS, rKOS-gDA3C and KOS-gDA3C failed to infect B78-H1 cells (results not shown).
  • Replication of the three viruses was comparable in AlO cells (Fig. 28A) and ClO cells (Fig. 28B), except that the titers of KOS- gDA3C were reduced at time 0 (at the end of the one-hour adsorption period), which reflects the entry defect seen in Example 19.
  • Multi-step growth curves were performed by infecting the cells at an MOI of 0.01 to allow multiple cycles of virus replication. Compared with KOS and rKOS-gDA3C, peak titers of KOS-gDA3C were reduced at 72 hours by approximately 1.5 loglO in AlO cells (Fig. 28C) and 2 loglO in C10 cells (Fig. 28D).
  • the virulence of the KOS-gDA3C mutant was evaluated in the mouse flank model. Mice were infected with 5x10 5 PFU of KOS, rKOS-gDA3C, or KOS-gDA3C and animals scored for disease at the inoculation and zosteriform sites. Mice infected with KOS-gDA3C had less severe disease at the inoculation site (Fig. 29A) and almost no zosteriform disease with only one of 30 mice developing 3 lesions on day 5 (Fig. 29B). Photographs of the zosteriform site disease are shown on day 10 (Fig. 29C). P-9066-PC [00310] These findings show that infection with the gD mutant herpes virus causes minimal disease.
  • mice were inoculated with 5x10 5 PFU of KOS, rKOS-gDA3C, or KOS-gDA3C and at 5 days post-infection, the DRG were harvested to measure viral titers (Fig. 30A) and viral genome copy number (Fig. 30B), which were reduced for KOS-gDA3C compared with KOS or rKOS-gDA3C.
  • mice were mock-infected or infected with rKOS-gDA3C or KOS-gDA3C and allowed to recover. Although rKOS-gDA3C produced extensive disease, all animals survived, as did all mice infected with KOS. Thirty days later, mice previously infected with KOS-gDA3C or rKOS-gDA3C were challenged on the opposite flank with HSV-I strain NS at 106 PFU (approximately 20 LD50). The challenge virus caused extensive disease at the inoculation (Fig. 31A) and zosteriform (Fig. 31B) sites in the mock group.
  • KOS-gDA3C and rKOS-gDA3C protected against disease at the inoculation site and both viruses totally prevented zosteriform disease. None of the rKOS-gDA3C or KOS-gDA3C infected mice died after the NS strain challenge, while 100% of the mock-infected mice died (result not shown).
  • mice were mock-infected or infected in the flank with 5x10 5 pfu of rKOS-gDA3C or KOS-gDA3C. Thirty days later, mice were challenged with 10 6 pfu of NS on the opposite flank. DRG that innervate the challenge site were harvested five days post-challenge. NS viral titers were approximately 6 loglO in DRG of mice that were previously mock infected, while no virus was recovered from DRG of mice previously infected with rKOS-gDA3C or KOS-gDA3C (Fig. 31 C).
  • KOS-gDA3C is attenuated in causing skin lesions at the inoculation and zosteriform sites and in infecting DRG, yet it is as effective as rKOS-gDA3C in protecting mice against WT HSV-I challenge.
  • Figure 32 shows a model in which at each step of the virus life cycle, less KOS- gDA3C is produced because of the defect in virus entry. These steps include the amount of virus produced in epidermal cells (labeled E), in DRG nuclei (labeled N), and that return to the skin at the zosteriform site.
  • the examples of the present invention provide experimental support for a method of vaccinating against HSV infection by contacting the subject with a mutant strain of HSV, containing one or more inactivating mutations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other proteins.

Description

P-9066-PC HSV-I AND HSV-2 VACCINES AND METHODS OF USE THEREOF
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[001] The invention described herein was supported in whole or in part by grants from the National
Institutes of Health (Grant No. R01AI33063). The government has certain rights in the invention.
FIELD OF INVENTION
[002] This invention provides methods of vaccinating a subject against Herpes Simplex Virus
(HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other protein, optionally containing an inactivating mutation in a gene encoding a gD.
BACKGROUND OF THE INVENTION
[003] Human infection with herpes simplex virus (HSV) type 1 or 2 is typically acquired through intimate contact and causes oral and genital lesions. HSV-I usually causes oral ulcers and HSV-2 normally causes genital ulcers, but the reverse can also occur. A person infected with HSV-I or HSV-2 will always be a carrier of the virus. After initial infection, lesions heal and HSV exists in a dormant, latent state in sensory neurons. Periodically, HSV reactivates from latently infected neurons and causes new ulcers to form at the skin surface. Newborn infants and immunosuppressed individuals are particularly vulnerable to HSV infection, often having a disseminated infection with fatal results. Ocular HSV infection, a leading cause of blindness, is another serious consequence of the virus. Furthermore, genital HSV infection results in a two-fold increase in HIV transmission rate. Therefore, a vaccine to prevent transmission of HSV is urgently needed.
SUMMARY OF THE INVENTION
[004] This invention provides methods of vaccinating a subject against a Herpes Simplex Virus
(HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other protein. P-9066-PC
[005] In another embodiment, the present invention provides method of treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection in a subject, comprising the step of contacting said subject with a composition comprising a mutant Herpes Simplex Virus vaccine strain, wherein said mutant HSV vaccine strain comprises an inactivating mutation in a Us8 gene. In one embodiment, the mutant HSV vaccine strain is an HSV-I strain, while in another embodiment, the mutant HSV vaccine strain is an HSV-2 strain. In one embodiment, the HSV infection is an HSV-I infection, while in another embodiment, the HSV infection is an HSV-2 infection.
[006] In one embodiment, the mutant strain is replication-competent in the skin tissue of said subject. In one embodiment, the neuronal viral spread of said mutant strain is impeded.
[007] In one embodiment, the mutant HSV vaccine strain further comprises an additional inactivating mutation in a Us7 gene, or, in another embodiment, in a Us9 gene, or, in another embodiment, in both Us7 and Us9 genes. In one embodiment, the mutant HSV vaccine strain further comprises an additional inactivating mutation in a gene encoding a membrane protein not required for virus entry, which in one embodiment, is Us5, in another embodiment, Us4, in another embodiment, UL53, in another embodiment, ULlO, or in another embodiment, any combination of Us5, Us4, UL53, and ULlO. In one embodiment, the mutant HSV vaccine strain further comprises an additional inactivating mutation in a gene encoding a membrane protein required for virus entry, which in one embodiment, is Us6.
[008] In one embodiment, the HSV infection is a genital HSV infection, while in another embodiment, the HSV infection is HSV encephalitis, while in another embodiment, the HSV infection is an ocular disease, while in another embodiment, the HSV infection is HSV labialis, while in another embodiment, the HSV infection is any combination of the above.
[009] In one embodiment, the subject is infected by HSV, while in another embodiment, the subject is at risk for infection by HSV, which in one embodiment, is a subject who is a neonate, in another embodiment, immunocompromised, in another embodiment, elderly, and in another embodiment, an immunocompromised neonate or an immunocompromised elderly subject.
[0010] In one embodiment, the method induces an anti-HSV immune response in a subject, which in one embodiment, is an anti-HSV neutralizing antibody response.
[001 1] In one embodiment, the step of contacting comprises epidermal injection, in another embodiment, intramuscular injection, in another embodiment, subcutaneous injection, and in another embodiment, intra-respiratory mucosal injection. P-9066-PC
[0012] In one embodiment, the present invention provides an isolated mutant HSV-I strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation. In another embodiment, the gene encoding a gE protein is a Us8 gene. In another embodiment, the second inactivating mutation is in a Us7 gene. In another embodiment, the second inactivating mutation is in a Us9 gene. In another embodiment, the second inactivating mutation is in any other HSV-I gene known in the art. In another embodiment, the isolated mutant HSV-I strain contains inactivating mutations in genes encoding a gE protein, a gl protein, and a Us9 protein.
[0013] In another embodiment, the present invention provides an isolated mutant HSV-2 strain comprising a first inactivating mutation in a gene encoding a gE protein and one or more additional inactivating mutations. In one embodiment, the gene encoding a gE protein is a Us8 gene. In one embodiment, the additional inactivating mutation is in a membrane protein not required for virus entry. In another embodiment, the additional inactivating mutation is in a Us7 gene. In another embodiment, the additional inactivating mutation is in a Us9 gene. In another embodiment, the additional inactivating mutation is in Us5, Us4, UL53, ULlO, or a combination thereof. In one embodiment, the additional inactivating mutation is in a membrane protein required for virus entry. In another embodiment, the additional inactivating mutation is in Us6. In another embodiment, the additional inactivating mutation is in any other HSV-2 gene known in the art. In another embodiment, the isolated mutant HSV-2 strain contains inactivating mutations in genes encoding a gE protein, a gl protein, and a Us9 protein.
BRIEF DESCRIPTION OF THE FIGURES
[0014] Figure 1. HSV spread in neurons.
[0015] Figure 2. Typical HSV-I infection of a mouse flank.
[0016] Figure 3. Spectrum of skin disease in the mouse flank/vaccination model.
[0017] Figure 4. Survival of mice following infection with HSV-l(gE nuii) vaccine or virulent HSV-
1 (Rescue gE null)-
[0018] Figure 5. Primary skin disease after infection with HSV-I (gE null) vaccine or virulent HSV-
1 (Rescue gE null)-
[0019] Figure 6. Secondary (zosteriform) skin disease after infection with HSV-I (gε nuio vaccine or virulent HSV-I (ReScUe 8E nuio-
[0020] Figure 7. Viral titers in skin after infection with vaccine or virulent HSV-I .
[0021] Figure 8. HSV detection in skin after infection with vaccine or wild-type HSV-I . P-9066-PC
[0022] Figure 9. Viral titers in dorsal root ganglia (DRG) after infection with vaccine or virulent
HSV-I .
[0023] Figure 10. Survival of vaccinated or mock- vaccinated mice following challenge with 10s pfu of WT HSV-I (NS).
[0024] Figure 11. Primary skin disease scores in vaccinated mice challenged with 105 pfu of WT
HSV-I (NS).
[0025] Figure 12. Viral titers in skin in vaccinated mice challenged with 105 pfu of WT HSV-I (NS).
[0026] Figure 13. HSV detection in skin of mock-vaccinated or vaccinated mice, challenged with 105 pfu ofWT HSV-I (NS).
[0027] Figure 14. Secondary skin disease in vaccinated mice challenged with 105 pfu of WT HSV-I
(NS). N=3.
[0028] Figure 15. Viral titers of ganglia from mock-vaccinated or vaccinated mice, challenged with
105 pfu of WT HSV-I (NS). N=3.
[0029] Figure 16. Vaccine protects ganglia from latent infection.
[0030] Figure 17. Cross protection of mice vaccinated with 5xlO5 pfu HSV-lΔgE against flank challenge with 105 pfu HSV-2(2.12). "Mock Vac" denotes mock vaccination; "DgE Vac" denotes vaccination with 5 x 105 pfu HSV-lΔgE. Error bars represent the Standard Error of the Mean ("SEM").
[0031] Figure 18. Protection of mice vaccinated with 5 x 105 pfu HSV-lΔgE against latency following flank challenge with 5 x 105 pfu HSV-I(KOS). Error bars represent the SEM.
[0032] Figure 19. Protection of mice vaccinated with 5 x 105 pfu HSV-lΔgE against death, visible
Disease and Extensive Viral Replication Following Vaginal Challenge with 105 pfu HSV-I (NS). A. Top panel- survival curves; bottom panel- viral titer as assessed by vaginal swabs. B. Photographs of mice on day 8 post-challenge. Error bars: SEM.
[0033] Figure 20. Protection of mice vaccinated with 5 x 10s pfu HSV-lΔgE by different routes
("Ep. Scar.": epidermal scarification; "SubQ": subcutaneously; IM: intramuscular) against flank challenge with 105 pfu HSV-I(NS). "DgE Vac" denotes HSV-lΔgE; Error bars represent the SEM.
[0034] Figure 21. Induction of neutralizing antibody response in mice vaccinated with 5 x 105 pfu
HSV-lΔgE by different routes. Percentages depicted are compared to serum from mock-vaccinated mice. n=3 (Ep. Scar & Sub Q), n=2 (IM), assays were done in duplicate. Error bars represent the SEM. P-9066-PC
[0035] Figure 22. Protection of mice vaccinated with 5 x 105 pfu HSV-I ΔgE against flank challenge with 105 pfu HSV-I(NS, F or 17). Error bars represent the SEM.
[0036] Figure 23. Protection of mice vaccinated with 5 x 105 pfu HSV-lΔgE against flank challenge with 105"7 pfu HSV-I(NS). Error bars represent the SEM.
[0037] Figure 24. A. Alignment of HSV-I(NS) gE (SEQ ID NO: 2) with HSV-2(HG52) gE (SEQ
ID NO: 6) B. Strategy for generation of gE-2 deletion.
[0038] Figure 25. Additional deletions to the Us region. Schematic diagram of the 4.5 kb region within the Us segment of the HSV-2 genome (155 kb total genome size) is depicted. The region equivalent to that deleted in the HSV-lΔgE vaccine strain and area of proposed additional deletions are noted.
[0039] Figure 26. A. Western blot to detect gD (Us6) and gl (Us7) in infected cell extracts. B.
Stability of the KOS-gDA3C virus in vitro. An Sspl digest of a PCR-amplified gD gene fragment of KOS or KOS-gDA3C. C. Stability of the KOS-gDA3C mutant virus in vivo. A PCR-amplified gD fragment obtained from the DRG of KOS-gDA3C-infected mice were cut with Sspl or left uncut.
[0040] Figure 27. Entry of KOS, rKOS-gDA3C and KOS-gDA3C virus into (A) Vera, (B) B78-H1 ,
(C) AlO or (D) ClO cells. Results are the mean + SE of three separate infections each done in triplicate.
[0041] Figure 28. Single-step (A, B) and multi-step (C, D) growth curves of KOS, rKOS-gDA3C and KOS-gDA3C performed in AlO (A, C) or ClO (B, D) cells. Results are the mean + SE of three separate infections.
[0042] Figure 29. Disease in the murine flank model. Inoculation (A) and zosteriform (B) site disease scores in mice inoculated with 5x105 PFU of KOS, rKOS-gDA3C or KOS-gDA3C. Error bars represent SE. C. Photographs of mice flanks taken 10 days post-infection with KOS, rKOS-gDA3C, or KOS-gDA3C.
[0043] Figure 30. Virus titers and genome copy numbers in DRG. DRG were dissected from mice infected with KOS, rKOS-gDA3C or KOS-gDA3C and assayed for virus titers (A) or viral genome copy number (B). Results represent the mean + SE.
[0044] Figure 31. Prior infection with KOS-gDA3C protects against WT HSV-I challenge. Results represent mean disease scores + SE at the inoculation (A) and zosteriform (B) sites from days 3-7 postinfection. DRG viral titers (C) and genome copy number (D) were measured 5 days post-challenge with NS. Results represent the mean + SE.
[0045] Figure 32. Model for KOS-gDA3C infection in mice. KOS infects epithelial cells (E) and P-9066-PC produces disease at the inoculation site. The virus spreads to neurons (N) in the DRG, replicates and spreads to adjacent neurons and then travels back to epithelial cells in the skin to cause zosteriform disease. KOS-gDA3C is impaired in entry and infects fewer epithelial cells, which results in fewer neurons becoming infected in the DRG. The defect in entry also reduces infection of adjacent neurons in the DRG and results in reduced zosteriform disease.
DETAILED DESCRIPTION OF THE INVENTION
[0046] This invention provides methods of vaccinating a subject against Herpes Simplex Virus
(HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, other protein, or combinations thereof. In another embodiment, the mutant strain of the HSV, comprises an inactivating mutation in a gene encoding gE, which in one embodiment, is a gE null mutation. In another embodiment, the present invention provides pharmaceutical compositions comprising a mutant strain of HSV which comprises an inactivating mutation in a gene encoding gE, which in one embodiment, is a gE null mutation. In another embodiment, this invention provides pharmaceutical compositions comprising a mutant strain of HSV which comprises an inactivating mutation in a gene encoding a gE, gl, Us9, other protein, or combinations thereof.
[0047] In one embodiment, the present invention provides a method of vaccinating a subject against an HSV infection, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[0048] In another embodiment, the present invention provides a method of impeding HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[0049] In another embodiment, the present invention provides a method of impeding HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[0050] In another embodiment, the present invention provides a method of impeding primary HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the present invention provides a method of impeding primary HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein In another embodiment, the present P-9066-PC invention provides a method of impeding primary HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein
[0051] The terms "impeding HSV infection" and "impeding primary HSV infection" refer, in one embodiment, to decreasing the titer of infectious virus by 90%. In another embodiment, the titer is decreased by 50%. In another embodiment, the titer is decreased by 55%. In another embodiment, the titer is decreased by 60%. In another embodiment, the titer is decreased by 65%. In another embodiment, the titer is decreased by 70%. In another embodiment, the titer is decreased by 75%. In another embodiment, the titer is decreased by 80%. In another embodiment, the titer is decreased by 85%. In another embodiment, the titer is decreased by 92%. In another embodiment, the titer is decreased by 95%. In another embodiment, the titer is decreased by 96%. In another embodiment, the titer is decreased by 97%. In another embodiment, the titer is decreased by 98%. In another embodiment, the titer is decreased by 99%. In another embodiment, the titer is decreased by over 99%.
[0052] In another embodiment, the terms refer to decreasing the extent of viral replication by 90%.
In another embodiment, replication is reduced by 50%. In another embodiment, replication is reduced by 55%. In another embodiment, replication is reduced by 60%. In another embodiment, replication is reduced by 65%. In another embodiment, replication is reduced by 70%. In another embodiment, replication is reduced by 75%. In another embodiment, replication is reduced by 80%. In another embodiment, replication is reduced by 85%. In another embodiment, replication is reduced by 92%. In another embodiment, replication is reduced by 95%. In another embodiment, replication is reduced by 96%. In another embodiment, replication is reduced by 97%. In another embodiment, replication is reduced by 98%. In another embodiment, replication is reduced by 99%. In another embodiment, replication is reduced by over 99%.
[0053] Methods for measuring HSV infection are well known in the art, and include, in one embodiment, determination of appearance and severity of skin lesions and viral-mediated illness (Examples 1 and 4). Other embodiments of methods for measuring viral infection are described, for example, in Burgos JS et al. (Herpes simplex virus type 1 infection via the bloodstream with apolipoprotein E dependence in the gonads is influenced by gender. J Virol. 2005 Feb;79(3): 1605-12) and Parr MB et al. (Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites. J Neurovirol. 2003 Dec;9(6):594-602). Other methods of determining the extent of HSV replication and HSV infection are well are described, for example, in Lambiase A et al. (Topical treatment with nerve growth factor in an animal model of herpetic keratitis. Graefes Arch Clin Exp Ophthalmol. 2007 May 4), Ramaswamy M et al. (Interactions and management issues in HSV and HIV coinfection. Expert Rev Anti Infect Ther. 2007 Apr;5(2):231-43), and Jiang C et al. (Mutations that decrease DNA binding of the processivity factor of the herpes simplex virus DNA polymerase reduce P-9066-PC viral yield, alter the kinetics of viral DNA replication, and decrease the fidelity of DNA replication. J Virol. 2007 Apr;81(7):3495-502).
[0054] As provided herein, vaccination with gE-null HSV strains of the present invention protects against subsequent infection with virulent HSV. In another embodiment, the vaccination protects against disease caused by virulent HSV. In another embodiment, the vaccine strain does not itself cause significant disease, which in one embodiment is herpes (Examples 1 and 4), or, in another embodiment, result in significant symptomology.
[0055] "Inactivating mutation" in gE refers, in one embodiment, to a mutation that abrogates HSV neuronal spread. In another embodiment, the terms refer to a mutation that abrogates cell-to-cell spread of HSV. In another embodiment, the terms refer to abrogation of spread along axons. In another embodiment, the spread is retrograde (defined herein below). In another embodiment, the spread is anterograde (defined herein below). In another embodiment, spread in both anterograde and retrograde directions is abrogated.
[0056] In one embodiment, neuronal spread is decreased by 90%. In another embodiment, neuronal spread is decreased by 60%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
[0057] In one embodiment, the term refers to abrogating ability of gE protein to sequester host anti-
HSV antibodies. In another embodiment, sequestration of anti-HSV antibodies by gE is reduced by 90%. In another embodiment, sequestration is reduced by 50%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
[0058] In one embodiment, the term refers to abrogating ability of gE protein to bind IgG monomers. In another embodiment, binding of IgG monomers by gE is reduced by 90%. In another embodiment, binding is reduced by 50%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In P-9066-PC another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
[0059] In one embodiment, the term refers to abrogating ability of gE protein to bind IgG complexes. In another embodiment, binding of IgG complexes by gE is reduced by 90%. In another embodiment, binding is reduced by 50%. In another embodiment, the reduction is 65%. In another embodiment, the reduction is 70%. In another embodiment, the reduction is 75%. In another embodiment, the reduction is 80%. In another embodiment, the reduction is 85%. In another embodiment, the reduction is 95%. In another embodiment, the reduction is 96%. In another embodiment, the reduction is 97%. In another embodiment, the reduction is 98%. In another embodiment, the reduction is 99%. In another embodiment, the reduction is over 99%.
[0060] In one embodiment, an inactivating mutation in gE comprises a deletion of amino acids 124-
508. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 110-500. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-552. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-50. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-100. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-250. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 100-300. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 1-400. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 200-500. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 24-71. In another embodiment, an inactivating mutation in gE comprises a deletion of amino acids 30-508. In another embodiment, an inactivating mutation in gE comprises a deletion of approximately amino acids 40-70. In another embodiment, an inactivating mutation in gE comprises insertion of a non-native sequence into a portion of the gene encoding gE, wherein said gE is inactivated as a result. In another embodiment, an inactivating mutation in gE comprises substitution of amino acid residues, such as a substitution of polar for non-polar residues, non-polar for polar residues, charged for uncharged residues, positively charged for negatively charged residues, or vice versa, or a combination thereof, as is known to one of skill in the art. In another embodiment, an inactivating mutation in gE consists essentially of any of the mutations listed hereinabove. In another embodiment, an inactivating mutation in gE consists of any of the mutations listed hereinabove. In another embodiment, an inactivating mutation in gE or other protein as described in the instant invention for a first HSV strain may also be mutated in an equivalent location of the corresponding protein in a second HSV strain, wherein the equivalent location of the insertion, deletion or substitution may be inferred by sequence alignment, as is well known in the art, wherein the region that aligns with the sequence of the mutation in the first strain would be mutated in the second strain. P-9066-PC
[0061] "Inactivating mutation", in gD refers, in one embodiment, to a mutation that inhibits protein/receptor interactions, which in one embodiment is an interaction with a HVEM cell receptor, a nectin-1 cell receptor, or both, and in another embodiment, to a mutation that inhibits viral entry into a cell, inhibits downstream activation of gB, gH, and gL, inhibits fusion of the viral envelope with cell membrane, or a combination thereof. In one embodiment, an inactivating mutation in gD is in the amino terminus of the gD peptide, which in one embodiment is residue 1-15, and in another embodiment, the mutation inhibits formation of a hairpin loop structure when gD is bound to HVEM. In another embodiment, the mutation is at amino acids 3, 38, or both, and in one embodiment, alanine and tyrosine residues at those locations are replaced with cysteine residues (A3C/Y38C) to create a 3-38 disulfide bond and/or a fixed hairpin loop at the amino terminus.
[0062] In one embodiment, inactivating mutations of the present invention are accomplished using tools known in the art. In one embodiment, the nucleic acids used in this invention and those encoding proteins of and for use in the methods of the present invention can be produced by any synthetic or recombinant process such as is well known in the art. Nucleic acids can further be modified to alter biophysical or biological properties by means of techniques known in the art. For example, the nucleic acid can be modified to increase its stability against nucleases (e.g., "end-capping"), or to modify its lipophilicity, solubility, or binding affinity to complementary sequences. In another embodiment, transposons may be used to create inactivating mutations of a gene, where in one embodiment, the transposon may be Tn551, Minos, Hermes or piggyback. In another embodiment, the transposon may be AT-2 (tyl based transposon, Perkin Elmer; Devine et al. (1997) Genome Res. 7:551-563), GPS-I (New England Biolabs), GPS-2 (New England Biolabs), EZ::tn (Tn5 based transposon, Epicenter Technologies), SIF (Tn7 based transposon, Biery et al. (2000) Nucl Acid Res 28:1067-1077), or Mu (Finnzymes, Haapa et al. (1999) Nucl Acid Res 13:2777-2784). In one embodiment, Southern blot analysis of digested DNA from individual transposon mutants may be used to verify transposon insertion. In another embodiment, sequence analysis, PCR and/or hybridization may be utilized to determine transposon insertion. Mutations may also be elicited using ethylmethanesulfonate (EMS) or radiation. In another embodiment, mutagenesis with chemical agents may be used. Such chemical mutagens may comprise, in other embodiments, chemicals that affect nonreplicating DNA such as HNO2 and NH2OH, as well as agents that affect replicating DNA such as acridine dyes, which have been shown to cause frameshift mutations. Methods for creating mutants using radiation or chemical agents are well known in the art, and any method may be utilized for the methods of this invention (see, for example, Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., Appl. Biochem. Biotechnol. 36, 227 (1992).
[0063] In one embodiment, DNA can be synthesized chemically from the four nucleotides in whole or in part by methods known in the art. Such methods include those described in Caruthers (1985; Science P-9066-PC
230:281-285). DNA can also be synthesized by preparing overlapping double-stranded oligonucleotides, filling in the gaps, and ligating the ends together (see, generally, Sambrook et al. (1989; Molecular Cloning - A Laboratory Manual, 2nd Edition. Cold Spring Habour Laboratory Press, New York)). In another embodiment, inactivating mutations may be prepared from wild-type DNA by site-directed mutagenesis (see, for example, Zoller et al. (1982; DNA. 1984 Dec;3(6):479-88); Zoller (1983); and Zoller (1984; DNA. 1984 Dec;3(6):479-88); McPherson (1991; Directed Mutagenesis: A Practical Approach. Oxford University Press, NY)). The DNA obtained can be amplified by methods known in the art. One suitable method is the polymerase chain reaction (PCR) method described in Saiki et al. (1988; Science. 1988 Jan 29;239(4839):487-491), Mullis et al., U.S. Pat. No.4,683,195, and Sambrook et al. (1989).
[0064] In one embodiment, the present invention provides a method of impeding the establishment of a latent HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the latent HSV infection that is prevented follows primary HSV infection. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in protecting a subject against latent HSV infection, following primary HSV infection.
[0065] In one embodiment, the present invention provides a method of inhibiting an HSV flare in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the flare that is prevented follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in protecting a subject against a formation of a flare, following an exposure of the subject to HSV.
[0066] In one embodiment, the present invention provides a method of protecting a subject against an HSV flare, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the flare that is prevented follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in protecting a subject against a formation of a flare, following exposure of the subject to HSV. P-9066-PC
[0067] In one embodiment, the present invention provides a method of reducing the incidence of an
HSV flare, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the flare that is prevented follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in reducing the incidence of a flare, following exposure of the subject to HSV.
[0068] In one embodiment, the present invention provides a method of inhibiting HSV recurrence in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the recurrence that is prevented follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in protecting a subject against a recurrence, following an exposure of the subject to an HSV.
[0069] In one embodiment, the present invention provides a method of reducing the incidence of
HSV recurrence, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the recurrence that is prevented follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in reducing the incidence of a recurrence, following exposure of the subject to HSV.
[0070] In another embodiment, the present invention provides a method of suppressing HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain.
[0071 ] In another embodiment, the present invention provides a method of suppressing HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain. P-9066-PC
[0072] According to any of the methods of the present invention and in one embodiment, the subject is human. In another embodiment, the subject is murine, which in one embodiment is a mouse, and, in another embodiment is a rat. In another embodiment, the subject is canine, feline, bovine, or porcine. In another embodiment, the subject is mammalian. In another embodiment, the subject is any organism susceptible to infection by HSV.
[0073] In another embodiment, the present invention provides a method of protecting a subject against formation of a zosteriform lesion or an analogous outbreak in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[0074] In another embodiment, the present invention provides a method of impeding formation of an HSV zosteriform lesion or an analogous outbreak in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[0075] In another embodiment, the zosteriform lesion or analogous outbreak that is impeded follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in impeding formation of a zosteriform lesion or analogous outbreak, following an exposure of the subject to an HSV.
[0076] In another embodiment, the present invention provides a method of impeding HSV zosteriform spread or an analogous condition in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the zosteriform spread or analogous condition that is impeded follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in impeding formation of a zosteriform spread or analogous condition, following exposure of the subject to HSV.
[0077] "Zosteriform" refers, in one embodiment, to skin lesions characteristic of an HSV infection, particularly during reactivation infection, which, in one embodiment, begin as a rash and follow a distribution near dermatomes, commonly occurring in a strip or belt-like pattern. In one embodiment, the rash evolves into vesicles or small blisters filled with serous fluid. In one embodiment, zosteriform lesions form in mice as a result of contact with HSV. In another embodiment, zosteriform lesions form in humans as a result of contact with HSV. P-9066-PC
[0078] "Zosteriform spread" refers, in one embodiment, to an HSV infection that spreads from the ganglia to secondary skin sites within the dermatome. In another embodiment, the term refers to spread within the same dermatome as the initial site of infection. In another embodiment, the term refers to any other definition of "zosteriform spread" known in the art. "Outbreak", in another embodiment, refers to a sudden increase in symptoms of a disease or in the spread or prevalence of a disease, and in one embodiment, refers to a sudden increase in zosteriform lesions, while in another embodiment, "outbreak" refers to a sudden eruption of zosteriform lesions.
[0079] In one embodiment, the present invention provides a method of impeding the formation of a dermatome lesion or an analogous condition in a human subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the dermatome lesion or analogous condition that is impeded follows exposure of the subject to HSV. In one embodiment, dermatome lesions form in humans as a result of contact with HSV. In another embodiment, dermatome lesions in humans most often develop when the virus reactivates from latency in the ganglia and in one embodiment, spreads down nerves, in one embodiment, causing a recurrent infection. In another embodiment, dermatome lesions form in mice as a result of contact with HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in impeding the formation of a dermatome lesion or analogous condition, following exposure of the subject to HSV.
[0080] As provided herein, vaccination with gE-null HSV strains of the present invention protects against latent HSV infection (Example 5) and formation of zosteriform and dermatome lesions (Example 4) after subsequent infection with virulent HSV. In another embodiment, the vaccination protects against disease caused by or associated with latent HSV infection. In another embodiment, the vaccination does not itself cause significant disease (Example 2).
[0081] "Virulent HSV" refers, in one embodiment, to a naturally occurring HSV strain. In another embodiment, the term refers to an HSV strain capable of causing infection. In another embodiment, the term refers to an HSV strain capable of establishing latent infection.
[0082] In another embodiment, the present invention provides a method of impeding neuronal spread of an HSV in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the neuronal spread that is impeded follows exposure of the subject to HSV. In another embodiment, the subject has been infected with HSV before vaccination. In another embodiment, the subject is at risk for HSV infection. In another embodiment, whether or not the subject has been P-9066-PC infected with HSV at the time of vaccination, vaccination by a method of the present invention is efficacious in impeding neuronal viral spread, following an exposure of the subject to HSV.
[0083] Methods of measuring neuronal HSV spread are well known in the art, and include, in one embodiment, determination of the presence and extent of secondary dermatome lesion (Example 2). Other embodiments of methods for measuring viral spread are described, for example, in Labetoulle M et al. (Neuronal propagation of HSVl from the oral mucosa to the eye. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2600-6) and Thompson KA et al. (Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000 Feb;6(l):25-32).
[0084] In one embodiment, the present invention provides a method of reducing the incidence of herpetic ocular disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by the HSV.
[0085] In one embodiment, the present invention provides a method of reducing the severity of herpetic ocular disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV. In another embodiment, the vaccine strain is from a different species from the challenge strain. In another embodiment, the vaccine strain is of the same species as the challenge strain.
[0086] In another embodiment, the present invention provides a method of reducing the incidence of an HSV-] corneal infection, herpes keratitis or any other herpetic ocular disease in a subject, the method comprising the step of administering to said subject a mutant strain of HSV of the present invention, thereby reducing an incidence of an HSV-I cornea] infection or herpes keratitis in a subject. In another embodiment, administering to said subject a mutant strain of HSV of the present invention elicits an immune response against the HSV-I .
[0087] Methods for determining the presence and extent of herpetic ocular disease, corneal infection, and herpes keratitis are well known in the art, and are described, for example, in Labetoulle M et al. (Neuronal propagation of HSVl from the oral mucosa to the eye. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2600-6) and Majumdar S i (Dipeptide monoester ganciclovir prodrugs for treating HSV-I- induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther. 2005 Dec;21(6):463-74). P-9066-PC
[0088] In one embodiment, the present invention provides a method of reducing the incidence of a genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV
[0089] In one embodiment, the present invention provides a method of reducing the severity of genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV.
[0090] In one embodiment, genital ulcer disease is characterized by ulcerative lesions on the genitals. Methods for determining the presence and extent of genital ulcer disease are well known in the art.
[0091] In one embodiment, the present invention provides a method of reducing the incidence of
HSV-I -mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. "HSV-I encephalitis" refers, in one embodiment, to encephalitis caused by HSV-I . In another embodiment, the term refers to encephalitis associated with HSV-I. In another embodiment, the term refers to any other type of HSV-I -mediated encephalitis known in the art. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV. In another embodiment, the vaccine strain is from a different species from the challenge strain. In another embodiment, the vaccine strain is of the same species as the challenge strain.
[0092] "HSV-I" refers, in one embodiment, to a Herpes Simplex Virus 1. In another embodiment, the term refers to a KOS strain. In another embodiment, the term refers to an F strain. In another embodiment, the term refers to an NS strain. In another embodiment, the term refers to a CLlOl strain. In another embodiment, the term refers to a "17" strain. In another embodiment, the term refers to a "17+syn" strain. In another embodiment, the term refers to a MacIntyre strain. In another embodiment, the term refers to an MP strain. In another embodiment, the term refers to an HF strain. In another embodiment, the term refers to any other HSV-I strain known in the art.
[0093] "HSV-2" refers, in one embodiment to a Herpes Simplex Virus 2. Tn another embodiment, the term refers to an HSV-2 333 strain. In another embodiment, the term refers to a 2.12 strain. In another embodiment, the term refers to an HG52 strain. In another embodiment, the term refers to an MS strain. In another embodiment, the term refers to an 186 strain. In another embodiment, the term refers to a G strain. In another embodiment, the term refers to any other HSV-2 strain known in the art. P-9066-PC
[0094] In another embodiment, the present invention provides a method of reducing the incidence of
HSV-2-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. "HSV-2 encephalitis" refers, in one embodiment, to encephalitis caused by HSV-2. In another embodiment, the term refers to encephalitis associated with HSV-2. In another embodiment, the term refers to any other type of HSV-2-mediated encephalitis known in the art. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV
[0095] In one embodiment, the present invention provides a method of reducing the severity of herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In one embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk ofinfection by HSV.
[0096] In one embodiment, the herpes-mediated encephalitis treated or prevented by a method of the present invention is a focal herpes encephalitis. In another embodiment, the herpes-mediated encephalitis is a neonatal herpes encephalitis. In another embodiment, the herpes-mediated encephalitis is any other type of herpes-mediated encephalitis known in the art.
[0097] In one embodiment, the present invention provides a method of reducing the incidence of disseminated HSV infection in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In one embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by the HSV.
[0098] In one embodiment, the present invention provides a method of reducing the severity of disseminated HSV infection in a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV.
[0099] In one embodiment, the present invention provides a method of reducing the incidence of a neonatal HSV-I infection in an offspring of a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In one embodiment, the offspring is contacted the subject with the mutant HSV strain. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV. P-9066-PC
[00100] In one embodiment, the present invention provides a method of reducing the incidence of a neonatal HSV-2 infection in an offspring of a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In one embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV.
[00101] In one embodiment, the present invention provides a method of reducing the transmission of an HSV-I infection from a subject to an offspring thereof, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00102] In one embodiment, the present invention provides a method of reducing the transmission of an HSV-2 infection from a subject to an offspring thereof, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00103] In one embodiment, the present invention provides a method of reducing HIV-] transmission to an offspring, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. As is known in the art, HSV-2 infection increases HIV-I viral shedding in genital secretions (Nagot N et at. Reduction of HIV-I RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007 Feb 22;356(8):790-9). Thus, methods of the present invention of inhibiting HSV-2 infection are also believed to be efficacious for reducing HIV-I transmission to an offspring. In another embodiment, the mutant HSV strain is an HSV-I strain. In another embodiment, the mutant HSV strain is an HSV-2 strain.
[00104] In one embodiment, the present invention provides a method of reducing HIV-I transmission to a sexual partner, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. As is known in the art, HSV-2 infection increases HIV-I viral shedding in genital secretions. Thus, methods of the present invention of inhibiting HSV-2 infection are also believed to be efficacious for reducing HIV-I transmission to a sexual partner. In another embodiment, the mutant HSV strain is an HSV-I strain. In another embodiment, the mutant HSV strain is an HSV-2 strain.
[00105] In one embodiment, the present invention provides a method of reducing susceptibility to
HIV-I, the method comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant HSV strain contains an inactivating mutation in a Us8 gene encoding a gE protein. As is known in the art, HSV-2 infection increases HIV-I replication (Ouedraogo A et al. Impact of suppressive herpes therapy on genital HlV-I RNA among women taking anti retroviral therapy: a randomized controlled trial. P-9066-PC
AE)S. 2006 Nov 28;20(18):2305-13). Thus, methods of the present invention of inhibiting HSV-2 infection are also believed to be efficacious for reducing susceptibility to HIV-I. In another embodiment, the mutant HSV strain is an HSV-I strain. In another embodiment, the mutant HSV strain is an HSV-2 strain.
[00106] In one embodiment, the present invention provides a method of reducing die severity of a neonatal HSV infection in an offspring of a subject, comprising the step of contacting the subject with a mutant strain of HSV, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the subject is infected by HSV. In another embodiment, the subject is at risk of infection by HSV.
[00107] In one embodiment, the present invention provides a method of reducing the incidence of a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00108] In one embodiment, the present invention provides a method of treating a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein, thereby treating a disease, disorder, or symptom associated with or secondary to a herpes-mediated encephalitis in a subject.
[00109] In one embodiment, the disease, disorder, or symptom is fever. In another embodiment, the disease, disorder, or symptom is headache. In another embodiment, the disease, disorder, or symptom is stiff neck. In another embodiment, the disease, disorder, or symptom is seizures. In another embodiment, the disease, disorder, or symptom is partial paralysis. In another embodiment, the disease, disorder, or symptom is stupor. In another embodiment, the disease, disorder, or symptom is coma. In another embodiment, the disease, disorder, or symptom is any other disease, disorder, or symptom known in the art that is associated with or secondary to herpes-mediated encephalitis.
[00110] Methods of determining the presence and severity of herpes-mediated encephalitis are well known in the art, and are described, for example, in Bonkowsky JL et al. (Herpes simplex virus central nervous system relapse during treatment of infantile spasms with corticotropin. Pediatrics. 2006 May;117(5):elO45-8) and Khan OA et al. (Herpes encephalitis presenting as mild aphasia: case report. BMC Fam Pract. 2006 Mar 24;7:22).
[001 11] In one embodiment, the present invention provides a method of treating a disease, disorder, or symptom associated with an HSV infection in a subject, comprising the step of contacting the subject P-9066-PC with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00112] In one embodiment, the present invention provides a method of reducing the incidence of a disease, disorder, or symptom associated with an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00113] In one embodiment, the present invention provides a method of treating a disease, disorder, or symptom secondary to an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00114] In one embodiment, the present invention provides a method of reducing the incidence of a disease, disorder, or symptom secondary to an HSV infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein.
[00115] In one embodiment, the disease, disorder, or symptom secondary to an HSV infection is oral lesions. In another embodiment, the disease, disorder, or symptom is genital lesions. In another embodiment, the disease, disorder, or symptom is oral ulcers. In another embodiment, the disease, disorder, or symptom is genital ulcers. In another embodiment, the disease, disorder, or symptom is fever. In another embodiment, the disease, disorder, or symptom is headache. In another embodiment, the disease, disorder, or symptom is muscle ache. In another embodiment, the disease, disorder, or symptom is swollen glands in the groin area. In another embodiment, the disease, disorder, or symptom is painful urination. In another embodiment, the disease, disorder, or symptom is vaginal discharge. In another embodiment, the disease, disorder, or symptom is blistering. In another embodiment, the disease, disorder, or symptom is flu-like malaise. In another embodiment, the disease, disorder, or symptom is keratitis. In another embodiment, the disease, disorder, or symptom is herpetic whitlow. In another embodiment, the disease, disorder, or symptom is Bell's palsy. In another embodiment, the disease, disorder, or symptom is herpetic erythema multiforme. In another embodiment, the disease, disorder, or symptom is a lower back symptom (e.g. numbness, tingling of the buttocks or the area around the anus, urinary retention, constipation, and impotence). In another embodiment, the disease, disorder, or symptom is a localized eczema herpeticum. In another embodiment, the disease, disorder, or symptom is a disseminated eczema herpeticum. In another embodiment, the disease, disorder, or symptom is a herpes gladiatorum. In another embodiment, the disease, disorder, or symptom is a herpetic sycosis. In another embodiment, the disease, disorder, or symptom is an esophageal symptom (e.g. difficulty swallowing or burning, squeezing throat pain while swallowing, weight loss, pain in or behind the upper chest while swallowing). In another P-9066-PC embodiment, the disease, disorder, or symptom is any other disease, disorder, or symptom is known in the art.
[00116] The HSV infection treated or ameliorated by methods and compositions of the present invention is, in one embodiment, a genital HSV infection. In another embodiment, the HSV infection is an oral HSV infection. In another embodiment, the HSV infection is an ocular HSV infection. In another embodiment, the HSV infection is a dermatologic HSV infection.
[00117] In one embodiment, the HSV infection is an HSV-2 infection. In another embodiment, the
HSV is an HSV-I infection. In another embodiment, the HSV infection is any other type of HSV infection known in the art.
[00118] In one embodiment, the present invention provides a method of inducing rapid clearance of an HSV-I infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain.
[00119] In one embodiment, the present invention provides a method of inducing rapid clearance of an HSV-2 infection in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain.
[00120] In one embodiment, the present invention provides a method of inducing an anti-HSV immune response in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein, thereby inducing an anti-HSV immune response in a subject. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain.
[00121] In one embodiment, the present invention provides a method of inducing an anti-HSV neutralizing antibody response in a subject, comprising the step of contacting the subject with a mutant HSV strain, wherein the mutant strain contains an inactivating mutation in a Us8 gene encoding a gE protein. In another embodiment, the mutant HSV strain is a mutant HSV-I strain. In another embodiment, the mutant HSV strain is a mutant HSV-2 strain.
[00122] In one embodiment, the present invention provides a method of inhibiting HSV labialis in a subject, comprising the step of vaccinating the subject against an HSV by a method of the present invention. P-9066-PC
[00123] In another embodiment, the present invention provides a method of inhibiting HSV labialis in a subject, comprising the step of impeding an HSV infection in the subject by a method of the present invention.
[00124] In one embodiment, the immune response induced by methods and compositions of the present invention is a cellular immune response. In another embodiment, the immune response comprises a CD8+ cytotoxic T lymphocyte (CTL) response. In another embodiment, the immune response comprises a CD4+ helper T cell response. In another embodiment, the immune response comprises a humoral immune response.
[00125] The route of administration of the mutant strains in the methods of the present invention is, in one embodiment, epidermal. In another embodiment, the mutant strain is administered by epidermal scarification or scratching. In another embodiment, the mutant strain is administered intramuscularly. In another embodiment, the mutant strain is administered subcutaneously. In another embodiment, the mutant strain is administered intranasally. In another embodiment, the mutant strain is administered transdermally. In another embodiment, the mutant strain is administered intravaginally. In another embodiment, the mutant strain is administered transmucosally, which in one embodiment, is intra- respiratory mucosally. In another embodiment, the mutant strain is administered intranasally. In another embodiment, the mutant strain is administered in an aerosol. In another embodiment, the mutant strain is administered via any other route known in the art.
[00126] In one embodiment, the inactivating mutation in the gE-encoding gene of HSV strains as described in the methods and compositions of the present invention is a deletion mutation. In another embodiment, the inactivating mutation is an insertion mutation. In another embodiment, the inactivating mutation is a substitution mutation. In another embodiment, the inactivating mutation is a gE-null mutation. In another embodiment, the inactivating mutation is any other type of mutation known in the art.
[00127] In one embodiment, the inactivating mutation in the glycoprotein-encoding gene of HSV strains as described in the methods and compositions of the present invention is a deletion mutation. In another embodiment, the inactivating mutation is an insertion mutation. In another embodiment, the inactivating mutation is a substitution mutation. In another embodiment, the inactivating mutation is a null mutation. In another embodiment, the inactivating mutation is any other type of mutation known in the art. In one embodiment, the insertion, deletion or substitution mutation comprises an insertion, deletion or substitution of a single amino acid, while in another embodiment, it comprises an insertion, deletion or substitution of 1-5 amino acids, 1-10 amino acids, 5-20 amino acids, 10-50 amino acids, 25-100 amino acids, 100-500 amino acids, 300-400 amino acids, 200-1000 amino acids, or 1000 or more amino acids. P-9066-PC
[00128] In one embodiment, the present invention provides an isolated mutant HSV-I strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation. In another embodiment, the gene encoding a gE protein is a Us8 gene. In another embodiment, the mutation is a gE-null mutation. In one embodiment, an isolated mutant HSV-I strain as described in the methods and compositions of the present invention further comprises one or more additional mutations, which in one embodiment are inactivating mutations. In another embodiment, the second or additional inactivating mutation is in a Us7 gene. In another embodiment, the second or additional inactivating mutation is in a Us9 gene. In another embodiment, the second inactivating mutation is in any gene which confers neurovirulence. In another embodiment, the second inactivating mutation is in any gene required for virus entry into a host cell. In another embodiment, the second inactivating mutation is in a host shut-off gene. In another embodiment, the second inactivating mutation is in the thymidine kinase gene. In another embodiment, the second inactivating mutation is in any other HSV-I gene known in the art. In another embodiment, the isolated mutant HSV-I strain contains inactivating mutations in a gene encoding a gE protein, a Us7 gene, and a Us9 gene. In another embodiment, an isolated mutant HSV-I strain as described in the methods and compositions of the present invention further comprises an additional mutation in a gene encoding a gD protein.
[00129] In one embodiment, the present invention provides an isolated mutant HSV-2 strain comprising a first inactivating mutation in a gene encoding a gE protein and a second inactivating mutation. In another embodiment, the gene encoding a gE protein is a Us8 gene. In another embodiment, the mutation is a gE-null mutation. In one embodiment, an isolated mutant HSV-2 strain as described in the methods and compositions of the present invention further comprises one or more additional mutations, which in one embodiment are inactivating mutations. In another embodiment, the second or additional inactivating mutation is in a Us7 gene. In another embodiment, the second or additional inactivating mutation is in a Us9 gene. In another embodiment, the second inactivating mutation is in any gene which confers neurovirulence. In another embodiment, the second inactivating mutation is in any gene required for virus entry into a host cell. In another embodiment, the second inactivating mutation is in a host shut-off gene. In another embodiment, the second inactivating mutation is in the thymidine kinase gene. In another embodiment, the second inactivating mutation is in any other HSV-2 gene known in the art. In another embodiment, the isolated mutant HSV-2 strain contains inactivating mutations in a gene encoding a gE protein, a Us7 gene, and a Us9 gene. In another embodiment, an isolated mutant HSV-2 strain as described in the methods and compositions of the present invention further comprises an additional mutation in a gene encoding a gD protein.
[00130] In one embodiment, the Us7 gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the Us7 gene that is mutated is required for anterograde spread of the virus. In another embodiment, the Us7 gene that is mutated is required for retrograde spread of the virus. P-9066-PC
[00131] In one embodiment, the Us9 gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the Us9 gene that is mutated is required for anterograde spread of the virus. In another embodiment, the Us9 gene that is mutated is required for retrograde spread of the virus.
[00132] In one embodiment, the mutation in Us7 and/or Us9 is an inactivating mutation. In another embodiment, the mutation is a deletion mutation. In another embodiment, the mutation is an insertion mutation. In another embodiment, the mutation is a substitution mutation. In another embodiment, the mutation is any other type of mutation known in the art.
[00133] In one embodiment, the additional gene that is mutated is highly conserved amongst alpha- herpesviruses. In another embodiment, the additional gene that is mutated is required for anterograde spread of the virus. In another embodiment, the additional gene that is mutated is required for retrograde spread of the virus.
[00134] In one embodiment, the additional gene that is mutated is a virion membrane protein. In one embodiment, the additional gene is a virion membrane protein not required, or non-essential, for virus entry. In another embodiment, the membrane protein is a glycoprotein. In another embodiment, the additional gene is glycoprotein J. In another embodiment, the additional gene is glycoprotein G. In another embodiment, the additional gene is glycoprotein K. In another embodiment, the additional gene is glycoprotein M. In another embodiment, the additional gene is selected from glycoproteins J, G, K, and M.
[00135] "Anterograde" refers, in one embodiment, to spread from ganglia to skin. In another embodiment, the term refers to spread from the cell body towards the axon. In another embodiment, the term refers to any other definition accepted in the art.
[00136] "Retrograde" refers, in one embodiment, to spread from the site of infection to ganglia. In another embodiment, the term refers to spread from the axon towards the cell body. In another embodiment, the term refers to any other definition accepted in the art.
[00137] In one embodiment, the additional mutation is introduced to enhance inhibition of anterograde spread of the mutant HSV-I strain. In another embodiment, the additional mutation is required, in combination with a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-I strain. In another embodiment, the gE mutation is insufficient to confer inhibition of anterograde spread of the mutant HSV-I strain. In another embodiment, the additional mutation is sufficient, in the absence of a gE mutation, to confer inhibition of anterograde spread of the mutant HSV- 1 strain.
[00138] In one embodiment, the additional mutation is introduced to enhance inhibition of anterograde spread of the mutant HSV-2 strain. In another embodiment, the additional mutation is P-9066-PC required, in combination with a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-2 strain. In another embodiment, the gE mutation is insufficient to confer inhibition of anterograde spread of the mutant HSV-2 strain. In another embodiment, the additional mutation is sufficient, in the absence of a gE mutation, to confer inhibition of anterograde spread of the mutant HSV-2 strain.
[00139] In one embodiment, the additional mutation is introduced to enhance attenuation of virulence in the HSV-I or HSV-2 strain or both. In another embodiment, the additional mutation is required, in combination with a gE mutation, to attenuate virulence.
[00140] In one embodiment, the additional gene that is mutated is a virion membrane protein. In another embodiment, the additional gene is a virion membrane protein required for virus entry. In another embodiment, the additional gene is glycoprotein B. In another embodiment, the additional gene is glycoprotein D. In .another embodiment, the additional gene is glycoprotein H. In another embodiment, the additional gene is glycoprotein L.
[00141] In one embodiment, the mutant HSV strain as described in the methods and compositions of the present invention is replication-competent in skin tissue of the subject. In another embodiment, the mutant strain is replication-competent in skin cell of the subject. In another embodiment, the mutant strain is replication-competent in skin tissue of the species to which the subject belongs. In another embodiment, the mutant strain is replication-competent in a cell line derived from skin tissue of the subject's species. In another embodiment, the mutant strain is replication-competent in a culture of skin cells of the subject's species. In another embodiment, the mutant strain is replication-competent in a cell line derived from a skin cell of the subject's species.
[00142] "Replication competent" refers, in one embodiment, to an ability to replicate. In another embodiment, the term includes strains that exhibit impaired but still detectable levels of replication. In another embodiment, the term refers to a strain that exhibits measurable replication.
[00143] In one embodiment, the mutant HSV strain as described in the methods and compositions of the present invention is defective in its ability to spread from the site of inoculation to the dorsal root ganglia (DRG). In one embodiment, the dorsal root ganglia contain the neuron cell bodies of nerve fibres. In another embodiment, the mutant HSV strain is defective in retrograde spread. In another embodiment, the mutant HSV strain is impaired in retrograde spread. In another embodiment, the mutant HSV strain is significantly impaired in retrograde spread. In another embodiment, the mutant HSV strain is impaired in retrograde spread but is replication-competent in skin.
[00144] In one embodiment, the mutant HSV strain as described in the methods and compositions of the present invention is defective in spread from DRG to the skin. In another embodiment, the mutant HSV strain is defective in anterograde spread. In another embodiment, the mutant HSV strain is impaired P-9066-PC in anterograde spread. In another embodiment, the mutant HSV strain is significantly impaired in anterograde spread. In another embodiment, the mutant HSV strain is impaired in anterograde spread but is replication-competent in skin.
[00145] "DRG" refers, in one embodiment, to a neuronal cell body. In another embodiment, the term refers to any other definition of "DRG" used in the art.
[00146] "Flare" or "recurrence" refers, in one embodiment, to reinfection of skin tissue following latent neuronal HSV infection. In another embodiment, the terms refer to reactivation of HSV after a latency period. In another embodiment, the terms refer to symptomatic HSV lesions following a non- symptomatic latency period.
[00147] In one embodiment, a mutant HSV strain of the present invention is replication-defective, either in a particular tissue or in general (e.g. in neural tissue). Methods for measuring viral replication are well known in the art and include, in one embodiment, titering assays of tissue samples near a site of inoculation (Examples herein). In another embodiment, recovery of infectious virus from tissues near a site of inoculation is utilized (Examples herein). Other embodiments as described in the methods for measuring viral replication are described, for example, in Thi TN et al. (Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR. Antiviral Res. 2006 Mar;69(3): 152-7); Schang LM et al. (Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol. 2000 Mar; 74(5):2107-20); and Kennedy PG et al. (Replication of the herpes simplex virus type 1 RLl mutant 1716 in primary neuronal cell cultures— possible relevance to use as a viral vector. J Neurol Sci. 2000 Oct 1 ;179(S l-2):108-14).
[00148] In one embodiment, a mutant strain as described in the methods and compositions of the present invention is impaired in its spread in neural tissue of the subject. In another embodiment, the mutant strain is impaired in its spread in a culture of neural cells of the subject. In another embodiment, the mutant strain is impaired in its spread in neural tissue of the species to which the subject belongs. In another embodiment, the mutant strain is impaired in its spread in a cell line derived from neural tissue of the subject's species. In another embodiment, the mutant strain is impaired in its spread in a culture of neural cells of the subject's species. In another embodiment, the mutant strain is impaired in its spread in a cell line derived from a neural cell of the subject's species.
[00149] In one embodiment, a mutant strain as described in the methods and compositions of the present invention is impaired in its ability to enter neural tissue of the subject. In another embodiment, the mutant strain is impaired in its ability to enter a culture of neural cells of the subject. In another embodiment, the mutant strain is impaired in its ability to enter neural tissue of the species to which the subject belongs. In another embodiment, the mutant strain is impaired in its ability to enter a cell line P-9066-PC derived from neural tissue of the subject's species. In another embodiment, the mutant strain is impaired in its ability to enter a culture of neural cells of the subject's species. In another embodiment, the mutant strain is impaired in its ability to enter a cell line derived from a neural cell of the subject's species.
[00150] In one embodiment, the mutant HSV strain as described in the methods and compositions of the present invention induces an anti-HSV immune response. In another embodiment, the immune response impedes replication of the HSV in the subject. In another embodiment, the immune response impedes neuronal spread of the HSV in the subject. In another embodiment, the immune response results in killing of HSV-infected cells in the subject.
[00151] In one embodiment, the mutant HSV strain as described in the methods and compositions of the present invention is a mutant HSV-I strain. In another embodiment, the mutant HSV-I strain confers protection against an HSV-I infection, spread, or a consequence thereof (e.g. zosteriform lesions or herpetic ocular disease). In another embodiment, the mutant HSV strain is a mutant HSV-2 strain. In another embodiment, the mutant HSV-2 strain confers protection against an HSV-2 infection, spread, or a consequence thereof (e.g. zosteriform lesions or herpetic ocular disease). In another embodiment, the mutant HSV strain is any other mutant HSV strain known in the art.
[00152] In one embodiment, a mutant HSV-I strain of the present invention protects a subject against infection and disorders and symptoms associated with infection with wild-type HSV-I. In another embodiment, the disorders and symptoms include herpes labialis (cold sores or fever blisters). In another embodiment, the disorders and symptoms include HSV-mediated cornea disease. In another embodiment, the disorders and symptoms include herpes-mediated retinitis. In another embodiment, the disorders and symptoms include herpes-mediated encephalitis. In another embodiment, the disorders and symptoms include HSV-1-mediated genital ulcer disease. In another embodiment, a mutant HSV-I strain of the present invention provides substantial protection against HSV-I infection and partial protection against one or more symptoms associated with HSV-2 infection. In another embodiment, these HSV-2 symptoms include the symptoms described hereinabove.
[00153] In another embodiment, the disorders and symptoms include HSV infections in an immunocompromised subject, including subjects with HIV. In another embodiment, a mutant HSV-I strain of the present invention prevents or inhibits transmission of genital HSV-I from a vaccinated mother to her newborn infant. In another embodiment, a mutant HSV strain of the present invention treats, suppresses, prevents or inhibits HSV in elderly subjects.
[00154] In one embodiment, a mutant HSV-2 strain of the present invention protects a subject against infection and disorders and symptoms associated with infection with wild-type HSV-2. In another embodiment, the mutant HSV-2 strain prevents or inhibits transmission of genital HSV-2 from the vaccinated mother to her newborn infant. In another embodiment, the mutant HSV-2 strain prevents or P-9066-PC inhibits genital ulcer disease. In another embodiment, the mutant HSV-2 strain provides substantial protection against both HSV-2 and HSV-I infection.
[00155] According to any of the methods of the invention, and in one embodiment, the infection is an
HSV-I infection. In another embodiment, the infection is an HSV-2 infection.
[00156] According to any of the methods of the invention, and in one embodiment, the vaccine strain is from a different species from the strain against which protection is conferred ("challenge strain"). In another embodiment, the vaccine strain is of the same species as the challenge strain.
[00157] In one embodiment, a vaccine as described in the methods and compositions of the present invention protects a subject against a challenge with heterologous HSV. In another embodiment, the heterologous challenge is a different strain of the same species. In another embodiment, in the case of a mutant HSV-I vaccine strain, the vaccine confers protection against a heterologous HSV-I strain. In another embodiment, in the case of a mutant HSV-2 vaccine strain, the vaccine confers protection against a heterologous HSV-2 strain. In another embodiment, the heterologous strain has an antigenic protein that is significantly heterologous relative to the vaccine strain. In another embodiment, the antigenic protein is gD. In another embodiment, the antigenic protein is gB. In another embodiment, the antigenic protein is any other antigenic protein known in the art.
[00158] In one embodiment, the heterologous strain has a gD protein that is significantly heterologous relative to the vaccine strain. In another embodiment, the gD protein of the heterologous strain shares 50% homology with the vaccine strain. In another embodiment, the homology shared between the gD protein of the heterologous strain and the vaccine strain is 55%. In another embodiment, the homology shared is 60%. In another embodiment, the homology shared is 65%. In another embodiment, the homology shared is 70%. In another embodiment, the homology shared is 75%. In another embodiment, the homology shared is 80%. In another embodiment, the homology shared is 85%. In another embodiment, the homology shared is 90%. In another embodiment, the homology shared is 95%. In another embodiment, the homology shared is 98%. In another embodiment, the homology shared is greater than 98%.
[00159] In one embodiment, the heterologous strain has a gB protein that is significantly heterologous relative to the vaccine strain. In another embodiment, the gB protein of the heterologous strain shares 50% homology with the vaccine strain. Tn another embodiment, the homology shared between the gB protein of the heterologous strain and the vaccine strain is 55%. In another embodiment, the homology shared is 60%. In another embodiment, the homology shared is 65%. In another embodiment, the homology shared is 70%. In another embodiment, the homology shared is 75%. In another embodiment, the homology shared is 80%. In another embodiment, the homology shared is 85%. In another embodiment, the homology shared is 90%. In another embodiment, the homology shared is P-9066-PC
95%. In another embodiment, the homology shared is 98%. In another embodiment, the homology shared is greater than 98%.
[00160] In one embodiment, the heterologous challenge strain is HSV-I NS. In another embodiment, the heterologous challenge strain is HSV-I(F). In another embodiment, the heterologous challenge strain is HSV-I (17). In another embodiment, the heterologous challenge strain is any other HSV-I strain known in the art.
[00161] In one embodiment, the heterologous challenge strain is HSV-2(2.12). In another embodiment, the heterologous challenge strain is any other HSV-2 strain known in the art.
[00162] In one embodiment, the heterologous challenge strain is a different HSV species. In another embodiment, in the case of a mutant HSV-I vaccine strain, the vaccine confers protection against HSV-2 challenge. In another embodiment, in the case of a mutant HSV-2 vaccine strain, the vaccine confers protection against HSV-I challenge.
[00163] In one embodiment, a vaccine as described in the methods and compositions of the present invention protects a subject against a challenge with a large inoculum of HSV. In another embodiment, the large inoculum is 106 plaque-forming units (pfu). In another embodiment, the inoculum is 1.5 x 106 pfu. In another embodiment, the inoculum is 2 x 106 pfu. In another embodiment, the inoculum is 3 x 106 pfu. In another embodiment, the inoculum is 4 x 106 pfu. In another embodiment, the inoculum is 5 x 106 pfu. In another embodiment, the inoculum is 7 x 106 pfu. In another embodiment, the inoculum is 1 x 107 pfu. In another embodiment, the inoculum is 1.5 x 107 pfu. In another embodiment, the inoculum is 2 x IO7 pfu. In another embodiment, the inoculum is 3 x 107 pfu. In another embodiment, the inoculum is 4 x 10 pfu. In another embodiment, the inoculum is 5 x 107 pfu. In another embodiment, the inoculum is 7 x 107 pfu. In another embodiment, the inoculum is 10s pfu. In another embodiment, the inoculum is 103- 106 pfu. In another embodiment, the inoculum is 103-105 pfu. In another embodiment, the inoculum is 104-106 pfu. In another embodiment, the inoculum is 3 x 104- 3 x 106 pfu. In another embodiment, the inoculum is Iθ4-107 pfu. In another embodiment, the inoculum is 3 x 104- 3 x 107 pfu. In another embodiment, the inoculum is 105-108 pfu. In another embodiment, the inoculum is 3 x 105-3 x 108 pfu. In another embodiment, the inoculum is more than 108 pfu.
[00164] In one embodiment, a vaccine as described in the methods and compositions of the present invention exhibits enhanced safety relative to gE-containing HSV vaccine strains, due to its inability to infect the ganglia. In another embodiment, a method of the present invention exhibits enhanced safety relative to gE-containing HSV vaccine strains, due to its inability to spread in neurons.
[00165] Various embodiments of dosage ranges of mutant HSV particles can be used, in another embodiment, in methods of the present invention. In another embodiment, the dosage is 103 pfu. In another P-9066-PC embodiment, the dosage is 2 x 103 pfu. In another embodiment, the dosage is 3 x 103 pfu. In another embodiment, the dosage is 5 x 103 pfu. In another embodiment, the dosage is 1O4 pfu. In another embodiment, the dosage is 1.5 x 104 pfu. In another embodiment, the dosage is 104 pfu. In another embodiment, the dosage is 2 x 104 pfu. In another embodiment, the dosage is 3 x 104 pfu. In another embodiment, the dosage is 5 x 104 pfu. In another embodiment, the dosage is 7 x 104 pfu. In another embodiment, the dosage is 10s pfu. In another embodiment, the dosage is 2 x 10s pfu. In another embodiment, the dosage is 3 x 105 pfu. In another embodiment, the dosage is 5 x 105 pfu. In another embodiment, the dosage is 7 x 105 pfu. In another embodiment, the dosage is 1O6 pfu. In another embodiment, the dosage is 2 x 105 pfu. In another embodiment, the dosage is 3 x 106 pfu. In another embodiment, the dosage is 5 x 105 pfu. In another embodiment, the dosage is 7 x 106 pfu. In another embodiment, the dosage is 107 pfu. In another embodiment, the dosage is 2 x 107 pfu. In another embodiment, the dosage is 3 x 107 pfu. In another embodiment, the dosage is 5 x 107 pfu. In another embodiment, the dosage is 7 x 107 pfu. In another embodiment, the dosage is 108 pfu. In another embodiment, the dosage is 2 x 10s pfu. In another embodiment, the dosage is 3 x 10s pfu. In another embodiment, the dosage is 5 x 108 pfu. In another embodiment, the dosage is 7 x 108 pfu.
[00166] In another embodiment, the dosage is 103 pfu/dose. In another embodiment, the dosage is 2 x
103 pfu dose. In another embodiment, the dosage is 3 x 103 pfu/dose. In another embodiment, the dosage is 5 x 103 pfu/dose. In another embodiment, the dosage is 104 pfu/dose. In another embodiment, the dosage is 1.5 x 104 pfu/dose. In another embodi ment, the dosage is 104 pfu/dose. In another embodiment, the dosage is 2 x 104 pfu/dose. In another embodiment, the dosage is 3 x 104 pfu/dose. In another embodiment, the dosage is 5 x 104 pfu/dose. In another embodiment, the dosage is 7 x I O4 pfu/dose. In another embodiment, the dosage is 105 pfu/dose. In another embodiment, the dosage is 2 x 105 pfu/dose. In another embodiment, the dosage is 3 x 10s pfu/dose. In another embodiment, the dosage is 5 x 103 pfu/dose. In another embodiment, the dosage is 7 x 10s pfu/dose. In another embodiment, the dosage is 106 pfu/dose. In another embodiment, the dosage is 2 x 106 pfu/dose. In another embodiment, the dosage is 3 x 106 pfu/dose. In another embodiment, the dosage is 5 x 106 pfu/dose. In another embodiment, the dosage is 7 x 106 pfu/dose. In another embodiment, the dosage is 107 pfu/dose. In another embodiment, the dosage is 2 x 107 pfu/dose. In another embodiment, the dosage is 3 x 107 pfu/dose. In another embodiment, the dosage is 5 x
107 pfu/dose. In another embodiment, the dosage is 7 x 107 pfu/dose. In another embodiment, the dosage is
108 pfu/dose. In another embodiment, the dosage is 2 x 108 pfu/dose. In another embodiment, the dosage is 3 x 10s pfu/dose. In another embodiment, the dosage is 5 x 10s pfu/dose. In another embodiment, the dosage is 7 x 10s pfu/dose. In another embodiment, the dose is more than 108 pfu. In another embodiment, the dose is 103-106 pfu. In another embodiment, the dose is 103- 105 pfu. In another embodiment, the dose is 10 -10 pfu. In another embodiment, the dose is 3 x 104- 3 x 106 pfu. In another embodiment, the dose is 104- 107 pfu. In another embodiment, the dose is 3 x 104- 3 x 107 pfu. In another embodiment, the dose is 105-108 pfu. In another embodiment, the dose is 3 x 105-3 x 108 pfu. P-9066-PC
[00167] In one embodiment, "treating" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove. Thus, in one embodiment, treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing, the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof. Thus, in one embodiment, "treating" refers inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. In one embodiment, "preventing" refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In one embodiment, "suppressing" or "inhibiting", refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
[00168] In one embodiment, symptoms are primary, while in another embodiment, symptoms are secondary. In one embodiment, "primary" refers to a symptom that is a direct result of the subject viral infection, while in one embodiment, "secondary" refers to a symptom that is derived from or consequent to a primary cause. In one embodiment, the compositions and strains for use in the present invention treat primary or secondary symptoms or secondary complications related to HSV infection.
[00169] In another embodiment, "symptoms" may be any manifestation of a HSV infection, comprising blisters, ulcerations, or lesions on the urethra, cervix, upper thigh, and/or anus in women and on the penis, urethra, scrotum, upper thigh, and anus in men, inflammation, swelling, fever, flu-like symptoms, sore mouth, sore throat, pharyngitis, pain, blisters on tongue, mouth or lips, ulcers, cold sores, neck pain, enlarged lymph nodes, reddening, bleeding, itching, dysuria, headache, muscle pain, etc., or a combination thereof.
[00170] The gE protein as described in the methods and compositions of the present invention has, in one embodiment, the sequence:
[00171 ] MDRGA VVGFLLGVCV VSCLAGTPKTS WRRVS VGEDVSLLPAPGPTGRGPTQKLLW .
AVEPLDGCGPLHPSWVSLMPPKQVPETVVD AACMRAPVPLAMA Y APPAPSATGGLRTDFVWQE RAAVVNRSLVEHGVRETDSGLYTLSVGDIKDPARQV ASVVLVVQPAPVPTPPPTPADYDEDDNDE GEDESLAGTPASGTPRLPPPPAPPRSWPSAPEVSHVRGVTVRMETPEAILFSPGETFSTNVSIHAIAH DDQTYSMDVVWLRFDVPTSCAEMRIYESCLYHPQLPECLSPADAPCAASTWTSRLAVRSYAGCS RTNPPPRCSAEAHMEPVPGLA WQAASVNLEFRDASPQHSGLYLCVVYVNDHIHAWGHITISTAA QYRNA VVEQPLPQRGADLAEPTHPHVGAPPHAPPTHGALRLGA VMGAALLLSALGLSVW ACMT P-9066-PC
CWRRRAWRAVKSRASGKGPTYIRV ADSELYADWSSDSEGERDQVPWLAPPERPDSPSTNGSGFE ILSPTAPSVYPRSDGHQSRRQLTTFGSGRPDRRYSQASDSSVFW (SEQ ID NO: 2). In another embodiment, the gE protein is a homologue of SEQ BD No: 2. In another embodiment, the gE protein is a variant of SEQ ID No: 2. In another embodiment, the gE protein is an isomer of SEQ BD No: 2. In another embodiment, the gE protein is a fragment of SEQ ID No: 2. In another embodiment, the gE protein comprises SEQ ID No: 2.
[00172] In another embodiment, the gE protein is encoded by a nucleotide sequence having the sequence: atggatcgcggggcggtggtggggtttcttctcggtgtttgtgttgtatcgtgcttggcgggaacgcccaaaacgtcctggagacgggtgagtgtcg gcgaggacgtttcgttgcttccagctccggggcctacggggcgcggcccgacccagaaactactatgggccgtggaacccctggatgggtgcgg ccccttacacccgtcgtgggtctcgctgatgccccccaagcaggtgcccgagacggtcgtggatgcggcgtgcatgcgcgctccggtcccgctgg cgatggcgtacgcccccccggccccatctgcgaccgggggtctacgaacggacttcgtgtggcaggagcgcgcggccgtggttaaccggagtct ggttattcacggggtccgagagacggacagcggcctgtataccctgtccgtgggcgacataaaggacccggctcgccaagtggcctcggtggtcc tggtggtgcaaccggccccagttccgaccccacccccgaccccagccgattacgacgaggatgacaatgacgagggcgaggacgaaagtctcg ccggcactcccgccagcgggaccccccggctcccgcctccccccgcccccccgaggtcttggcccagcgcccccgaagtctcacatgtgcgtg gggtgaccgtgcgtatggagactccggaagctatcctgttttcccccggggagacgttcagcacgaacgtctccatccatgccatcgcccacgacg accagacctactccatggacgtcgtctggttgaggttcgacgtgccgacctcgtgtgccgagatgcgaatatacgaatcgtgtctgtatcacccgcag ctcccagaatgtctgtccccggccgacgcgccgtgcgccgcgagtacgtggacgtctcgcctggccgtccgcagctacgcggggtgttccagaac aaaccccccaccgcgctgttcggccgaggctcacatggagcccgtcccggggctggcgtggcaggcggcctccgtcaatctggagttccgggac gcgtccccacaacactccggcctgtatctgtgtgtggtgtacgtcaacgaccatattcacgcctggggccacattaccatcagcaccgcggcgcagt accggaacgcggtggtggaacagcccctcccacagcgcggcgcggatttggccgagcccacccacccgcacgtcggggcccctccccacgcg cccccaacccacggcgccctgcggttaggggcggtgatgggggccgccctgctgctgtctgcactggggttgtcggtgtgggcgtgtatgacctg ttggcgcaggcgtgcctggcgggcggttaaaagcagggcctcgggtaaggggcccacgtacattcgcgtggccgacagcgagctgtacgcgga ctggagctcggacagcgagggagaacgcgaccaggtcccgtggctggcccccccggagagacccgactctccctccaccaatggatccggcttt gagatcttatcaccaacggctccgtctgtatacccccgtagcgatgggcatcaatctcgccgccagctcacaacctttggatccggaaggcccgatc gccgttactcccaggcctccgattcgtccgtcttctggtaa (SEQ ID No: 3). In another embodiment, the gE protein is encoded by a nucleotide molecule that a homologue of SEQ ED No: 3. In another embodiment, the nucleotide molecule is a variant of SEQ ID No: 3. Tn another embodiment, the nucleotide molecule is an isomer of SEQ ID No: .3. In another embodiment, the nucleotide molecule is a fragment of SEQ ID No: 3. In another embodiment, the nucleotide molecule comprises SEQ ID No: 3.
[00173] In another embodiment, the gE protein as described in the methods and compositions of the present invention has the sequence:
[00174] MDRGA VVGFLLG VCV VSCLAGTPKTS WRRVS VGED VSLLPAPGPTGRGPTQKLL
WA VEPLDGCGPLHPSWVSLMPPKQVPETVVDAACMRAPVPLAMA Y APPAPSATGGLRTDFV WQERAAVVNRSLVIYGVRETDSGLYTLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDE P-9066-PC
DDNDEGEGEDESLAGTPASGTPRLPPSPAPPRSWPSAPEVSHVRGVTVRMETPEAILFSPGEAFS TNVSIHAIAHDDQTYTMDVVWLRFDVPTSCAEMRIYESCLYHPQLPECLSPADAPCAASTWTS RLAVRSYAGCSRTNPPPRCSAEAHMEPFPGLA WQAASVNLEFRDASPQHSGLYLCVVYVNDH IHAWGHITINTAAQYRNAVVEQPLPQRGADLAEPTHPHVGAPPHAPPTHGALRLGAVMGAAL LLSALGLSVWACMTCWRRRAWRAVKSRASGKGPTYIRV ADSELY ADWSSDSEGERDQVPWL APPERPDSPSTNGSGFEILSPTAPSVYPRSDGHQSRRQLTTFGSGRPDRRYSQASDSSVFW (SEQ ID No: 4). In another embodiment, the gE protein is a homologue of SEQ ID No: 4. In another embodiment, the gE protein is a variant of SEQ ID No: 4. In another embodiment, the gE protein is an isomer of SEQ ID No: 4. In another embodiment, the gE protein is a fragment of SEQ ID No: 4. In another embodiment, the gE protein comprises SEQ ID No: 4.
[00175] In another embodiment, the gE protein is encoded by a nucleotide sequence having the sequence:
[00176] atggatcgcggggcggtggtggggtttcttctcggtgtttgtgttgtatcgtgcttggcgggaacgcccaaaacgtcctggagacg ggtgagtgtcggcgaggacgtttcgttgctaccagctccggggcctacggggcgcggcccgacccagaaactactatgggccgtggaacccctgg atgggtgcggccccttacacccgtcgtgggtctcgctgatgccccccaagcaggtacccgagacggtcgtggatgcggcgtgcatgcgcgctccg gtcccgctggcgatggcatacgcccccccggccccatctgcgaccgggggtctacggacggacttcgtgtggcaggagcgcgcggccgtggtta accggagtctggttatttacggggtccgagagacggacagcggcctgtataccctgtctgtgggcgacataaaggacccggctcgccaagtggcct cggtggtcctggtggtgcaaccggccccagttccgactccacccccgaccccagccgattacgacgaggatgacaatgacgagggcgagggcga ggacgaaagtctagccggcactcccgccagcgggaccccccggctcccgccttcccccgcccccccgaggtcttggcccagcgcccccgaagtc tcacacgtgcgtggggtgaccgtgcgtatggagactccggaagctatcctgttttcccccggggaggcgtttagcacgaacgtctccatccatgccat cgcccacgacgaccagacctacaccatggacgtcgtctggttgaggttcgacgtgccgacctcgtgtgccgagatgcgaatatacgaatcgtgtctg tatcatccgcagctcccagagtgtctgtccccggccgacgctccgtgcgccgcgagtacgtggacgtctcgcctggccgtccgcagctacgcgggg tgttccagaacaaaccccccgccgcgctgttcggccgaggctcacatggagcccttcccggggctggcgtggcaggcggcctcagtcaatctgga gttccgggacgcgtccccacaacactccgggctgtatctgtgcgtggtgtacgtcaacgaccatattcacgcatggggccacattaccatcaacaccg cggcgcagtaccggaacgcggtggtggaacagcccctcccacagcgcggcgcggatttggccgagcccacccacccgcacgtcggggcccctc cccacgcgcccccaacccacggcgccctgcggttaggggcggtgatgggggccgccctgctgctgtctgcgctggggttgtcggtgtgggcgtgt atgacctgttggcgcaggcgtgcctggcgggcggttaaaagcagggcctcgggtaaggggcccacgtacattcgcgtggccgacagcgagctgt acgcggactggagctcggacagcgagggagaacgcgaccaggtcccgtggctggcccccccggagagacccgactctccctccaccaatggat ccggctttgagatcttatcaccaacggctccgtctgtatacccccgtagcgatgggcatcaatctcgccgccagctcacaacctttggatccggaagg cccgatcgccgttactcccaggcctccgattcgtccgtcttctggtaa (SEQ ID No: 5). In another embodiment, the gE protein is encoded by a nucleotide molecule that a homologue of SEQ ED No: 5. In another embodiment, the nucleotide molecule is a variant of SEQ ID No: 5. In another embodiment, the nucleotide molecule is an isomer of SEQ ID No: 5. In another embodiment, the nucleotide molecule is a fragment of SEQ ID No: 5. In another embodiment, the nucleotide molecule comprises SEQ ID No: 5. P-9066-PC
[00177] In another embodiment, the gE protein as described in the methods and compositions of the present invention has the sequence:
[00178] MARGAGLVFFVGVWVVSCLAAAPRTSWKRVTSGEDVVLLPAPAERTRAHKLLWA
AEPLDACGPLRPSWVALWPPRRVLETWDAACMRAPEPLAIAYSPPFPAGDEGLYSELA WRDRV AVVNESLVIYGALETDSGLYTLSVVGLSDEARQVASVVLVVEPAPVPTPTPDDYDEEDDAGVTN ARRSAFPPQPPPRRPPVAPPTHPRVIPEVSHVRGVTVHMETLEAILFAPGETFGTNVSIHAIAHDDG PYAMDVVWMRFDVPSSCADMRIYEACLYHPQLPECLSPADAPCAVSSWAYRLAVRSYAGCSRT TPPPRCFAEARMEPVPGLAWLASTVNLEFQHASPQHAGLYLCVVYVDDHIHAWGHMTISTAAQY RNA VVEQHLPQRQPEPVEPTRPHVRAPHPAPSARGPLRLGAVLGAALLLAALGLSAW ACMTCW RRRSWRAVKSRASATGPTYTRVADSELYADWSSDSEGERDGSLWQDPPERPDSPSTNGSGFEILSP TAPSVYPHSEGRKSRRPLTTFGSGSPGRRHSQASYPSVLW (SEQ ID NO: 6; this protein was mutated in Examples 1-5 herein). In another embodiment, the gE protein is a homologue of SEQ BD No: 6. In another embodiment, the gE protein is a variant of SEQ ID No: 6. In another embodiment, the gE protein is an isomer of SEQ ID No: 6. In another embodiment, the gE protein is a fragment of SEQ ID No: 6. In another embodiment, the gE protein comprises SEQ ID No: 6.
[00179] In another embodiment, the gE protein is encoded by a nucleotide sequence having the sequence:
[00180] atggctcgcggggccgggttggtgttttttgttggagtttgggtcgtatcgtgcctggcggcagcacccagaacgtcctggaaacgggt aacctcgggcgaggacgtggtgttgcttccggcgcccgcggaacgcacccgggcccacaaactactgtgggccgcggaacccctggatgcctgcggt cccctgcgcccgtcgtgggtggcgctgtggcccccccgacgggtgctcgagacggtcgtggatgcggcgtgcatgcgcgccccggaaccgctcgcca tagcatacagtcccccgttccccgcgggcgacgagggactgtattcggagttggcgtggcgcgatcgcgtagccgtggtcaacgagagtctggtcatcta cggggccctggagacggacagcggtctgtacaccctgtccgtggtcggcctaagcgacgaggcgcgccaagtggcgtcggtggttctggtcgtggag cccgcccctgtgccgaccccgacccccgacgactacgacgaagaagacgacgcgggcgtgacgaacgcacgccggtcagcgttccccccccaaccc cccccccgtcgtccccccgtcgcccccccgacgcaccctcgtgttatccccgaggtgtcccacgtgcgcggggtaacggtccatatggagaccctggag gccattctgtttgcccccggggagacgtttgggacgaacgtctccatccacgccattgcccacgacgacggtccgtacgccatggacgtcgtctggatgc ggtttgacgtgccgtcctcgtgcgccgatatgcggatctacgaagcttgtctgtatcacccgcagcttccagagtgtctatctccggccgacgcgccgtgcg ccgtaagttcctgggcgtaccgcctggcggtccgcagctacgccggctgttccaggactacgcccccgccgcgatgttttgccgaggctcgcatggaac cggtcccggggttggcgtggctggcctccaccgtcaatctggaattccagcacgcctccccccagcacgccggcctctacctgtgcgtggtgtacgtgga cgatcatatccacgcctggggccacatgaccatcagcaccgcggcgcagtaccggaacgcggtggtggaacagcacctcccccagcgccagcccga gcccgtcgagcccacccgcccgcacgtgagagccccccatcccgcgccctccgcgcgcggcccgctgcgcctcggggcggtgctgggggcggccc tgttgctggccgccctcgggctgtccgcgtgggcgtgcatgacctgctggcgcaggcgctcctggcgggcggttaaaagccgggcctcggcgacggg ccccacttacattcgcgtggcggacagcgagctgtacgcggactggagttcggacagcgagggggagcgcgacgggtccctgtggcaggaccctccg gagagacccgactctccctccacaaatggatccggctttgagatcttatcaccaacggctccgtctgtatacccccatagcgaggggcgtaaatctcgccg cccgctcaccacctttggttcgggaagcccgggccgtcgtcactcccaggcctcctatccgtccgtcctctggtaa (SEQ ID No: 7; this gene was mutated in Examples 1-5 herein. In another embodiment, the gE protein is encoded by a nucleotide P-9066-PC molecule that a homologue of SEQ ID No: 7. In another embodiment, the nucleotide molecule is a variant of SEQ ID No: 7. In another embodiment, the nucleotide molecule is an isomer of SEQ ID No: 7. In another embodiment, the nucleotide molecule is a fragment of SEQ ID No: 7. In another embodiment, the nucleotide molecule comprises SEQ ID No: 7.
[00181] In one embodiment, the gE protein is encoded by one of the following GenBank Accession
Numbers: DQ889502, NC_001806, NC_001798, Z86099, X14112, L00036, X02138, and X04798, and any of AJ626469-AJ626498. In another embodiment, the gE protein is homologous to a sequence disclosed in one of the above GenBank Accession Numbers. In another embodiment, the gE protein is a variant of a sequence disclosed in one of the above GenBank Accession Numbers. In another embodiment, the gE protein is a fragment of a sequence disclosed in one of the above GenBank Accession Numbers.
[00182] In one embodiment, a gE protein HSV-I glycoprotein E (gE) is a virion surface protein which is necessary for spread in neurons, and in one embodiment, is necessary for spread along axons in either direction, both to ("retrograde"), and from ("anterograde"), the neuronal cell body. In another embodiment, gE also facilitates evasion of the host immune system by sequestering host antibodies against HSV-I, rendering them inactive. In one embodiment, a gE-deleted HSV-I replicates in the skin, but cannot spread along neurons to establish latency or escape the host's antibody response. Thus, in one embodiment, infection with the live attenuated gE-deleted HSV-I or HSV-2 will elicit a robust immune response in the skin and protect the host from future encounters with the wild-type virus.
[00183] In one embodiment, the gE protein is a HSV-I gE protein. In another embodiment, the gE protein is a HSV-I (NS) gE protein. In another embodiment, the gE protein is a HSV-1(17) gE protein. In another embodiment, the gE protein is a HSV-I (F) gE protein. In another embodiment, the gE protein is a HSV-I(KOS) gE protein. In another embodiment, the gE protein is a HSV-I(CLlOl) gE protein. In another embodiment, the gE protein is a HS V- 1 (Maclntyre) gE protein. In another embodiment, the gE protein is a HSV-I(MP) gE protein. In another embodiment, the gE protein is a HSV-l(17+syn) gE protein. In another embodiment, the gE protein is a HSV-I(HF) gE protein. In another embodiment, the gE protein is any other HSV-I gE protein known in the art.
[00184] In one embodiment, the gE protein is a HSV-2 gE protein. In another embodiment, the gE protein is a HSV-2(HG52) gE protein. In another embodiment, the gE protein is a HSV-2(2.12) gE protein. In another embodiment, the gE protein is a HSV-2(MS) gE protein. In another embodiment, the gE protein is a HSV-2(186) gE protein. In another embodiment, the gE protein is a HSV-2(G) gE protein. In another embodiment, the gE protein is any other HSV-2 gE protein known in the art.
[00185] In another embodiment, the gE protein is any other HSV-I or HSV-2 gE protein which in one embodiment has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology P-9066-PC to one of the gE proteins or nucleic acid sequences listed hereinabove. In another embodiment, the gE protein has 98.6 % homology to HSV(NS) or HSV(17), or both.
[00186] In one embodiment, the gE protein is any other gE protein known in the art. In another embodiment, the gE protein is encoded by any Us8 nucleotide known in the art. In one embodiment, the Us8 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703448 or GenelD: 1487360, or encodes a protein sequence of glycoprotein E, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044670.1 or NP_044538.1.
[00187] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us6 gene. In one embodiment, the Us6 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703444, GenelD: 1487358, NC_001806, NC_001798, EU029158, EF177451, EF177450, EF157322, EF157321, EF157320, EF157319, Z86099, AJ004801, X14112, AF147806, AY779754, AY779753, AY779752, AY779751, AY779750, AY517492, AY155225, AB016432, AF021342, U12183, U12182, U12181, U12180, or InterPro:IPR002896, or encodes a protein sequence of glycoprotein D, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044668.1, NPJM4536.1, CAA38245, AAB59754, AAA19629, AAA19631, AAA19630, AAK93950, ABS84899, ABM66848, ABM66847, AAW23134, AAW23133, AAW23132, AAW23131, AAW23130, AAS01730, ABM52981, ABM52980, ABM52979, ABM52978, AAN74642, AAO26211, AAL90884, AAL90883, AAKl 9597, AAA45785, BAA00020, AAB60555, AAB60554, AAB60553, AAB60552, AAA98962, AAA98963, AAA45842, AAA45786, VGBEDZ, CAB06713, CAA32283, AAB72102, or CAB06713.1.
[00188] In another embodiment, the gD protein is any other HSV-I or HSV-2 gD protein which in one embodiment has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology to one of the gD proteins or nucleic acid sequences listed hereinabove.
[00189] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us9 gene. In one embodiment, the Us9 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneBD:2703452 or GenelD: 1487362, or encodes a protein sequence of Us9 membrane protein, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044672.1 or NP_044540.1.
[00190] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us5 gene. In one embodiment, the Us5 gene has a nucleic acid sequence that corresponds to that set forth in P-9066-PC
Genbank Accession Nos: GeneID:2703406 or GenelD: 1487357, or encodes a protein sequence of glycoprotein J, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044667.1 or NP_044535.1. '
[00191] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the Us4 gene. In one embodiment, the Us4 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneDZ>:2703404 or GenelD: 1487356, or encodes a protein sequence of glycoprotein G, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: •NP_044666.1 or NP_044534.1.
[00192] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in. one embodiment, is an inactivation of the UL53 gene. In one embodiment, the UL53 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703425 or GenelD: 1487342, or encodes a protein sequence of glycoprotein K, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044656.1 or NP_044524.1.
[00193] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the ULlO gene. In one embodiment, the ULl 0 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703379 or GenelD: 1487293, or encodes a protein sequence of glycoprotein M, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044611.1 or NP_044479.1.
[00194] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the ULl gene. In one embodiment, the ULl gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703393 or GenelD: 1487292, or encodes a protein sequence of glycoprotein L, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044602.1 or NP_044470.1.
[00195] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL22 gene. In one embodiment, the UL22 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703373 or GenelD: 1487306, or encodes a protein sequence of glycoprotein H, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044623.1 or NP_044491.1. P-9066-PC
[00196] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL27 gene. In one embodiment, the UL27 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703455 or GenelD: 1487312, or encodes a protein sequence of glycoprotein B, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044629.1 or NP_044497.1.
[00197] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL44 gene. In one embodiment, the UL44 gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703410 or GenelD: 1487331, or encodes a protein sequence of glycoprotein C, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044646.1 or NP_044514.1.
[00198] In one embodiment, the HSV strain of and for use in the methods of the present invention comprise an additional inactivating mutation, which in one embodiment, is an inactivation of the UL49a ' gene. In one embodiment, the UL49a gene has a nucleic acid sequence that corresponds to that set forth in Genbank Accession Nos: GeneID:2703419 or GenelD: 1487337, or encodes a protein sequence of glycoprotein N, which in one embodiment, corresponds to that set forth in Genbank Accession Nos: NP_044652.1 or NP_044520.1.
[00199] In another embodiment, the additional mutation is in an HSV-I or HSV-2 glycoprotein that, in one embodiment, has greater than 80% homology, in another embodiment, greater than 85% homology, in another embodiment greater than 95% homology, and in another embodiment greater than 98% homology to one or more of the glycoproteins listed hereinabove.
[00200] In one embodiment, HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gD, which in one embodiment is Us6. In another embodiment, HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gE, which in one embodiment is Us8. In another embodiment, HSV strains of and for use in the instant invention may comprise an inactivating mutation in a gene encoding gE and in a gene encoding gD. In one embodiment, the Us6 mutation is introduced to attenuate an HSV strain comprising a Us8 mutation that is highly virulent. In one embodiment, the Us6 mutation reduces virus entry. Us6 mutations, as well as any of the mutations of the present invention may be in either HSV-I or HSV-2 or both. In one embodiment, HSV-I gD and HSV-2 gD have a large degree of homology. In one embodiment, the amino acid sequences of HSV-I gD and HSV-2 gD have 81% homology, or in another embodiment, greater than 80% homology, or in another embodiment, greater than 85% homology, or in another embodiment, greater than 90% homology, or in another embodiment, greater than 95% homology. In one embodiment, the P-9066-PC nucleic acid sequences of HSV-I gD and HSV-2 gD have 85% homology, or in another embodiment, greater than 80% homology, or in another embodiment, greater than 85% homology, or in another embodiment, greater than 90% homology, or in another embodiment, greater than 95% homology.
[00201] In one embodiment, the gD protein derived of the methods and compositions of the present invention has the sequence:
[00202] MGGTAARLGAVILFVVIVGLHGVRGKYALADASLKMADPNRFRGKDLPVLDQLTD PPGVRR WHIQAGLPDPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTI AWFRMGGNCAIPΓΓVMEYTECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETA
GTYLRLVKINDWTEΓΓQFILEHRAKGSCKYALPLRIPPSACLS PQAYQQGVTVDSIGMLPRFIPENQ RTVAVYSLKIAGWHGPKAPYTSTLLPPELSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNW HffSIQDAATPYHPPATPNNMGLL^GAVGGSLLAALVICGrVYWMHRRTRKAPKRIRLPHIREDDQ PSSHQPL (SEQ ID No: 14). In another embodiment, the gD protein is a homologue of SEQ ID No: 14. In another embodiment, the gD protein is a variant of SEQ ID No: 14. In another embodiment, the gD protein is an isomer of SEQ ED No: 14. In another embodiment, the gD protein is a fragment of SEQ ID No: 14. In another embodiment, the gD protein comprises SEQ ID No: 14. In one embodiment, the gD amino acid sequence is an HSV-I amino acid sequence.
[00203] In another embodiment, the gD protein is encoded by a nucleotide sequence having the sequence:
[00204] gtggccccggcccccaacaaaaatcacggtagcccggccgtgtgacactatcgtccataccgaccacaccgacgaacccctaaggg ggaggggccattttacgaggaggaggggtataacaaagtctgtctttaaaaagcaggggttagggagttgttcggtcataagcttcagcgcgaacgacca actaccccgatcatcagttatccttaaggtctcttttgtgtggtgcgttccggtatgggggggactgccgccaggttgggggccgtgattttgtttgtcgtcata gtgggcctccatggggtccgcggcaaatatgccttggcggatgcctctctcaagatggccgaccccaatcgctttcgcggcaaagaccttccggtcctgg accagctgaccgaccctccgggggtccggcgcgtgtaccacatccaggcgggcctaccggacccgttccagccccccagcctcccgatcacggtttac tacgccgtgttggagcgcgcctgccgcagcgtgctcctaaacgcaccgtcggaggccccccagattgtccgcggggcctccgaagacgtccggaaac aaccctacaacctgaccatcgcttggtttcggatgggaggcaactgtgctatccccatcacggtcatggagtacaccgaatgctcctacaacaagtctctgg gggcctgtcccatccgaacgcagccccgctggaactactatgacagcttcagcgccgtcagcgaggataacctggggttcctgatgcacgcccccgcgt ttgagaccgccggcacgtacctgcggctcgtgaagataaacgactggacggagattacacagtttatcctggagcaccgagccaagggctcctgtaagta cgccctcccgctgcgcatccccccgtcagcctgcctctccccccaggcctaccagcagggggtgacggtggacagcatcgggatgctgccccgcttcat ccccgagaaccagcgcaccgtcgccgtatacagcttgaagatcgccgggtggcacgggcccaaggccccatacacgagcaccctgctgcccccgga gctgtccgagacccccaacgccacgcagccagaactcgccccggaagaccccgaggattcggccctcttggaggaccccgtggggacggtggcgcc gcaaatcccaccaaactggcacatcccgtcgatccaggacgccgcgacgccttaccatcccccggccaccccgaacaacatgggcctgatcgccggc gcggtgggcggcagtctcctggcagccctggtcatttgcggaattgtgtactggatgcaccgccgcactcggaaagccccaaagcgcatacgcctcccc cacatccgggaagacgaccagccgtcctcgcaccagcccttgttttactagatacccccccttaatgggtgcgggggggtcaggtctgcggggttgggat gggaccttaactccatataaagcgagtctggaaggggggaaaggcggacagtcgataagtcggtagcgggggacgcgcacctgttccgcctgtcgcac P-9066-PC ccacagctttttcgcgaaccgtcccgttttcgggat (SEQ ID No: 15). In another embodiment, the gD protein is encoded by a nucleotide molecule that a homologue of SEQ ID No: 15. In another embodiment, the nucleotide molecule is a variant of SEQ ID No: 15. In another embodiment, the nucleotide molecule is an isomer of SEQ ID No: 15. In another embodiment, the nucleotide molecule is a fragment of SEQ ID No: 15. In another embodiment, the nucleotide molecule comprises SEQ ID No: 15. In one embodiment, the gD nucleotide sequence is an HSV-I nucleotide sequence.
[00205] In one embodiment, the gD protein as described in the methods and compositions of the present invention has the sequence:
[00206] MGRLTSGVGTAALLVVAVGLRWCAKYALADPSLKMADPNRFRGKNLPVLDQLTD PPGVKRVYHIQPSLEDPFQPPSIPΓΓVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTI AWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETA GTYLRLVKINDWTEΓΓQΠLEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQ RTVALYSLKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNW HIPSIQDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPP
SHQPLFY (SEQ ID No: 16). In another embodiment, the gD protein is a homologue of SEQ ID No: 16. In another embodiment, the gD protein is a variant of SEQ ID No: 16. In another embodiment, the gD protein is an isomer of SEQ DD No: 16. In another embodiment, the gD protein is a fragment of SEQ ED No: 16. In another embodiment, the gD protein comprises SEQ DD No: 16. In one embodiment, the gD amino acid sequence is an HSV-2 amino acid sequence.
[00207] In another embodiment, the gD protein is encoded by a nucleotide sequence having the sequence:
[00208] atggggcgtt tgacctccgg cgtcgggacg gcggccctgc tagttgtcgc ggtgggactc cgcgtcgtct gcgccaaata cgccttagca gacccctcgc ttaagatggc cgatcccaat cgatttcgcg ggaagaacct tccggttttg gaccagctga ccgacccccc cggggtgaag cgtgtttacc acattcagcc gagcctggag gacccgttcc agccccccag catcccgatc actgtgtact acgcagtgct ggaacgtgcc tgccgcagcg tgctcctaca tgccccatcg gaggcccccc agatcgtgcg cggggcttcg gacgaggccc gaaagcacac gtacaacctg accatcgcct ggtatcgcat gggagacaat tgcgctatcc ccatcacggt tatggaatac accgagtgcc cctacaacaa gtcgttgggg gtctgcccca tccgaacgca gccccgctgg agctactatg acagctttag cgccgtcagc gaggataacc tgggattcct gatgcacgcc cccgccttcg agaccgcggg tacgtacctg cggctagtga agataaacga ctggacggag atcacacaat ttatcctgga gcaccgggcc cgcgcctcct gcaagtacgc tctccccctg cgcatccccc cggcagcgtg cctcacctcg aaggcctacc aacagggcgt gacggtcgac agcatcggga tgctaccccg ctttatcccc gaaaaccagc gcaccgtcgc cctatacagc ttaaaaatcg ccgggtggca cggccccaag cccccgtaca ccagcaccct gctgccgccg gagctgtccg acaccaccaa cgccacgcaa cccgaactcg ttccggaaga ccccgaggac tcggccctct tagaggatcc cgccgggacg gtgtcttcgc agatcccccc aaactggcac atcccgtcga tccaggacgt cgcgccgcac cacgcccccg ccgcccccag caacccgggc ctgatcatcg gcgcgctggc cggcagtacc ctggcggtgc tggtcatcgg cggtattgcg ttttgggtac gccgccgcgc tcagatggcc cccaagcgcc tacgtctccc ccacatccgg gatgacgacg cgcccccctc P-9066-PC gcaccagcca ttgttttact ag (SEQ ID No: 17). In another embodiment, the gD protein is encoded by a nucleotide molecule that a homologue of SEQ ID No: 17. In another embodiment, the nucleotide molecule is a variant of SEQ ID No: 17. In another embodiment, the nucleotide molecule is an isomer of SEQ ID No: 17. In another embodiment, the nucleotide molecule is a fragment of SEQ ID No: 17. In another embodiment, the nucleotide molecule comprises SEQ ED No: 17. In one embodiment, the gD nucleic acid sequence is an HSV-2 nucleic acid sequence.
[00209] In one embodiment, an inactivating mutation in a gene encoding gD comprises a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C). In another embodiment, an inactivating mutation in a gene encoding gD comprises a mutation in which an alanine at residue 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C), a tyrosine at residue 2 to alanine (Y2A), a leucine at residue 4 to alanine (WA), or a combination thereof. In another embodiment, an inactivating mutation in a gene encoding gD comprises a deletion of the alanine at residue 3 of HSV-I gD or HSV-2 gD, a deletion of the tyrosine at residue 2, a deletion of leucine at residue 4, or a combination thereof. In another embodiment, an inactivating mutation in a gene encoding gD comprises a mutation at amino acid positions 38, 222, 223, 215, or a combination thereof. In another embodiment, an inactivating mutation in a gene encoding gD comprises a Y38C mutation, while in another embodiment, it comprises a R222N, F223I, D215G mutation, or combination thereof.
[00210] In another embodiment, an inactivating mutation in a gene encoding gD comprises mutations in amino acids 2 and 3, 3 and 4, 2-4, 1-5, 1-7, or 1-10. In another embodiment, an inactivating mutation in a gene encoding gD consists essentially of a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C). In another embodiment, an inactivating mutation in a gene encoding gD consists of a mutation in which an alanine at amino acid 3 of HSV-I gD or HSV-2 gD is mutated to a cysteine (A3C). In one embodiment, the numbering used to describe the location of the mutation refers to amino acid numbering of the mature peptide after cleaving of the signal sequence, which in one embodiment, is the first 25 amino acids for HSV-I or HSV-2 gD, as is known in the art.
[00211] As provided herein and in one embodiment, a mutant HSV strain of the present invention comprising a mutation in gD has reduced virulence (Example 21) and ability to reach DRG (Example 22). In another embodiment, vaccination with a mutant HSV strain comprising a mutation in gD of the present invention protects against latent HSV infection (Example 23) after subsequent infection with virulent HSV. In another embodiment, the vaccination protects against disease caused by or associated with latent HSV infection. In another embodiment, the vaccination does not itself cause significant disease.
[00212] In some embodiments, any of the mutant HSV strains of and for use in the methods of this invention will comprise an inactivating mutation of the present invention, in any form or embodiment as described herein. In some embodiments, any of the mutant HSV strains of this invention will consist of an P-9066-PC inactivating mutation of the present invention, in any form or embodiment as described herein. In some embodiments, the mutant HSV strains of this invention will consist essentially of an inactivating mutation of the present invention, in any form or embodiment as described herein. In some embodiments, the term "comprise" refers to the inclusion of the inactivating mutation, such as a mutation in gE or in gD, as well as inclusion of other mutations that may be known in the art. In some embodiments, the term "consisting essentially of refers to a strain, whose only functional mutation is the indicated functional mutation, however, other mutations may be included that are not involved directly in the utility of the strain. In some embodiments, the term "consisting" refers to a strain, which contains mutation of a particular gene or a particular mutation.
[00213] In one embodiment, plasmid complementation may be used to complement the inactivating mutation, which in one embodiment, allows at least one round of infection with a mutant HSV of the invention.
[00214] In one embodiment, the present invention provides a composition for impeding formation of zosteriform lesions in a subject, the composition comprising a mutant HSV strain of the present invention.
[00215] In one embodiment, the present invention provides a composition for impeding herpetic ocular disease in a subject, the composition comprising a mutant HSV strain of the present invention.
[00216] In one embodiment, the present invention provides a composition for vaccinating a subject against an HSV infection, the composition comprising a mutant HSV strain of the present invention.
[00217] In one embodiment, the present invention provides a composition for impeding HSV infection in a subject, the composition comprising a mutant HSV strain of the present invention.
[00218] In one embodiment, the present invention provides a composition for impeding herpes- mediated encephalitis in a subject, the composition comprising a mutant HSV strain of the present invention.
[00219] In one embodiment, a gE protein of the present invention is homologous to a peptide disclosed or enumerated herein. The terms "homology," "homologous," etc., when in reference to any protein or peptide, refer, in one embodiment, to a percentage of amino acid (AA) residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Methods and computer programs for the alignment are well known in the art.
[00220] Homology is, in one embodiment, determined by computer algorithm for sequence alignment, by methods well described in the art. For example, computer algorithm analysis of nucleic acid P-9066-PC sequence homology can include the utilization of any number of software packages available, such as, for example, the BLAST, DOMAIN, BEAUTY (BLAST Enhanced Alignment Utility), GENPEPT and TREMBL packages.
[00221] In one embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 70%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 72%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 75%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 78%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 80%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 82%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 83%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 85%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 87%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 88%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 90%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 92%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 93%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 95%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 2-7 of greater than 96%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 97%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 98%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of greater than 99%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 2-7 of 100%.
[00222] In one embodiment, homology is determined via determination of candidate sequence hybridization, methods of which are well described in the art (See, for example, "Nucleic Acid Hybridization" Hames BD and Higgins SJ, Eds. (1985); Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N. Y). In other embodiments, methods of hybridization are carried out under moderate to stringent conditions, to the complement of a DNA encoding a native caspase peptide. Hybridization conditions being, for example, overnight incubation at 42°C in a solution comprising: 10-20 % formamide, 5 X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7. 6), 5 X Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA.
[00223] Protein and/or peptide homology for any AA sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer P-9066-PC algorithm analysis of AA sequences, utilizing any of a number of software packages available, via established methods. Some of these packages include the FASTA, BLAST, MPsrch or Scanps packages, and, in another embodiment, employ the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example.
[00224] Tn one embodiment, "variant" refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants.
[00225] In one embodiment, "isomer" refers to one of any of two or more substances that are composed of the same elements in the same proportions but differ in chemical and/or bological properties because of differences in the arrangement of atoms, which in one embodiment are stereoisomers, in another embodiment, constitutional isomers or tautomers. In one embodiment, an isomer is an optical isomer or entantiomer, a geometric isomer, a D- and L- isomer, positional isomer, or a cis-trans isomer.
[00226] In one embodiment of the present invention, "nucleic acids" or "nucleotide" refers to a string of at least two base-sugar-phosphate combinations. The term includes, in one embodiment, DNA and RNA. "Nucleotides" refers, in one embodiment, to the monomelic units of nucleic acid polymers. RNA is, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, small inhibitory RNA (siRNA), micro RNA (miRNA) and ribozymes. The use of siRNA and miRNA has been described (Caudy AA et al., Genes & Devel 16: 2491-96 and references cited therein). DNA can be, in other embodiments, in form of plasmid DNA, viral DNA, linear DNA, or chromosomal DNA or derivatives of these groups. In addition, these forms of DNA and RNA can be single-, double-, triple-, or quadruple-stranded. The term also includes, in another embodiment, artificial nucleic acids that contain other types of backbones but the same bases. In one embodiment, the artificial nucleic acid is a PNA (peptide nucleic acid). PNA contain peptide backbones and nucleotide bases and are able to bind, in one embodiment, to both DNA and RNA molecules. In another embodiment, the nucleotide is oxetane-modified. In another embodiment, the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond. In another embodiment, the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art. The use of phosphothiorate nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al. Biochem Biophys Res Commun.297:1075-84. The production and use of nucleic acids is known to those skilled in art and is described, for example, in Molecular Cloning, (2001), Sambrook and Russell, Eds.,.and Methods in Enzymology: Methods for molecular cloning in eukaryotic cells (2003) Purchio and G. C. Fareed.
[00227] In one embodiment, the present invention provides a kit comprising a compound or P-9066-PC composition utilized in performing a method of the present invention. In another embodiment, the present invention provides a kit comprising a composition, tool, or instrument of the present invention.
[00228] "Contacting," in one embodiment, refers to directly contacting the target cell with a mutant
HSV strain of the present invention. In another embodiment, "contacting" refers to indirectly contacting the target cell with a mutant HSV strain of the present invention. Thus, in one embodiment, methods of the present invention include methods in which the subject is contacted with a mutant HSV strain which is brought in contact with the target cell by diffusion or any other active transport or passive transport process known in the art by which compounds circulate within the body.
[00229] In one embodiment of the methods of the present invention, the mutant HSV strain is carried in the subjects' bloodstream to the target cell. In another embodiment, the mutant HSV strain is carried by diffusion to the target cell. In another embodiment, the mutant HSV strain is carried by active transport to the target cell. In another embodiment, the mutant HSV strain is administered to the subject in such a way that it directly contacts the target cell.
Pharmaceutical Compositions and Methods of Administration
[00230] In one embodiment, the methods of the present invention comprise administering a pharmaceutical composition comprising the mutant HSV strain and a pharmaceutically acceptable carrier.
[00231] "Pharmaceutical composition" refers, in one embodiment, to a therapeutically effective amount of the active ingredient, i.e. the mutant HSV strain, together with a pharmaceutically acceptable carrier or diluent. A "therapeutically effective amount" refers, in one embodiment, to that amount which provides a therapeutic effect for a given condition and administration regimen.
[00232] The pharmaceutical compositions containing the mutant HSV strain can be, in one embodiment, administered to a subject by any method known to a person skilled in the art, such as parenterally, transmucosally, transdermally, intramuscularly, intravenously, intra-dermally, subcutaneously, intra- peritonealy, intra-ventricularly, intra-cranially, intra-vaginally or intra-tumorally.
[00233] In another embodiment as described in the methods and compositions of the present invention, the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation. Suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like. Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In another embodiment of the present invention, the active ingredient is foπnulated in a capsule. In accordance with this embodiment, the compositions of the present invention comprise, in addition to the active compound and the inert carrier or diluent, a hard gelating capsule. P-9066-PC
[00234] In another embodiment, the pharmaceutical compositions are administered by intravenous, intraarterial, or intra-muscular injection of a liquid preparation. Suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In another embodiment, the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration. In another embodiment, the pharmaceutical compositions are administered intra-arterially and are thus formulated in a form suitable for intra-arteiial administration. In another embodiment, the pharmaceutical compositions are administered intra-muscularly and are thus formulated in a form suitable for intra-muscular administration.
[00235] In another embodiment, the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration. Suitable topical formulations include gels, ointments, creams, lotions, drops and the like. For topical administration, the mutant HSV strain is prepared and applied as a solution, suspension, or emulsion in a physiologically acceptable diluent with or without a pharmaceutical carrier.
[00236] In another embodiment, the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the mutant HSV strain is released over a period of time after administration. Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). In another embodiment, the composition is an immediate-release composition, i.e. a composition in which all the mutant HSV strain is released immediately after administration.
[00237] Each of the above additives, excipients, formulations and methods of administration represents a separate embodiment of the present invention.
EXPERIMENTAL DETAILS SECTION
EXAMPLE 1: HSVt.*. win .IΛ DOES NOT CAUSE DISEASE
MATERIALS AND EXPERIMENTAL METHODS (EXAMPLES 1-4)
Virus Strains
[00238] Wild-type HSV-I strain NS, a low-passage-number clinical isolate, was used for generation of mutant viruses. To construct HSV-l(gEnuii), the entire gE coding sequence was excised from ρCMV3gE-l with Xbal and cloned into pSPT18. pSPT18 has the sequence:
[00239] gaatacaagcttgcatgcctgcaggtcgactctagaggatccccgggtaccgagctcgaattccggtctccctatagtgagtcgtattaatttcg ataagccagctgggcctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtcacagcttgtctgtaagcggatgcc gggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggcgcagccatgacccagtcacgtagcgatagcggagtgtatata ctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcagg cgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacaga P-9066-PC atcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctcc gcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctcc ctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgtaggtatct cagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaa cccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtg gcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaaca aaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgac gctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatct aaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccc cgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagca ataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgat caaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcat ggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcg gcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaa aactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgag caaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatca gggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaa gaaaccattattatcatgacattaacctataaaaataggcgtatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgc agctcccggagacggtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggct ggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatcgacgctctcccttatgcgactcctgcattaggaagcagcccagtagtaggtt gaggccgttgagcaccgccgccgcaaggaatggtgcatgcaaggagatggcgcccaacagtcccccggccacgggcctgccaccatacccacgcc gaaacaagcgctcatgagcccgaagtggcgagcccgatcttccccatcggtgatgtcggcgatataggcgccagcaaccgcacctgtggcgccggtg atgccggccacgatgcgtccggcgtagaggatctggctagcgatgaccctgctgattggttcgctgaccatttccgggtgcgggacggcgttaccagaa actcagaaggttcgtccaaccaaaccgactctgacggcagtttacgagagagatgatagggtctgcttcagtaagccagatgctacacaattaggcttgta catattgtcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactata (SEQ ID No: 1).
[00240] A 1.1-kb Hpal-BglH fragment from amino acids (AA) 124-508 was excised, and the Hpal site was changed to a BgIII site. A 4.3-kb fragment derived from pD6P containing the Escherichia coli β- galactosidase gene (β-gal) under the control of the HSV ICP6 promoter was cloned into the BgIII site. The resultant vector contains 374 bp of NS DNA sequences 5" and 225 bp 3' of the ICP6::lacZ cassette and was used to construct the gE null virus. The Xbal fragment containing the flanking sequence vector was isolated, and 750 ng was cotransfected into Vero cells with 1.0 μg of NS DNA by calcium phosphate transfection. The DNA-calcium phosphate mixture was removed, and cells were shocked with 15% glycerol. Cells were harvested when cytopathic effects were noted in 30-40% of cells and were sonicated to prepare a virus pool. Recombinant gE null virus expressing β-gal was selected by infecting Vero cells and overlaying with 0.5% agarose, 5.0% fetal bovine serum (FBS), and 300 μg of 5-bromo-D- P-9066-PC galactopyranoside (X-GaI). Blue plaques were picked and purified twice in X-GaI agarose overlay and once by limiting dilution. Virus was purified from supernatant fluids of infected Vero cells on a 5-70% sucrose gradient.
[00241] HSV-l(Rescue sE miii) was prepared by co-transfection of Vero cells with 1.0 μg of NS-gEnull DNA and 1.5 μg of wild-type gE fragment purified from ρCMV3gE-l , which was obtained by digesting HSV-I (NS) DNA with Nrul. Progeny viruses were examined by immunoperoxidase staining using anti-gE MAb IBAlO to confirm expression of gE on the surface of infected cells. Plaques were purified by limiting dilution, and virus pools were prepared.
[00242] Virus stocks were grown on confluent Vero cells (an African green monkey kidney epithelial cell line) at an MOI of 2.0. 24 hours post-infection, cells were scraped in the media and centrifuged at 3,000 x g. All but 1 mL of supernatant was removed, and cells were resuspended, sonicated for 3 seconds and distributed into 50 mcL (microliter) aliquots. For mock infections, similar aliquots were made using uninfected cells.
Mouse Flank Infection Protocol
[00243] All experimental protocols were approved by the University of Pennsylvania animal and laboratory resources IACUC committee. Five- to six-week-old BaIbC mice (National Cancer Institute) were allowed to acclimate to the biosafety level 2 animal facility with constant temperature and photoperiod (12 hours of light, 12 hours of darkness) for 1 week. Mice were shaved and depilated with depilatory cream (Nair™) along the right flank (for vaccination) or the left flank (for challenge), then washed with warm water. The next day, mice were anesthetized via intraperitoneal injection of 75 mcL of 14.3 mg/ml ketamine and 1.8 mg/ml xylazine in PBS, then infected by making 60 superficial scratches in a 1 cm2 area of the flank, 1 cm dorsal to the spine, with a 26 3/8-gauge needle through a 10 mcL droplet containing 5 x 103 — 5 x 105 pfu HSV (Figure 1). In HSV flank-infected mice, secondary spread back to the skin from the neurons of one or more spinal ganglia results in a belt-like lesion (Figure 2). Mice were sacrificed by asphyxiation with CO2, followed by cervical dislocation. Mice were observed at 24-hour intervals starting at day 3 post-inoculation to record the appearance and severity of skin lesions and illness. A standardized scoring system to describe lesion severity was used to provide consistency in observations (Figure 3).
Vaccination and Challenge
[00244] For vaccination, mice were infected by making scratches through the inoculum, containing either HSV- l(gE null) or virus-free cell lysate (described above), on the right flank. Mice were challenged 28 days later on the opposite (left) flank by scratching through a droplet containing 1 x 105 pfu HSV- 1 (NS).
Dissections of Dorsal Root Ganglia and Skin
[00245] Dorsal root ganglia (DRG) along either the right (for analysis of HSV-I (gE nuii) vaccination or HSV- P-9066-PC
1 (Rescue gE null) infection), or left (for analysis of HSV-I(NS) challenge) sides of the spinal column were removed, pooled, and placed in 110 mcL DMEM (2.5% FBS) and frozen at -800C until analysis.
[00246] A 1-cm2 area of skin at the site of inoculation was removed. Half of the sample was placed in a tube containing 110 mcL DMEM (2.5% FBS) and frozen at -800C until analysis. The other half was placed on an index card with like-samples and immersed in 4% paraformaldehyde in IX PBS for 24 hours at 4°C, then the solution was replaced with IX PBS. Samples remained at 4°C until processing for histological analysis.
Sectioning, Histology and Immunohistochemistry
[00247] Paraffin embedding, sectioning and staining of skin samples was performed by the Pathology Core Facility at Children's Hospital of Philadelphia. Skin sections were stained for HSV-I antigen using anti- HSV-I rabbit polyclonal antibody (DAKO) and counter-stained with hematoxylin.
RESULTS
[00248] Groups of five mice were flank-infected by scarification of 103"5, 104 S, or 105'5 plaque-forming units (pfu) of the vaccine strain, HSV-I (gE nuii)- For comparison to the virulent form of HSV-I, another group of five mice was flank-infected with 105'5 pfu of HSV-I (Rescuε gE nun), the vaccine strain backbone with the gene encoding gE restored. HSV-l(Rescue gE nuii) infection resulted in illness and 60% mortality (Figure 4). However, no clinical signs of disease, illness or death occurred following HSV-I (SE nuιi) vaccination.
[00249] In addition, the HSV-l(RescuC gE nun) infection caused severe primary lesions that appeared ulcerative and necrotic (Figure 5). In contrast, HSV-I (gE null) infection caused a mild skin pathology at the site of inoculation indistinguishable from that of mock vaccination. Thus, all or essentially all of the skin pathology following the administration of HSV-lrgE nuji) resulted from the process of scratch inoculation itself.
[00250] These findings show that infection with gE null herpes viruses does not cause disease.
EXAMPLE 2: HSVfpF MITT.IΛ DOES NOT SPREAD WITHIN SENSORY NEURONS
[00251] HSV-I (Rescue gE nuii) infection caused severe secondary (zosteriform) ulcerative and necrotic lesions that first appeared at 4-5 (days post-infection) dpi (Figure 6). In contrast, no secondary lesions were seen following HSV-l(gE null) infection. Since secondary lesion formation along the dermatome depends on the ability of the virus to spread along neurons from the skin to the ganglia, and then back again, these results show that the vaccine is not able to spread within sensory neurons. Therefore, HSV(gEnuii) is unable to cause recurrent infection.
EXAMPLE 3: HSVrpR Mi.i i > REPLICATES WITHIN SKIN CELLS P-9066-PC
[00252] To determine the extent of replication of HSV-l(gE nuio in skin cells, mice (n=3) were infected with HSV-I (gE nuii) or virulent HSV-I(ReS_ue gE nuti)- On days 1 , 3, 6, 8 and 13 post-inoculation, mice were sacrificed, skin at the site of inoculation was removed, and DRG from the right side of each mouse were pooled. Titerihg to determine viral content of the homogenized tissue revealed that HSV-l(gE null) replicated in skin following vaccination, but less extensively than HSV- 1 (Rescue g&nuio (Figure 7). Further, HSV-I (gE nuiir vaccinated skin was infiltrated by immune cells, and the virus was cleared by day 6 (Figure 8).
[00253] These results show that HSV(gE null) replicates in the skin, and thus is expected to elicit an inflammatory response by the host.
[00254] Levels of HSV-l(RESCue gEnuii) exceeded that of HSV-l(gE nuii) by 4 orders of magnitude (Figure 9). In addition, no infectious virus was detected in DRG of mice infected with HSV-I (EB nuii). The absence of the characteristic belt-like pattern of lesions and of detectable virus in the ganglia confirmed that no neuronal viral spread occurred after HSV-I (gEnuii) vaccination.
[00255] Thus, HSV infection in the absence of gE is limited to the skin of the host, and the immune system is able to detect and clear the virus rapidly.
EXAMPLE 4: HSV-1#.IΓ. NIII.I Λ VACCINATION IS PROTECTIVE AGAINST WILD-TYPE HSV l
INFECTION
[00256] Mock-vaccinated or HSV-I (gE nuii) vaccinated mice were challenged with a lethal dose of 10s pfu WT HSV-I (NS strain) 28 days after vaccination. Whereas 100% of mock- vaccinated mice died following challenge, 100% of HSV-l(gE nuiιrvaccinated mice survived the lethal challenge (Figure 10). All tested doses of HSV-l(gE nuii) (1035, 104'5, and 105'5 pfu) were protective against challenge. Additionally, very little primary (inoculation site) disease was observed after challenge of the HSV-I (gE nuii)-vaccinated mice (Figure 11). Vaccinated mice had undetectable levels of challenge virus in skin, at least 5 orders of magnitude less than mock- vaccinated mice (Figure 12).
[00257] In contrast to the severely diseased mock- vaccinated mice, primary disease healed rapidly in vaccinated mice. Confirming this observation, immunohistochemistry of equivalent skin samples demonstrated the presence of very little antigen in vaccinated mice on day 3, and clearance by day 6 (Figure 13). Histological analyses also revealed that vaccinated mice had significant infiltration of immune cells, showing that the vaccine successfully primed the host immune system.
[00258] Unlike the severe dermatome lesions resulting from zosteriform spread of the virus in mock- vaccinated mice, no zosteriform disease was seen in vaccinated mice (Figure 14). In addition, viral titers in pulverized DRG were undetectable in vaccinated mice and thus, at least 4 orders of magnitude less than in mock-vaccinated mice (Figure 15). P-9066-PC
EXAMPLE 5: HSVtop NI n.fΛ VACCINATION PREVENTS ESTABLISHMENT OFLATENT WILD-TYPE HSV-I INFECTION AFTER SUBSEQUENT CHALLENGE
MATERIALS AND EXPERIMENTAL METHODS
Recovery of Infectious Virus From Tissues
[00259] DRG and skin samples were removed from mice immediately after sacrifice (at 1, 3, 6, 8 or 13 dpi). Three mice were infected for each data point, but like tissues from these mice were analyzed individually. Tissues were placed in 110 mcL DMEM containing 2.5% FBS and stored at -80 0C until analysis. To determine viral titer, tissue was thawed and pulverized with a disposable pestle. Infectious virus in 50 mcL of the supernatant, serially diluted (1: 10, 1:100 and 1:1000), was quantified by plaque assay on confluent Vero cells in 12-well dishes.
Explant of DRG
[00260] To recover infectious virus from latently infected mice, DRG were removed from the same (right) side of infection with HSV-l(gE miii). All DRG from an individual mouse were placed in one well of a 12- well dish of confluent Vero cells bathed in DMEM (2.5% FBS). Medium was changed every 2 days and cells were monitored for signs of CPE, an indication that DRG contained infectious virus.
RESULTS
[00261] DRG were removed from vaccinated mice, 28 days post-challenge, and explanted in order to reactivate latent challenge virus. Reactivation from associated neurons of only 1/15 of the vaccinated mice occurred upon removal (Figure 16).
[00262] Results of this and the previous Example show that HSV (gE nu]|) protects mice from neuronal infection upon challenge and from developing latent infection typically associated with WT HSV infections.
EXAMPLE 6: VACCINATION OF MICE WITH HSV-IAgE CROSS PROTECTS AGAINST
HSV-2 CHALLENGE
MATERIALS AND EXPERIMENTAL METHODS
[00263] Female Balb/C mice, 6-8 weeks old, were acclimated to the animal facility for 10 days. Mice were anesthetized and shaved and hair was removed by Nair treatment of the right flank. The following day, anesthetized mice were mock-vaccinated or vaccinated with 5 x 105 pfu HSV-lΔgE (which is referred to, in one embodiment, as gE null) by scratching 60 times through a 10 mcl (microliter) droplet of inoculum with a 26 (5/8)-gauge needle. The opposite flank (left side) of each mouse was shaved and denuded as before, twenty-seven days later. Mice were challenged the following day (day 28) by scratch inoculation P-9066-PC of 10s pfu HSV-2 (strain 2.12). Mice were observed and scored daily for inoculation site disease, zosteriform disease and survival. (Scoring: 0=no disease => 4=severe necrotic disease). Error bars represent the standard error of the mean (SEM).
RESULTS
[00264] To test the ability of HSV-lΔgE vaccination to protect against HSV-2 disease, HSV-lΔgE- vaccinated mice were epidermally challenged with wild-type HSV-2. None of the HSV-lΔgE vaccinated mice died, while 80% of mock vaccinated mice died (Figure 17, top panel). Vaccinated mice exhibited inoculation site disease that healed rapidly compared to the unvaccinated mice (Figure 17, middle panel). Additionally, vaccinated mice were completely protected from the zosteriform disease and death observed in the mock-vaccinated mice (Figure 17, bottom panel).
[00265] Thus, ΔgE HSV vaccination is capable of protecting subjects against heterologous HSV disease, even of a different species of herpes simplex.
EXAMPLE 7: VACCINATION WITH HSV-lΔgE PROTECTS AGAINST HSV-I(KOS) AND INHIBITS ESTABLISHMENT OF HSV-I LATENCY
MATERIALS AND EXPERIMENTAL METHODS
[00266] Vaccination and assessment of disease were performed as described for the previous Example, except that 5 x 105 pfu HSV-I, strain KOS, was used for the challenge. For measurement of latent infection, mice were sacrificed 41 d post-challenge, and DRG from both right and left sides were removed, placed in DMEM/10% FBS, minced with scissors, and explanted onto sub-confluent Vero cell monolayers. Cultures were monitored daily for 20 d for plaque formation, indicative of reactivation from latency.
RESULTS
[00267] This experiment tested the ability of HSV-lΔgE vaccination to protect mice from the disease associated with a heterologous HSV-I wild-type strain. HSV-lΔgE-vaccinated mice challenged with wild-type HSV-I, strain KOS, exhibited inoculation site disease that healed rapidly compared to unvaccinated mice (Figure 18, top panel). Additionally, HSV-lΔgE vaccination protected HSV-I KOS- challenged mice completely against zosteriform disease (Figure 18, middle panel). Since HSV-I KOS infection of mice is not lethal, this strain was utilized to compare viral reactivation from latency in mock- versus HSV-lΔgE-vaccinated mice at 4 weeks post-challenge. In mock- vaccinated mice, HSV-I(KOS) virus reactivated from explanted DRG in 100% of mice (n=10), whereas only 1/10 HSV-lΔgE vaccinated mice (10%) exhibited reactivation (Figure 18, table in bottom panel), which could have been latent infection by either the vaccine or the challenge virus. Therefore, HSV-lΔgE vaccination is effective at P-9066-PC protecring mice from both disease and establishment of latency by heterologous HSV viruses.
EXAMPLE 8: VACCINATION WITH HSV lAgE PROTECTS AGAINST HSV-I VAGINAL
CHALLENGE
MATERIALS AND EXPERIMENTAL METHODS
[00268] Vaccination was performed as described for Example 6. Medroxyprogesterone acetate (2 mg) (Sicor Pharmaceuticals, Inc., Irvine CA), diluted to 100 mcl total volume in a 0.9% NaCl/10 mM HEPES buffer, was injected subcutaneously 33 days later into the neck area of each' mouse. Five days later (day 38), mice were anesthetized, intra-vaginally swabbed with a calcium alginate swab dipped in PBS, and challenged by intra-vaginal instillation of 5 x 105 pfu HSV-I (strain NS). Mice were allowed to recover in their cages, resting in a prone position. Challenged mice were observed daily for vaginal disease and survival. Daily intra-vaginal swabs were taken for analysis by viral titering on Vera cells.
RESULTS
[00269] The ability of HSV-I ΔgE vaccination to protect against vaginal challenge with wild-type HSV-I was tested. All mice vaccinated with HSV-I ΔgE survived the challenge, whereas 60% of mock- vaccinated mice succumbed (Figure 19A, top panel). All mock-vaccinated mice showed some sign of visible disease in the vaginal area; however HSV-I ΔgE- vaccinated mice showed no obvious visible signs of disease (Figure 19B). By day 1 post- vaginal challenge, HSV-I ΔgE- vaccinated mice had 100-fold less infectious virus than mock-vaccinated animals, as detected in vaginal swab samples. By day three post- challenge, no infectious virus was detected in swabs from HSV-I ΔgE- vaccinated mice, a value that is at least 30,000-fold less than mock- vaccinated mice on the same day. Additionally, infection of HSV-I ΔgE- vaccinated mice cleared nearly three times faster than mock- vaccinated mice (Figure 19A, bottom panel). Thus, vaccination with HSV-lΔgE protects from death and disease associated with HSV-I vaginal challenge and confers the ability to rapidly clear HSV infection.
EXAMPLE 9: VACCINATION WITH HSV-lΔgE BY EPIDERMAL, SUBCUTANEOUS, AND INTRAMUSCULAR ROUTES PROTECTS AGAINST HSV-I CHALLENGE
MATERIALS AND EXPERIMENTAL METHODS
[00270] Vaccination was performed with 5 x 105 pfu HSV-lΔgE by scratching 60 times through a 10 mcl droplet of inoculum with a 26 (5/8)-gauge needle, injection of 100 mcl inoculum into the scruff of the neck subcutaneously, or by intramuscular injection of 100 mcl inoculum into the right rear thigh muscle.
[00271] For measurement of latent infection, mice were sacrificed 32 days post-challenge, and DRG from both right and left sides were removed, placed in DMEM/10% FBS, minced with scissors and explanted P-9066-PC onto sub-confluent Vero cell monolayers. Cultures were monitored daily (for 15 days) for plaque formation, indicating reactivation from latency.
RESULTS
[00272] The efficacy of intramuscular and subcutaneous routes of administration of the HSV- lΔgE vaccine was compared to epidermal scarification used in previous Examples. All routes of vaccination were effective at protecting mice against death upon epidermal challenge with HSV-I(NS) (Figure 20, top panel). Mice vaccinated by each of the three routes exhibited inoculation site disease upon HSV-I(NS) challenge that was only slightly greater than mock-challenged mice (Figure 20, bottom left panel). HSV- lΔgE vaccination by epidermal scarification or intramuscular injection protected mice completely against zosteriform disease (Figure 20, bottom right panel). Following challenge, 1/5 mice vaccinated by the subcutaneous route had several discrete zosteriform lesions, which were not severe and resolved quickly (Figure 20, bottom right panel). In addition, the ability of the vaccine to prevent latent infection was measured. HSV- lΔgE vaccination by all routes protected against the establishment of latency (Table 1). Mock-vaccinated mice showed 100% reactivation (Table 1 ; also see Figure 18).
[00273] Table 1. HSV-I vaccination by different routes protects against HSV latency.
Vaccination Route Reactivation from Latency
Mock 1 of 1
Epidermal Scarification 0 of 4
Intra-Muscular 0 of 5
Subcutaneous . 1 of 5
[00274] Thus, HSV-lΔgE administered by epidermal, intramuscular or subcutaneous routes each protects against acute disease, flares and latent disease by wild-type HSV challenge.
EXAMPLE IQ: VACCINATION WITH HSV-lΔgE BY EPIDERMAL SCARIFICATION. SUBCUTANEOUS INJECTION AND INTRAMUSCULAR INJECTION INDUCES
NEUTRALIZING ANTIBODIES
MATERIALS AND EXPERIMENTAL METHODS
[00275] Mice were vaccinated as described in the previous Example. On day 21, mice were bled through jugular veins. On day 28, the opposite flank (left side) of each mouse was shaved and denuded as before. Neutralization assays on serum samples were done by incubating 50 me] serum dilution (1 :10 to 1 :320) with 102 pfu HSV-I (NS) in 5 mcl for 1 hour at 37°C, and then inoculating Vero cell monolayers.
RESULTS
[00276] The efficacy of HSV-lΔgE vaccination by the epidermal scarification, intramuscular, and P-9066-PC subcutaneous routes of administration for induction of neutralizing antibodies were measured. HSV-lΔgE vaccination of mice by all three routes induced neutralizing antibody formation; the epidermal scarification and intramuscular routes yielded significantly higher levels than subcutaneous vaccination (Figure 21).
EXAMPLE 11: VACCINATION WITHHSV-IAeE PROTECTS AGAINST FLANK CHALLENGE WITH VARIOUS HETEROLOGOUS HSV-I STRAINS
[00277] Ability of HSV-lΔgE vaccination to protect against heterologous, higher virulence wild-type HSV-I strains (F and 17) was measured; with vaccination and challenged performed as described for Example 7, except that challenge utilized various strains. HSV-lΔgE vaccination protected mice completely from death upon epidermal challenge with HSV-I(NS), HSV-I(F) and HSV-1(17) (Figure 22, top panel). Vaccination also reduced inoculation site disease, although challenge with HSV-I(F) caused slightly more disease at the inoculation site than HSV-I(NS) or HSV- 1(17) (Figure 22, middle panel). Moreover, HSV-lΔgE vaccination completely protected all mice challenged with HSV-I(NS) and HSV- 1(17) from zosteriform disease and 2/3 mice challenged with HSV-I(F); the other mouse challenged with HSV-I(F) had two small zosteriform lesions (Figure 22, bottom panel). Thus, HSV-lΔgE vaccination protects mice against various heterologous strains of HSV-I .
EXAMPLE 12: VACCINATION WITH HSV-lΔgE PROTECTS AGAINST FLANK CHALLENGE WITH DOSES UP TO 1 X IQ7 PFU OF HSV-IfNS)
[00278] The ability of HSV-lΔgE vaccination to protect against higher doses of wild-type HSV-I was measured; with vaccination and challenged performed as described for Example 7, except that challenge utilized higher doses of 105, 106 or 107 pfu of HSV-I(NS). Vaccinated mice were all completely protected from death and zosteriform disease (Figure 23, top and bottom panels). Vaccinated mice challenged with 10s pfu HSV-I(NS) exhibited inoculation site disease that was slightly more severe than mock-challenged mice, indicating that most of the disease was caused by the scarification (needle scratch). Challenge of HSV-lΔgE vaccinated mice with 106 or 107 pfu was associated with significantly reduced disease at the inoculation site, which healed rapidly compared with mock- vaccinated mice (middle panel).
Figure imgf000056_0001
MATERIALS AND EXPERIMENTAL METHODS
Cells and viruses
[00279] Vera cells (ATCC CCL81) are cultured in Dulbecco's modified Eagle's medium containing heat- inactivated 10% newborn calf serum (Life Technologies, Gaithersburg, Md.) plus 50 micrograms (meg) of penicillin/ml, 50 mcg/ml of streptomycin/ml, and 0.15 mcg/ml of Fungizone® (Life Technologies) at P-9066-PC
37°C and 5% CO2. Clarified stocks of HSV-2 strains are prepared from infected Vero monolayers and stored at -8O0C until used. Titers of virus are determined by standard plaque assays.
[00280] A deletion in base pairs (bp) 369-1479 of the 1635 bp HSV-2 (2.12) Us8 gene, encoding HSV-2 gE, was introduced as follows. Two PCR fragments from HSV-2(2.12), namely a 658 bp fragment corresponding to the region 5' of the intended deletion and a 536 bp fragment 3' of the intended deletion, were subcloned into the pBluescript SK+ multiple cloning site (MCS). The 5' flanking region was subcloned into the Kpnl and HindETl sites of the pBluescript SK+ MCS, and the 3'flanking region was subcloned into the Pstl and Sad sites of the MCS. This left a short stretch of the MCS between the 5' and 3' flanking regions that includes the EcoRI and EcoRV restriction sites and causes a frameshift such that only the first 123 amino acids of gE were expressed (Figure 24B). The vector was co-transfected into Vero cells with HSV-2(2.12) genomic DNA to allow for homologous recombination. The virion DNA purified from resulting plaques was screened by PCR to detect incorporation of the deletion.
Mouse vaginal model of HSV-2 infection
[00281] Mice are treated with 2.0 mg of Depo-Provera (Upjohn, Kalamazoo, MI) subcutaneously in the scruff of the neck 7 and 1 day prior to viral inoculation to synchronize their estrus cycles and to increase their susceptibility to HSV-2 vaginal infection. HSV-2 virus (104 pfu) is instilled in the vaginal cavity following wet and then dry vaginal swabbing with a calcium alginate swab (Fisher Scientific, Pittsburgh, Pa.). Animals are assessed daily for symptomatic disease (as indicated by hair loss and erythema near the vagina) through 14 days post-inoculation (p.i.). Survival is followed through 21 days p.i. As an additional indicator of infection, vaginal swabs are collected and tested for viral content on Vero cells.
RESULTS
[00282] gE null HSV-2 virus is constructed from strain HG52, using a similar strategy as that used for HSV-I (Example 1). The HSV-I (NS) gE (Examples 1-5) and HSV-2 (HG52) gE sequences are 72% identical and 79% similar (positive) (Figure 24A). In addition, an HSV-2(Resα,e gE null) strain is constructed.
[00283] To test whether the HSV-2(gE n_ii) strain causes disease, a dose of 104 pfu (lethal in the case of wt virus) of wt HSV-2 and the HSV-2(gE null) strain are administered to separate groups of mice. While the mice receiving the wt and HSV-2(Rescue SE nuιi) virus are expected to die, those receiving the HSV -2(gE null) strain are expected to survive, and are not expected to exhibit significant signs of disease.
Figure imgf000057_0001
INFECTION
MATERIALS AND EXPERIMENTAL METHODS
[00284] Mice are vaccinated with HSV-2(gE nuii) or mock- vaccinated as described in the previous Example, P-9066-PC and are challenged 28 days later with a lethal dose of WT HSV-2. HSV-2(gE nuιi)-vaccinated mice are expected to be protected from the lethal challenge, whereas mock-vaccinated mice are expected to succumb to the infection. Additionally, HS V-2(8E nuin vaccination is expected to substantially decrease or eliminate primary (inoculation site) disease after challenge with wt HSV-2. Unlike the hair loss and erythema expected near the vagina in mock-vaccinated mice, no zosteriform disease is expected to be observed in vaccinated mice. Confirming this observation, immunohistochemistry of equivalent skin samples is expected to demonstrate substantially reduced antigen levels in vaccinated mice several days post-challenge. Histological analyses are expected to reveal that vaccinated mice exhibit significant infiltration of immune cells.
[00285] In additional experiments, the HSV-2(gE nuii) vaccine is tested in the mouse flank model (Examples 4-5), and is expected to be protective against HSV-2 infection.
EXAMPLE 15: EFFICACY OF HSV-2/,κ wιi».i VACCINATION AGAINST EXISTING HSV-2 GENITAL INFECTION IN A GUINEA PIG MODEL
MATERIALS AND EXPERIMENTAL METHODS
Guinea pig model of genital herpes
[00286] On the day of inoculation, vaginal closure membranes are ruptured with a pre-moistened calcium alginate swab. Vaginal vault is swabbed with a dry calcium alginate swab, and 105'7 pfu of HSV-2 is instilled into the vaginal vault with a syringe and a 20-gauge plastic catheter. This dose is sublethal, while providing infection of nearly every inoculated animal. During acute genital infection, animals are evaluated daily through day 14 p.i. for genital skin disease and urinary retention. Disease is quantified by a skin lesion scoring system ranging from 0 (no disease) to 4 (severe disease characterized by large ulcers with maceration). Following acute disease, animals are distributed to produce statistically similar groups based upon disease severity. Daily scoring of each animal proceeds from day 21-56 p.i. to establish frequency of external recurrent herpetic lesions.
Viral shedding detection
[00287] Guinea pigs spontaneously shed HSV-2 from the vaginal cavity even in the absence of signs of disease. Viral DNA can be detected in 10 to 20% of the vaginal swabs from latently infected guinea pigs, allowing for the study of viral shedding frequencies and comparisons of the magnitudes. Vaginal cavities are swabbed daily with a calcium alginate-tipped swab from days 22-43 p.i. DNA is extracted from each swab sample using the QIAmp® DNA extraction system (Qiagen, Inc, Chats worth, CA), including mock swab blanks as monitors for sample contamination, and subjected to quantitative PCR for HSV-2 DNA, using primers targeting the DNA polymerase gene. A separate reaction is performed for each of the specimens to address template quality and quantity, using a second set of primers to amplify the single- copy guinea pig albumin gene. The resulting 498-bp amplimer is utilized for normalization of DNA P-9066-PC concentration and a more quantitative estimate of the HSV-2 burden in each specimen. Positive specimens are compared to amplification of a series of 10-fold serial dilutions of established genomic equivalents using MS HSV-2 stocks. Reactions are run in a GeneAmp® PCR System 9600 (Perkin-Elmer Corp, Norwalk, Conn.) beginning with a "hot start" at 95°C for 2 min; then 35 cycles of denaturation at 95°C for 1 min, annealing for 1 min at 65°C, and 72°C extension for 1 min 30 s; and a final 7-min extension at 72°C. Amplification products of each sample, positive and negative controls, and the series of known standards are detected by Southern blotting. HSV-2 burdens are extrapolated from the linear relationship established from band density of a dilution series of known genomic equivalents amplified in parallel to the samples.
Determination of HSV-2 DNA copy numbers in guinea pig dorsal root ganglia.
[00288] Sacral dorsal root ganglia (6-8 per animal) are dissected and weighed, viral DNA is extracted by using a QIAamp® DNA minikit (QIAGEN), and real-time PCR is performed. A standard curve is constructed for each experiment, using purified plasmid containing HSV-2 gD gene sequences. Data are normalized to probes specific for guinea pig lactalbumin DNA.
RESULTS
[00289] The guinea pig model is utilized to evaluate the efficacy of ISS against recurrent herpetic disease. This model provides a naturally occurring recurrent disease similar to that seen in human HSV-2 infections, and latently infected guinea pigs shed virus vaginally at a frequency similar to that observed in humans.
[00290] Guinea pigs are vaccinated with HSV-2(gE nuii) or mock-vaccinated and are challenged 28 days later with 105'7 pfu of HSV-2. HSV-2(gg null) vaccination is expected to significantly reduce the frequency of genital lesion development compared to mock- vaccinated animals and reduce the number of animals that experience any recurrences. In addition, HSV-2(ge null) vaccination is expected to significantly reduce the magnitude of viral shedding.
[0029I] To test the effect of HSV-2(gE nuii) vaccination on the establishment of latent HSV-2 infection, accumulation of wt HSV-2 viral genomes in guinea pig DRG is evaluated. HSV-2<SE nuii) vaccination is expected to significantly reduce the number of viral genomes in the DRG.
[00292] This and the previous Example are expected to provide additional evidence that HSV-2(gE null) vaccines are efficacious in protecting subjects against HSV-2 infection and subsequent genital reactivation.
EXAMPLE 16: INTRODUCTION OF ADDITIONAL DELETIONS TO THE Us REGION IN ORDER TO FURTHER IMPAIR THE ANTEROGRADE SPREAD OF THE AeE-2 VACCINE
STRAIN P-9066-PC
[00293] In order to further attenuate the ΔgE-2 vaccine strain, additional deletions are introduced into Us7 and Us9, encoding the gl and Us9 proteins (Figure 25), using a similar approach to that used to construct the HSV-2 Us8 deletion. A cloning vector that contains two 500-1000 base pair flanking regions, each homologous to either the DNA sequence 5' or 3' of the intended deletion, is constructed. The DNA for these two regions is obtained by PCR of HSV-2(2.12) genomic DNA. The cloning vector is co- transfected with HSV-2 genomic DNA, so that the deletions are incorporated into the viral DNA by homologous recombination. The resulting plaques are screened for the correct Us deletion by PCR.
EXAMPLE 17: IDENTIFICATION OF ADDITIONAL MUTATIONS THAT IMPAIR ANTEROGRADE SPREAD OF THE ΔgE-2 VACCINE STRAIN
[00294] RNAi gene silencing methodology is utilized to identify genes other than gE, Us7 and Us9 that are involved in virus spread. RNAi technology uses approximately 20-22 base-pair double-stranded RNA fragments with sequences identical to the viral gene targeted for silencing. To target sequences on viral genes of HSV-I or HSV-2, small RNA double-stranded fragments identical in sequence to the viral RNA are synthesized using standard techniques known in the art, and are introduced by transfection technology into cells that are then infected with HSV-I or HSV-2 wild-type or mutant virus. Spread of defective virus is detected by screening for small plaques in human epidermal keratinocytes (HaCaT) cells (Collins WJ et al. Herpes simplex virus gE/gl expressed in epithelial cells interferes with cell-to- cell spread. J Virol. 2003 Feb;77(4):2686-95). The genes targeted by the RNAi fragments that induce small plaques are used in gene deletion studies. Inactivating mutations are then introduced into the gene or genes identified by the above RNAi screening method to create mutant viruses. Spread properties of mutant viruses are evaluated in vitro using rat superior cervical ganglion cell neuron cultures (Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, and Friedman HM. J. Virol 79:13362-72, 2005) and the mouse retina eye infection model (Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, Friedman HM. J. Virol 79:13362-72, 2005). The viral mutant strains identified that modify spread in vitro or in vivo are introduced into strains containing deletions of gE, Us7 or Us9 to develop strains containing deletions in multiple genes to identify the optimum combination of mutations that causes little or no disease when inoculated into laboratory animals, that results in low levels or no viral DNA in DRG, and that provides maximum protection against disease and establishment of viral latency when challenged by infection with wild type HSV-I or HSV-2.
[00295] Tn other experiments, efforts are focused on virion membrane proteins, e.g. glycoproteins J, G, K, and M. Membrane glycoproteins required for virus entry, e.g. glycoproteins B, D, H and L, are excluded. These virion membrane proteins are analyzed as described in the previous paragraph.
EXAMPLE 18: CHARACTERIZATION AND STABILITY OF HSV gD MUTANT
MATERIALS AND EXPERIMENTAL METHODS (Examples 18-23> P-9066-PC
Virus Strains
[00296] Wild-type HSV-I strain KOS was used to prepare gD mutants. To construct HSV-l(gDπuii). plasmid pSC594 was constructed by inserting A3C (alanine to cysteine) and Y38C (tyrosine to cysteine) mutations into plasmid pRM416 which contains the KOS gD open reading frame flanked by 474 base pairs 5' and 985 base pairs 3' of the open reading frame. HSV-I gD-mull DNA and pSC594 DNA were co-transfected into VD60 cells. Recombinant virus was screened by replication in Vera cells and then plaque-purified. After each plaque purification, 600 base pairs were amplified by PCR at the 5' end of the gD gene that included the sites of the mutations. The amplified gD fragments were screened by restriction enzyme mapping. Introduction of a new Sspl site confirmed the presence of the A3C mutation and the loss of an Rsal site confirmed the presence of the Y38C mutation. Following further plaque purification, DNA sequencing to confirm the presence of the mutations. The clones were grown to high titer on Vero cells, purified on a 10% to 60% sucrose gradient, and subjected to a final DNA sequence analysis and restriction mapping, which revealed that only the A3C mutation remained. The KOS-gDA3C was further purified on a sucrose gradient and the entire gD gene was sequenced to confirm the presence of the A3C mutation and the absence of additional unintended mutations.
[00297] Rescued KOS-gDA3C virus, referred to as rKOS-gDA3C, was generated by co-transfection of Vero cells with KOS-gDA3C and pRM416 DNA.
[00298] Virus stocks were grown in Dulbecco's minimum essential medium (DMEM), supplemented with 10% fetal calf serum (FCS). B78-H1 cells, mouse melanoma cells that are non-permissive for HSV-I entry, were grown in DMEM with 5% FCS. B78-H1-A10 cells (AlO) and B78-H1-C10 cells (ClO) stably express HVEM and nectin-1, respectively, and were grown in DMEM containing 5% FCS and 500 μg/ml of G418. The gD-null virus was propagated in Vero cells stably transfected with gD DNA (VD60 cells). HSV-I strain NS, a low-passage clinical isolate, was used for challenge studies in mice. Viruses were grown in Vero cells, unless otherwise noted, purified on sucrose gradients and stored at -800C.
Mouse Flank Infection Protocol
[00299] All experimental protocols were approved by the University of Pennsylvania animal and laboratory resources IACUC committee. Five-six- week-old Balb/c mice (Charles River were allowed to acclimate to the biosafety level 2 animal facility with constant temperature and photoperiod (12 hours of light, 12 hours of darkness) for 1 week. Mice were shaved and depilated with depilatory cream (Nair™) along the right flank (for vaccination) or the left flank (for challenge), then washed with warm water. The next day, mice were anesthetized via intraperitoneal injection of 75 mcL of 14.3 mg/ml ketamine and 1.8 mg/ml xylazine in PBS, then infected by making 60 superficial scratches in a 1 cm2 area of the flank, 1 cm dorsal to the spine, with a 30-gauge needle through a 10 mcL droplet containing 5 x 10s pfu HSV. Mice were observed at 24-hour intervals starting at day 3 post-inoculation to record the appearance and severity of skin lesions and illness. Scores at the inoculation site ranged from 0 to 5 and at the zosteriform site P-9066-PC from 0 to 10. One point was assigned per vesicle or if lesions were confluent multiple points were assigned based on the size of the confluent lesions.
Entry Assay
[00300] KOS-gDA3C, rKOS-gDA3C or KOS (400 pfu) was incubated for one hour at 4°C with B78-H1, AlO, ClO or Vero cells. Cells were warmed to 37°C for 0, 10, 30, 60 or 120 minutes followed by washing to remove unbound virus and exposed to a citrate buffer pH 3.0 wash for 1 minute to inactivate vims that had bound but had not entered cells. After an additional wash, cells were overlaid with 0.6% low-melt agar in DMEM, and plaques were visualized and counted after 68 hours.
Single-step and multi-step growth curves
[00301] Single-step growth curves were performed on B78-H1 , AlO and ClO cells inoculated with KOS, KOS-gDA3C or rKOS-gDA3C virus at an MOI of 3. After one hour .at 37°C, cells were treated with citrate buffer pH 3.0 for one minute, and cells and supernatant fluids were collected immediately (time 0) or at 2, 4, 8, 10, 12, 20 and 24 hours. Samples were freeze-thawed once, sonicated three times each for 10 seconds and titered on Vero cells. Multi-step growth curves were performed in a similar fashion, except infection was performed at an MOI of 0.01 and titers measured at 24, 48 and 72 hours.
Real-time quantitative PCR for viral DNA in dorsal root ganglia (DRG)
[00302] DRG nearest the site of inoculation were harvested and DNA was isolated using the Qia Amp- mini DNA kit (Qiagen). The Us9 gene was amplified to quantify viral genome copy number in DRG. The PCR reaction was performed in a 50 mcl volume with a minimum of 200 ng of DNA from DRG. Fifty pmol of forward 5'cgacgccttaataccgactgtt (SEQ ID NO: 8) and reverse 5'acagcgcgatccgacatgtc (SEQ ID NO: 9) primers and 15 pmol of Taqmaπ probe 5'tcgttggccgcctcgtcttcgct (SEQ ID NO: 10) were added. One unit of Ampli Taq Gold (Applied Bioscience) per 50 mcl reaction was added. Real time PCR amplification was performed on an ABI Prism7700 Sequence Detector (Applied Biosystems). A standard curve was generated from purified HSV-I (NS) DNA. Mouse adipsin, a cellular housekeeping gene was also amplified from DRG DNA under identical conditions. The primers used for amplification were forward 5'gatgcagtcgaaggtgtggtta (SEQ ID NO: 1 1) and reverse 5' cggtaggatgacactcgggtat (SEQ ID NO: 12), while Taqman probe 5'tctcgcgtctgtggcaatggc (SEQ ID NO: 13) was used for detection. The viral DNA copies were then normalized based on the murine adipsin copy number.
RESULTS
[00303] Since the gD transcript is co-terminal 3' with gl and gj, the molecular mass of gD and gl was evaluated by western blots of cells infected with WT, rKOS-gDA3C, or KOS-gDA3C virus. The size of the proteins was similar for the three viruses (Fig. 26A), while DNA sequencing confirmed the integrity of the gJ gene in KOS-gDA3C (result not shown). The stability of the gDA3C mutation was confirmed by restriction digestion using Sspl of PCR-amplified DNA fragments to confirm the presence of the cysteine P-9066-PC residue at position 3. The Sspl site was maintained through 30 passages, suggesting that the change of alanine to cysteine at residue 3 was stable (Fig. 26B). This was confirmed by DNA sequence analysis after every five passages.
[00304] Mice were scratch-inoculated on the flank with KOS-gDA3C, and DRG harvested five days postinfection to confirm the stability of the gDA3C mutation in vivo. Virus was isolated from three individual plaques. All three isolates retained the Sspl site {Fig. 26C), suggesting that the cysteine residue at amino acid 3 was maintained, which was confirmed by DNA sequencing.
EXAMPLE 19: HSVgDMUTANT AS AN ENTRY-IMPAIRED LIVE VIRUS VACCINE
[00305] The entry of KOS, rKOS-gDA3C, and KOS-gDA3C into cells that express HVEM (AlO), nectin-1 (ClO), both (Vero), or neither receptor (B78-H1) was evaluated. Entry of the three viruses into Vero cells was comparable (Fig. 27A), while each virus failed to enter B78-H1 cells (Fig. 27B). Entry of KOS- gDA3C into AlO cells was reduced by approximately 50% compared with KOS or rKOS-gDA3C (Fig. 27C), and entry into ClO cells was reduced by approximately 70% (Fig. 27D).
[00306] These findings show that the gDA3C mutation reduces entry mediated by both HVEM and nectin- 1 receptors.
EXAMPLE 20: GROWTH CURVES OF HSV gD MUTANT VIRUS
[00307] Virus replication was examined by performing single-step growth curves at an MOI of 3. KOS, rKOS-gDA3C and KOS-gDA3C failed to infect B78-H1 cells (results not shown). Replication of the three viruses was comparable in AlO cells (Fig. 28A) and ClO cells (Fig. 28B), except that the titers of KOS- gDA3C were reduced at time 0 (at the end of the one-hour adsorption period), which reflects the entry defect seen in Example 19.
[00308] Multi-step growth curves were performed by infecting the cells at an MOI of 0.01 to allow multiple cycles of virus replication. Compared with KOS and rKOS-gDA3C, peak titers of KOS-gDA3C were reduced at 72 hours by approximately 1.5 loglO in AlO cells (Fig. 28C) and 2 loglO in C10 cells (Fig. 28D).
EXAMPLE 21: HSV gD MUTANT HAS REDUCED VIRULENCE
[00309] The virulence of the KOS-gDA3C mutant was evaluated in the mouse flank model. Mice were infected with 5x105 PFU of KOS, rKOS-gDA3C, or KOS-gDA3C and animals scored for disease at the inoculation and zosteriform sites. Mice infected with KOS-gDA3C had less severe disease at the inoculation site (Fig. 29A) and almost no zosteriform disease with only one of 30 mice developing 3 lesions on day 5 (Fig. 29B). Photographs of the zosteriform site disease are shown on day 10 (Fig. 29C). P-9066-PC [00310] These findings show that infection with the gD mutant herpes virus causes minimal disease.
EXAMPLE 22: HSV gP MUTANT HAS REDUCED ABILITY TO REACH DRG
[00311] Mice were inoculated with 5x105 PFU of KOS, rKOS-gDA3C, or KOS-gDA3C and at 5 days post-infection, the DRG were harvested to measure viral titers (Fig. 30A) and viral genome copy number (Fig. 30B), which were reduced for KOS-gDA3C compared with KOS or rKOS-gDA3C.
[00312] These findings show that the gD mutant herpes virus is defective in reaching the DRG.
EXAMPLE 23: HSVgDMUTANT AS AN ATTENTUATED LIVE VIRUS VACCINE
[00313] Mice were mock-infected or infected with rKOS-gDA3C or KOS-gDA3C and allowed to recover. Although rKOS-gDA3C produced extensive disease, all animals survived, as did all mice infected with KOS. Thirty days later, mice previously infected with KOS-gDA3C or rKOS-gDA3C were challenged on the opposite flank with HSV-I strain NS at 106 PFU (approximately 20 LD50). The challenge virus caused extensive disease at the inoculation (Fig. 31A) and zosteriform (Fig. 31B) sites in the mock group. KOS-gDA3C and rKOS-gDA3C protected against disease at the inoculation site and both viruses totally prevented zosteriform disease. None of the rKOS-gDA3C or KOS-gDA3C infected mice died after the NS strain challenge, while 100% of the mock-infected mice died (result not shown).
[00314] These findings show that KOS-gDA3C provided protection against challenge that was comparable to protection provided by the more virulent rKOS-gDA3C.
[00315] The ability of a prior infection with KOS-gDA3C to prevent the WT virus from reaching the DRG was evaluated. Mice were mock-infected or infected in the flank with 5x105 pfu of rKOS-gDA3C or KOS-gDA3C. Thirty days later, mice were challenged with 106 pfu of NS on the opposite flank. DRG that innervate the challenge site were harvested five days post-challenge. NS viral titers were approximately 6 loglO in DRG of mice that were previously mock infected, while no virus was recovered from DRG of mice previously infected with rKOS-gDA3C or KOS-gDA3C (Fig. 31 C).
[00316] Quantitative PCR was performed on the DRG at five days post-challenge. Approximately 5.8 loglO HSV-I genome copies were detected in DRG of previously mock-infected mice compared with 3.4 or 3.2 loglO DNA copies in mice previously infected with rKOS-gDA3C or KOS-gDA3C, respectively (Fig. 31D).
[00317] These findings show that KOS-gDA3C is attenuated in causing skin lesions at the inoculation and zosteriform sites and in infecting DRG, yet it is as effective as rKOS-gDA3C in protecting mice against WT HSV-I challenge.
[00318] These examples suggest that an HSV strain with a mutation in gD may be used as an attenuated P-9066-PC live HSV vaccine. Figure 32 shows a model in which at each step of the virus life cycle, less KOS- gDA3C is produced because of the defect in virus entry. These steps include the amount of virus produced in epidermal cells (labeled E), in DRG nuclei (labeled N), and that return to the skin at the zosteriform site.
[00319] In one embodiment, the examples of the present invention provide experimental support for a method of vaccinating against HSV infection by contacting the subject with a mutant strain of HSV, containing one or more inactivating mutations.

Claims

P-9066-PC WHAT IS CLAIMED IS:
1. A mutant HSV-I strain comprising a first inactivating mutation in a Us8 gene and a second inactivating mutation in a Us7 gene , Us9 gene, or a combination thereof.
2. The HSV-I strain of claim 1, wherein said first or second inactivating mutation is an addition, deletion, or substitution mutation.
3. A mutant HSV-2 strain comprising a first inactivating mutation in a Us8 gene and a second inactivating mutation in one or more additional genes.
4. The HSV-2 strain of claim 3, wherein said second inactivating mutation is in a gene encoding a membrane protein not required for virus entry.
5. The HSV-2 strain of claim 4, wherein said gene encoding a membrane protein not required for virus entry is the Us7 gene, Us9 gene, or a combination thereof.
6. The HSV-2 strain of claim 4, wherein said gene encoding a membrane protein not required for virus entry is Us5, Us4, UL53, ULlO, or a combination thereof.
7. The HSV-2 strain of claim 3, wherein said second inactivating mutation is in a gene encoding a membrane protein required for virus entry.
8. The HSV-2 strain of claim 7, wherein said gene encoding a membrane protein required for virus entry is Us6.
9. The HSV-2 strain of claim 3, wherein said first or second inactivating mutation is an addition, deletion, or substitution mutation. '
10. A method of treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection in a subject, comprising the step of contacting said subject with a composition comprising. a mutant Herpes Simplex Virus vaccine strain, wherein said P-9066-PC mutant HSV vaccine strain comprises an inactivating mutation in a Us8 gene.
11. The method of claim 10, wherein said mutant HSV vaccine strain is an HSV-I strain or an HSV-2 strain.
12. The method of claim 10, wherein said HSV infection is an HSV-I infection or an HSV-2 infection.
13. The method of claim 10, wherein the neuronal viral spread of said mutant strain is impeded.
14. The method of claim 10, wherein said mutant strain is replication-competent in the skin tissue of said subject.
15. The method of claim 10, wherein said mutant HSV vaccine strain further comprises an additional inactivating mutation in a gene encoding a membrane protein not required for virus entry.
16. The method of claim 15, wherein said gene encoding a membrane protein not required for virus entry is the Us7 gene, Us9 gene, or a combination thereof.
17. The method of claim 15, wherein said gene encoding a membrane protein not required for virus entry is Us5, Us4, UL53, ULlO, or a combination thereof.
18. The method of claim 10, wherein said mutant HSV vaccine strain further comprises an inactivating mutation in a gene encoding a membrane protein required for virus entry.
19. The method of claim 18, wherein said gene encoding a membrane protein required for virus entry is Us6.
20. The method of claim 10, wherein said HSV infection is a genital HSV infection, an HSV encephalitis, an ocular disease, HSV labialis or a combination thereof.
21. The method of claim 10, wherein said subject is infected by or is at risk for infection by HSV.
22. The method of claim 21, wherein said subject is a neonate, an immunocompromised subject, an P-9O66-PC elderly subject, or a combination thereof.
23. The method of claim 10, wherein said treating, reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, reducing the incidence of, prolonging the latency to a relapse of a Herpes Simplex Virus (HSV) infection is by inducing an anti-HSV immune response in said subject.
24. The method of claim 23, wherein said anti-HSV immune response is an anti-HSV neutralizing antibody response.
25. The method of claim 10, wherein the step of contacting comprises epidermal, intramuscular, subcutaneous, or intra-respiratory mucosal injection.
PCT/US2007/019537 2006-09-08 2007-09-07 Hsv-1 and hsv-2 vaccines and methods of use thereof WO2008030560A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002663109A CA2663109A1 (en) 2006-09-08 2007-09-07 Hsv-1 and hsv-2 vaccines and methods of use thereof
JP2009527427A JP5639361B2 (en) 2006-09-08 2007-09-07 HSV-1 and HSV-2 vaccines and methods of use thereof
AU2007292905A AU2007292905B2 (en) 2006-09-08 2007-09-07 HSV-1 and HSV-2 vaccines and methods of use thereof
CN200780038798.7A CN101583381B (en) 2006-09-08 2007-09-07 HSV-1 and HSV-2 vaccines and methods of use thereof
US12/440,223 US8871223B2 (en) 2006-09-08 2007-09-07 HSV-1 and HSV-2 vaccines and methods of use thereof
EP07837889A EP2059255A4 (en) 2006-09-08 2007-09-07 Hsv-1 and hsv-2 vaccines and methods of use thereof
US12/415,152 US8865185B2 (en) 2006-09-08 2009-03-31 Methods of use for HSV-1 and HSV-2 vaccines
US13/260,835 US8911747B2 (en) 2006-09-08 2010-03-31 HSV-1 and HSV-2 vaccines and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84294706P 2006-09-08 2006-09-08
US60/842,947 2006-09-08
US92905007P 2007-06-11 2007-06-11
US60/929,050 2007-06-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/440,223 A-371-Of-International US8871223B2 (en) 2006-09-08 2007-09-07 HSV-1 and HSV-2 vaccines and methods of use thereof
US12/415,152 Continuation-In-Part US8865185B2 (en) 2006-09-08 2009-03-31 Methods of use for HSV-1 and HSV-2 vaccines

Publications (2)

Publication Number Publication Date
WO2008030560A2 true WO2008030560A2 (en) 2008-03-13
WO2008030560A3 WO2008030560A3 (en) 2008-08-07

Family

ID=39157863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019537 WO2008030560A2 (en) 2006-09-08 2007-09-07 Hsv-1 and hsv-2 vaccines and methods of use thereof

Country Status (7)

Country Link
US (1) US8871223B2 (en)
EP (1) EP2059255A4 (en)
JP (1) JP5639361B2 (en)
CN (1) CN101583381B (en)
AU (1) AU2007292905B2 (en)
CA (1) CA2663109A1 (en)
WO (1) WO2008030560A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114930A1 (en) 2009-03-31 2010-10-07 The Trustees Of The University Of Pennsylvania Methods of use for hsv-1 and hsv-2 vaccines
WO2010135747A1 (en) * 2009-05-22 2010-11-25 Genocea Biosciences Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2013545761A (en) * 2010-11-24 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccines against herpes simplex virus type 2: Compositions and methods for inducing an immune response
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3113801A4 (en) * 2014-03-03 2017-10-25 Albert Einstein College of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
WO2023178191A1 (en) * 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system
EP3999093A4 (en) * 2019-07-19 2023-11-22 Merck Sharp & Dohme LLC Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205360B2 (en) 2011-08-22 2017-09-27 ナノバイオ コーポレーション Herpes simplex virus nanoemulsion vaccine
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
CN104707135B (en) * 2013-12-11 2017-11-07 深圳先进技术研究院 Recombinant protein vaccine, the recombinant expression carrier containing the gene for encoding the recombinant protein vaccine and its application
CN103740736B (en) * 2013-12-31 2016-08-17 李越希 The HSV2 virus gE glucoprotein extracellular region gene fragment of chemosynthesis and expression, application
CN105641692A (en) * 2015-12-30 2016-06-08 暨南大学 Herpes simplex virus I gene recombinant attenuated live vaccine and preparation method thereof
WO2020056411A1 (en) * 2018-09-14 2020-03-19 Excell Biotech, Llc Recombinant herpes simplex virus 1 (hsv-1)
EP3937960A4 (en) * 2019-03-14 2023-03-29 Research Institute at Nationwide Children's Hospital Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709011A (en) 1982-02-18 1987-11-24 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US4762708A (en) 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
CA2211743A1 (en) * 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ506602A (en) 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
PL346213A1 (en) * 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
GB9918283D0 (en) 1999-08-03 1999-10-06 Int Centre Genetic Eng & Bio Hsv vaccines
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
GB0110431D0 (en) 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1387694A2 (en) * 2001-05-09 2004-02-11 M'S Science Corporation Composition and method for treating cancer using herpes virus
US20030215463A1 (en) 2002-03-22 2003-11-20 David Knipe Means of inducing durable immune responses
US20040197347A1 (en) 2002-09-23 2004-10-07 Board Of Regents, The University Of Texas System Methods for vaccine identification and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the herpesvirus family
EP1415665A3 (en) 2002-11-01 2004-06-30 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. BHV5 mutants
US7592169B2 (en) 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2663109A1 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
CA2674051C (en) 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2331639B1 (en) * 2008-10-03 2020-04-08 Sun Chemical Corporation Inks and coatings that prevent the migration of heavy metals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Molecular Cloning", 2001
"Nucleic Acid Hybridization", 1985
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, GREEN PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
BIERY ET AL., NUCL ACID RES, vol. 28, 2000, pages 1067 - 1077
BONKOWSKY JL ET AL.: "Herpes simplex virus central nervous system relapse during treatment of infantile spasms with corticotropin", PEDIATRICS, vol. 117, no. 5, May 2006 (2006-05-01), pages E1045 - 8
BURGOS JS ET AL.: "Herpes simplex virus type 1 infection via the bloodstream with apolipoprotein E dependence in the gonads is influenced by gender", J VIROL., vol. 79, no. 3, February 2005 (2005-02-01), pages 1605 - 12
CARUTHERS, SCIENCE, vol. 230, 1985, pages 281 - 285
CAUDY AA ET AL., GENES & DEVEL, vol. 16, pages 2491 - 96
DESHPANDE; MUKUND V., APPL. BIOCHEM. BIOTECHNOL., vol. 36, 1992, pages 227
DEVINE ET AL., GENOME RES., vol. 7, 1997, pages 551 - 563
FINNZYMES; HAAPA ET AL., NUCL ACID RES, vol. 13, 1999, pages 2777 - 2784
JIANG C ET AL.: "Mutations that decrease DNA binding of the processivity factor of the herpes simplex virus DNA polymerase reduce viral yield, alter the kinetics of viral DNA replication, and decrease the fidelity of DNA replication.", J VIROL., vol. 81, no. 7, April 2007 (2007-04-01), pages 3495 - 502
KENNEDY PG ET AL.: "Replication of the herpes simplex virus type 1 RL1 mutant 1716 in primary neuronal cell cultures--possible relevance to use as a viral vector", J NEUROL SCI., vol. 179, no. S 1-2, 1 October 2000 (2000-10-01), pages 108 - 14
KHAN OA ET AL.: "Herpes encephalitis presenting as mild aphasia: case report", BMC FAM PRACT., vol. 7, 24 March 2006 (2006-03-24), pages 22, XP021015407, DOI: doi:10.1186/1471-2296-7-22
LABETOULLE M ET AL.: "Neuronal propagation of HSV1 from the oral mucosa to the eye", INVEST OPHTHALMOL VIS SCI, vol. 41, no. 9, August 2000 (2000-08-01), pages 2600 - 6
LABETOULLE M ET AL.: "Neuronal propagation of HSV1 from the oral mucosa to the eye", INVEST OPHTHALMOL VIS SCI., vol. 41, no. 9, August 2000 (2000-08-01), pages 2600 - 6
LAMBIASE A ET AL.: "Topical treatment with nerve growth factor in an animal model of herpetic keratitis", GRAEFES ARCH CLIN EXP OPHTHALMOL., 4 May 2007 (2007-05-04)
MAJUMDAR S I: "Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations", J OCUL PHARMACOL THER., vol. 21, no. 6, December 2005 (2005-12-01), pages 463 - 74
MCPHERSON: "Directed Mutagenesis: A Practical Approach", 1991, OXFORD UNIVERSITY PRESS
NAGOT N ET AL.: "Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus", N ENGL J MED., vol. 356, no. 8, 22 February 2007 (2007-02-22), pages 790 - 9, XP002509748, DOI: doi:10.1056/NEJMoa062607
NEILSEN PE, CURR OPIN STRUCT BIOL, vol. 9, pages 353 - 57
OUEDRAOGO A ET AL.: "Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial", AIDS, vol. 20, no. 18, 28 November 2006 (2006-11-28), pages 2305 - 13
PARR MB ET AL.: "Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites", J NEUROVIROL., vol. 9, no. 6, December 2003 (2003-12-01), pages 594 - 602
PURCHIO; G. C. FAREED, METHODS IN ENZYMOLOGY: METHODS FOR MOLECULAR CLONING IN EUKARYOTIC CELLS, 2003
RAMASWAMY M ET AL.: "Interactions and management issues in HSV and HIV coinfection", EXPERT REV ANTI INFECT THER., vol. 5, no. 2, April 2007 (2007-04-01), pages 231 - 43
RAZ NK ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 297, pages 1075 - 84
SAIKI ET AL., SCIENCE, vol. 239, no. 4839, 29 January 1988 (1988-01-29), pages 487 - 491
SAMBROOK ET AL.: "Molecular Cloning - A Laboratory Manual", 1989, COLD SPRING HABOUR LABORATORY PRESS
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR PRESS
SCHANG LM ET AL.: "Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins", J VIROL., vol. 74, no. 5, March 2000 (2000-03-01), pages 2107 - 20, XP001070109, DOI: doi:10.1128/JVI.74.5.2107-2120.2000
See also references of EP2059255A4
THI TN ET AL.: "Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR", ANTIVIRAL RES., vol. 69, no. 3, March 2006 (2006-03-01), pages 152 - 7, XP025031452, DOI: doi:10.1016/j.antiviral.2005.11.004
THOMAS D.: "Brock in Biotechnology: A Textbook of Industrial Microbiology", 1989, SINAUER ASSOCIATES, INC.
THOMPSON KA ET AL.: "Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis", J NEUROVIROL., vol. 6, no. 1, February 2000 (2000-02-01), pages 25 - 32
ZOLLER ET AL., DNA., vol. 3, no. 6, 1982, pages 479 - 88
ZOLLER, DNA., vol. 3, no. 6, December 1984 (1984-12-01), pages 479 - 88

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911747B2 (en) 2006-09-08 2014-12-16 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US9492533B2 (en) 2006-09-08 2016-11-15 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2010114930A1 (en) 2009-03-31 2010-10-07 The Trustees Of The University Of Pennsylvania Methods of use for hsv-1 and hsv-2 vaccines
US8617564B2 (en) 2009-05-22 2013-12-31 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2015178529A (en) * 2009-05-22 2015-10-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccine to herpes simplex virus type 2: compositions and methods for eliciting immune responses
AU2010249330B2 (en) * 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
JP2012527486A (en) * 2009-05-22 2012-11-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccines against herpes simplex virus type 2: Compositions and methods for eliciting an immune response
WO2010135747A1 (en) * 2009-05-22 2010-11-25 Genocea Biosciences Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US10653771B2 (en) 2009-05-22 2020-05-19 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9895436B2 (en) 2009-05-22 2018-02-20 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2013545761A (en) * 2010-11-24 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccines against herpes simplex virus type 2: Compositions and methods for inducing an immune response
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US10076568B2 (en) 2014-03-03 2018-09-18 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10391165B2 (en) 2014-03-03 2019-08-27 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US9999665B2 (en) 2014-03-03 2018-06-19 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
EP3113801A4 (en) * 2014-03-03 2017-10-25 Albert Einstein College of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10751411B2 (en) 2014-03-03 2020-08-25 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10980874B2 (en) 2014-03-03 2021-04-20 Albert Einstein College Of Medicine Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
EP3999093A4 (en) * 2019-07-19 2023-11-22 Merck Sharp & Dohme LLC Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
WO2023178191A1 (en) * 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system

Also Published As

Publication number Publication date
EP2059255A2 (en) 2009-05-20
WO2008030560A3 (en) 2008-08-07
CN101583381B (en) 2014-05-07
EP2059255A4 (en) 2011-08-31
JP5639361B2 (en) 2014-12-10
CA2663109A1 (en) 2008-03-13
CN101583381A (en) 2009-11-18
JP2010502219A (en) 2010-01-28
AU2007292905B2 (en) 2013-05-23
US20110177125A1 (en) 2011-07-21
AU2007292905A1 (en) 2008-03-13
US8871223B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
US8871223B2 (en) HSV-1 and HSV-2 vaccines and methods of use thereof
US9492533B2 (en) HSV-1 and HSV-2 vaccines and methods of use thereof
Meignier et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents
Morrison et al. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection
AU2007342345B9 (en) Herpes Simplex Virus combined subunit vaccines and methods of use thereof
US8501194B2 (en) Vaccine for viruses that cause persistent or latent infections
JPH08507784A (en) Virus vaccine
US8057804B2 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
Prichard et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs
US20130028925A1 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
Wachsman et al. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs
Reszka et al. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein
US10034935B2 (en) Neuroattenuated herpes simplex virus
WO2006004878A1 (en) Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof
US11390650B2 (en) Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
US10478490B2 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
Krug A host-dependent mechanism of herpes simplex virus type 1 reactivation
Visalli et al. Herpes Simplex Virus Type 2 UL24 Gene Is

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780038798.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837889

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009527427

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2663109

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1331/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007837889

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007837889

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007292905

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007292905

Country of ref document: AU

Date of ref document: 20070907

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12440223

Country of ref document: US